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1 CARDIOVASCULAR	  DISEASE	  
Cardiovascular	   disease	   (CVD),	   which	   defines	   a	   heterogeneous	   class	   of	   pathological	   conditions	  
occurring	  heart	  and	  circulatory	  system,	  is	  among	  the	  leading	  causes	  death	  and	  disability	  in	  the	  world.	  
From	  1998	  to	  2008,	  the	  rate	  of	  death	  attributable	  to	  CVD	  declined	  30.6%	  (Kovacic	  JC	  et	  al.,	  2011).	  In	  
2008	   about	   20%	  of	   death	   due	   to	   CVD	  occurred	  before	   65	   years	   old	   and	   33%	  before	   75	   years	   old,	  
which	  is	  well	  before	  the	  average	  life	  expectancy	  of	  77.9	  years	  (Roger	  VL	  et	  al.,	  2012).	  
The	   mortality	   is	   associated	   to	   several	   non-­‐modifiable	   risk	   factors	   as	   age,	   family’s	   history	   of	  
cardiovascular	  disease,	  gender	  and	  race.	  
In	  particular	  CVD	  risk	  is	  higher	  for	  black	  than	  for	  white	  people	  and	  for	  males	  than	  for	  females	  (Roger	  
VL	  et	  al.,	  2012).	  
The	   most	   important	   modifiable	   risk	   factors	   associated	   with	   CVD	   are	   tobacco	   and	   alcohol	   use,	  
hypertension,	  high	  cholesterol,	  obesity,	  physical	  inactivity	  and	  unhealthy	  diets.	  
The	   association	  of	   two	  or	  more	  of	   these	   factors	   increase	   the	   likelihood	  of	   a	   CV	   event,	   so	   it’s	   very	  
important	  to	  modify	  the	  exposure	  to	  risk	  factors	  to	  prevent	  them	  compromising	  heart	  health.	  	  
Among	   CVDs,	   ischemic	   heart	   disease	   (IHD)	   and	   cerebrovascular	   disease	   (stroke)	   are	   the	   two	  most	  
common	  with	  incidence	  of	  43%	  and	  33%	  respectively.	  
Ischemic	  heart	  disease	   is	  caused	  by	  an	  occlusion	  of	  coronary	  arteries	  due	  to	  atherosclerotic	  plaque	  
fissuring.	  A	   complete	  blockage	  of	  an	  artery	   causes	  myocardial	   infarction,	  which	   is	   characterized	  by	  
necrosis	   and	   damage	   to	   the	   tissues.	   IHD	   is	   one	   of	   the	   causes	   of	   heart	   failure	   (HF),	   a	   progressive	  
disorder	  in	  which	  damage	  to	  the	  heart	  causes	  weakening	  of	  the	  cardiovascular	  system.	  It	  manifests	  
by	  insufficient	  cardiac	  pump	  function,	  fluid	  congestion	  and	  inadequate	  blood	  flow	  to	  tissues.	  	  
Stroke	   is	  a	  pathological	  condition	  caused	  by	  disruption	  of	  blood	  supply	  to	  the	  brain.	  This	  may	  result	  
from	  either	  blockage	  (ischemic	  stroke)	  or	  rupture	  of	  a	  blood	  vessel	  (hemorrhagic	  stroke).	  As	  result	  a	  
rapid	   loss	   of	   brain	   function	   occurs	  which	  may	   lead	   to	   difficult	   or	   inability	   to	  move,	   understand	   or	  
formulate	  speech.	  
The	  other	  events	  are	  indicated	  as	  minor	  types	  of	  CVDs,	  briefly	  described	  below.	  
Peripheral	  vascular	  disease	  affects	  the	  circulation	  in	  legs	  and	  arms.	  Patients	  with	  this	  disease	  typically	  
complain	  of	  pain	  in	  their	  calves	  especially	  when	  walking.	  
Rheumatic	   heart	   disease	   is	   a	   major	   problem	   in	   many	   poor	   countries.	   This	   disease	   begins	   with	   a	  
bacterial	   infection	   (commonly	   streptococcal	   bacteria)	   in	   childhood	   but	   the	   heart	   problems	   appear	  
many	  years	  later.	  It	  affects	  joints	  and	  heart	  valves,	  which	  often	  have	  to	  be	  replaced	  by	  surgery.	  Other	  
infections	  can	  occur	  attacking	  pericardium	  (pericarditis).	  




genetic	  factors	  or	  adverse	  exposures	  during	  gestation.	  These	  anatomical	  defects	  can	  be	  a	  small	  hole	  
in	   one	   of	   the	   inside	   walls	   of	   the	   heart,	   abnormal	   valves	   or	   abnormal	   heart	   chambers.	   Some	  
congenital	  heart	  problems	  result	  in	  death	  unless	  immediately	  corrected	  by	  surgical	  intervention.	  	  
Aortic	  aneurysm	  and	  Dissection	  is	  characterized	  by	  dilatation	  and	  rupture	  of	  the	  aorta.	  
Deep	  venous	  thrombosis	  and	  pulmonary	  embolism	  is	  a	  pathological	  condition	  in	  which	  blood	  clotted	  
in	  the	  leg	  veins,	  can	  dislodge	  and	  move	  to	  the	  heart	  and	  lungs	  leading	  tissue	  infections.	  
	  
Twenty	  years	  ago,	  a	  group	  of	  experts	  framed	  CVDs	  as	  a	  chain	  of	  events,	  caused	  by	  a	  lots	  of	  related	  
and	  unrelated	  risk	  factors,	  and	  progressing	  through	  numerous	  physiological	  pathways	  and	  processes	  
to	  the	  end-­‐stage	  heart	  disease	  (Figure	  1)	  (Dzau	  V	  et	  al.,	  1991).	  
Furthermore,	  although	  the	  original	  concept	  focused	  on	  risk	  factors	  for	  coronary	  artery	  disease	  (CAD),	  
the	  CVD	  continuum	  has	  expanded	  to	  include	  other	  areas	  such	  as	  cerebrovascular	  disease,	  peripheral	  
vascular	  disease,	  and	  renal	  disease	  (Dzau	  VJ	  et	  al.,	  2006).	  
The	   intervention	   along	   the	   chain	   of	   events	   leading	   to	   CVD	   could	   modify	   the	   pathophysiological	  
process	  and	  confer	  cardioprotection	  (Dzau	  VJ	  et	  al.,	  2006).	  
So	  the	  development	  of	  new	  technologies	  for	  diagnosis,	  the	  release	  of	  new	  landmark	  and	  the	  research	  




Figure	  1.	  The	  cardiovascular	  disease	  continuum.	  Adapted	  from	  Dzau	  VJ	  et	  al.,	  2006.	  to disease at both the systemic and local level, exerting direct
trophic and inflammatory effects on tissue.
Oxidative Stress and Endothelial Dysfunction
Advances in pathophysiological research suggest that the
CVD continuum begins with risk factors that initiate the
process that leads to tissue damage. The pathophysiological
continuum includes oxidative stress, endothelial dysfunction,
inflammatory processes, and vascular remodeling in the
initiation and continuation of atherosclerotic disease. An
understanding of these processes has enabled the develop-
ment of therapeutic strategies targeting individual factors
along the CVD continuum.
Normal endothelial function appears to depend greatly
on the homeostatic balance between nitric oxide (NO) and
reactive oxygen species, such as superoxide anion and
hydrogen peroxide.3 Oxidative stress results when an
increase in reactive oxygen species generation leads to a
reduction in NO activity and subsequent endothelial dys-
function. This imbalance is a known effect of established
CVD risk factors such as cigarette smoking, diabetes
mellitus, and obesity. In addition, oxidative stress induces
the expression of proinflammatory mediators such as
vascular cell adhesion molecule, intracellular adhesion
molecule, and chemoat r ctant proteins that play a role in
early atherogenesis.3
Through receptor-mediated and non–receptor-mediated
mechanisms, endothelial cells regulate vascular tone, in-
flammation, lipid metabolism, cell growth and migration,
and interactions with the extracellular matrix.4 Any dis-
ruption of normal endothelial function can induce patho-
logical vascular responses, such as smooth muscle cell
proliferation, vasoconstriction, inflammation, and throm-
bosis. For example, endothelial dysfunction may shift
relative concentrations of tissue-type plasminogen activa-
tor and plasminogen activator inhibitor type 1 toward
thrombosis. Plasminogen activator inhibitor-1 is the pri-
mary inhibitor of tissue-type plasminogen activator, and
elevated levels of plasminogen activator inhibitor-1 rela-
tive to tissue-type plasminogen activator lead to inhibition
of the fibrinolytic system.5 Endothelial dysfunction is also
associated with changes in concentrations of important
local inflammatory mediators, such as chemokines, adhe-
sion molecules, and cytokines.
Role of Risk Factors in Oxidative Stress and
Endothelial Dysfunction
Oxidized low-density lipoprotein (LDL) inactivates NO,
which results in increased oxidative stress and enhanced
Figure 1. The cardiovascular disease continuum. LVH indicates left ventricular hypertrophy; CHF, congestive heart failure. Adapted
from Dzau et al1 with permission from Elsevier.
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2 HEART	  ANATOMY	  AND	  FUNCTION:	  IMPORTANCE	  OF	  LEFT	  ATRIUM	  	  
2.1 Left	  Ventricle	  
2.1.1 Anatomy	  And	  Morphology	  
The	  heart	  is	  divided	   into	  four	  chambers,	  two	  ventricles	  and	  two	  atria.	  Left	  ventricle	   is	  connected	  to	  
left	  atrium	  by	  mitral	  valve,	  while	  right	  ventricle	  and	  atrium	  are	  connected	  through	  tricuspid	  valve.	  
Left	  and	  right	  ventricles	  are	  divided	  by	  septum;	  normally,	  the	  left	  ventricular	  free	  wall	   is	  thickest	  at	  
the	   cardiac	   base	   (12-­‐15	  mm)	   and	   it	   gradually	   becomes	   thinner	   towards	   the	   apex.	   The	   endocardial	  
aspect	   of	   the	   ventricle	   is	   characterized	   by	   a	   criss-­‐crossing	   meshwork	   of	   thin	   muscle	   bundles	  
(trabeculations)	   at	   the	   apical	   third	   of	   the	   ventricle.	   Left	   ventricle	   wall	   consists	   of	   three	   ‘layers’	  
according	  to	  the	  longitudinal	  alignment	  of	  the	  myocardial	  strands:	  superficial	  (subepicardial),	  middle,	  
and	  deep	  (subendocardial)	  (Ho	  SY	  et	  al.,	  2002).	  
2.1.2 Function	  
The	  ventricles	  function	  is	  to	  pump	  blood	  into	  the	  entire	  body;	  while	  right	  ventricle	  receives	  venous	  
blood	   from	   the	   right	   atrium	   and	   pumps	   it	   into	   pulmonary	   arteries,	   left	   ventricle	   (LV)	   receives	  
oxygenated	  blood	  from	  left	  atrium	  and	  pumps	  it	  into	  the	  aorta.	  
During	  cardiac	  cycle	  we	  can	   recognize	   two	  phases:	  diastole	  during	  which	   left	  ventricle,	   relaxes	  and	  
fills	   rapidly	   with	   oxygenated	   blood	   flowing	   from	   atrium,	   and	   systole	   when	   left	   ventricle	   contracts	  
rapidly	  and	  forcibly	  to	  pump	  blood	  into	  the	  aorta,	  overcoming	  the	  much	  higher	  aortic	  pressure.	  
End-­‐diastolic	  volume	  (EDV)	  and	  end-­‐systolic	  volume	  (ESV)	  are	  respectively	  the	  volume	  of	  blood	  in	  left	  
ventricle	   at	   the	   end	   of	   diastolic	   filling	   phase	   and	   at	   the	   end	   of	   contraction;	   ejection	   fraction	  (EF)	  
represents	  the	  fractional	  volume	  of	  blood	  pumped	  into	  aorta	  for	  each	  beat.	  The	  stroke	  volume	  (SV),	  
amount	  of	  blood	  ejected	  per	  each	  beat,	  is	  the	  difference	  between	  EDV	  and	  ESV	  and	  is	  an	  important	  
determinant	  of	  cardiac	  output	  (CO),	  which	  increase	  or	  decrease	  in	  response	  to	  changes	  in	  heart	  rate	  
or	  SV	  (CO	  is	  the	  product	  of	  SV	  and	  heart	  rate).	  
SV	  is	  ruled	  Frank-­‐Starling	  law,	  which	  defines	  the	  ability	  of	  the	  heart	  to	  change	  its	  force	  of	  contraction,	  
and	  therefore	  SV,	   in	   response	  to	  changes	   in	  venous	  return.	   Increased	  venous	  return	   increases	  EDV	  
and,	  consequently,	   the	  stretching	  of	   the	  cardiac	  myocytes	  prior	   to	  contraction.	  Myocyte	  stretching	  
increases	   the	  sarcomere	   length,	   which	   causes	   an	   increase	   in	   force	   generation.	   This	   mechanism	  






In	  response	  to	  a	  transmural	  myocardial	  infarction	  (MI),	  LV	  undergoes	  significant	  remodeling	  leading	  
to	  LV	  volume	   increases,	  ejection	  fraction	  decrease,	  anterior	  wall	   thinning	  and	  a	   loss	  of	  contractility	  
due	  to	  fibrosis.	   It	   is	  believed	  that	   initially	  remodeling	  is	  required	  for	  maintenance	  of	  cardiac	  output	  
but	  ultimately	  leads	  to	  LV	  dysfunction.	  	  
2.2 Left	  Atrium	  	  
2.2.1 Anatomy	  And	  Morphology	  
The	   left	  atrium	  (LA)	   receives	  oxygenate	  blood	   from	  4	  pulmonary	  veins	   (PVs)	  and	  pumps	   it	   into	   left	  
ventricle	  through	  the	  mitral	  valve.	  
The	   LA	  presents	   three	  different	   structures:	   a	   venous	   component	   that	   receives	   the	  PVs,	   a	   vestibule	  
and	  an	  atrial	  appendage	  (LAA).	  The	  venous	  component	  is	  LA’s	  largest	  part,	  is	  located	  posteriorly	  and	  
has	   four	   venous	   orifices,	   one	   at	   each	   corner	   (Ho	   SY	   et	   al.,	   2002).	   The	   vestibule	   is	   the	   tissue	  
surrounding	  the	  mitral	  valve	  orifice.	  The	  LAA	  is	  a	  characteristic	  tubular	  small	  finger-­‐like	  extension,	  its	  
junction	   with	   the	   left	   atrium	   is	   narrow	   and	   well-­‐defined,	   it	   has	   lobes	   that	   are	   potential	   sites	   for	  
deposition	   of	   thrombus	   (Cabrera	   JA	   et	   al.,	   1999;	   Veinot	   JP	   et	   al.,	   1997).	   Venous	   component	   and	  
vestibule	  are	  relatively	  smooth-­‐walled,	  whereas	  LAA	  is	  rough	  with	  pectinate	  muscles.	  
During	   embryo	   development	   the	   primordial	   pulmonary	   vein	   and	   its	   branches	   are	   incorporated	  
gradually	  into	  the	  LA	  and	  extend	  themself	  around	  the	  dorsal	  wall	  as	  the	  atrium	  grows	  in	  volume.	  The	  
four	  pulmonary	  veins	  with	  separate	  atrial	  orifices	  are	  formed	  at	  about	  8	  weeks	  and	  LAA	  has	  formed	  
from	  the	  primordial	  LA	  (Hara	  H	  et	  al.,	  2009)	  (Figure	  2).	  	  
	  
	  
Figure	  2.	  Illustration	  of	  absorption	  of	  the	  pulmonary	  vein	  into	  LA.	  A:	  common	  pulmonary	  vein	  opening	  into	  the	  
primordial	   LA;B:	  partial	   absorption	  of	   the	   common	  pulmonary	  vein.	  C:	   the	  openings	  of	   two	  pulmonary	  veins	  
into	  LA	  due	  to	  the	  advanced	  absorption	  of	  the	  common	  pulmonary	  vein	  at	  6	  weeks.	  D:	  four	  pulmonary	  veins	  
with	  separate	  atrial	  orifices	  enter	  the	  LA	  (Hara	  H	  et	  al.,	  2009).	  
primordial left atrial wall becomes the tubular LAA
with its rough and trabeculated internal surface,
attached to the LA [6].
Structure
LAA structure was initially characterized from 1,842
autopsy hearts [7]. A study of 220 LAA casts revealed
varying anatomic shapes and volumes [8]. Complex
LAA shapes are categorized as straight, slightly bent,
extremely bent, slightly spiraled, or extremely spiraled.
In most hearts, the appendage axis was angulated less
than 100 degrees and in a minority the ppendage was
extremely bent. LAA volume ranged from 770 to
19,270 mm3. Another study of 500 autopsy hearts char-
acterized LAA structure by external features, counting
the number of lobes [9]. Table II defines LAA lobes in
this study. Fifty four percent of LAAs had two lobes,
unrelated to age or gender. Lobes occurred in 1–4 car-
diac planes so that three-dimensional (3D) imaging may
be eeded to define LAA anatomy. Most specimens
(97%) had pectinate muscles !1 mm in width (Fig. 2).
Pectinate muscles <1 mm (3%) were found in only the
first and last decades of life.
The LAA has a narrow base, a hooked tubular apex
typically pointing downward, and confined pectinate
muscles without a terminal crest. These features are
comparable to the RAA with a broad base and hooked
apex pointing upward [7].












%/y from five randomized trials
Current smoker 158 2.5
Onset of AF >1 y 1087 4.4
History of HT 750 5.6
Intermittent AF 207 5.7
Female 439 5.8
PVD 99 6.0
Clinical heart disease 657 6.1
History of angina 363 6.7
History of CHF 349 6.8
History of MI 217 8.2
History of diabetes 250 8.6
Prior stroke/TIA 101 11.7
Fig. 1. Illustration of absorption of the pulmonary vein into
LA. A, common pulmonary vein opening into the primordial LA
in 5 weeks. B, partial absorption of the common pulmonary
vein in the later stage. C, showing the openings of two pulmo-
nary veins into LA due to the advanced absorption of the
common pulmonary vein in 6 weeks. D, 8 weeks, showing four
pulmonary with separate atrial orifices. The primordial LA
becomes the LAA. Most of the LA are formed by the absorp-
tion of the primordial pulmonary vein and its branches. [Color
figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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The	   atrial	   walls	   are	   composed	   of	   one	   to	   three	   (or	  more)	   overlapping	   layers	   of	   differently	   aligned	  
myocardial	   fibers.	   From	  birth	   to	   third	  decade,	   there	   is	  proliferation	  of	   smooth	  muscle	   cells,	   elastic	  
fibers,	   and	   collagen;	   by	   the	   eighth	  decade,	   there	   is	   increased	   infiltration	  of	   fatty	   tissue,	   as	  well	   as	  
increased	  collagen	  and	  atrial	  amyloid	  deposition	  (Kitzman	  DW	  et	  al.,	  1990).	  
The	  atrial	  wall	  presents	  marked	  regional	  thickness	  differences	  (Ho	  SY	  et	  al.,	  2002)	  and,	  for	  example	  in	  
normal	   adult,	   the	   superior	  wall	   is	   the	   thickest	  part	   of	   LA	   (3.5–6.5	  mm),	  whereas	   the	   anterior	   (just	  
behind	  the	  aorta)	  and	  the	  posterior	  (between	  the	  superior	  PVs)	  walls	  are	  usually	  the	  thinnest	  (Ho	  SY	  
et	  al.,	  1999).	  
2.2.2 Function	  	  
Left	  atrium	  is	  both	  structurally,	  through	  mitral	  valve,	  and	  functionally	  linked	  to	  LV	  function	  (Khoo	  CW	  
et	  al.,	  2011).	  	  
Functionally,	   the	   LA	   has	   been	   described	   by	   three	   phases	  within	   the	   cardiac	   cycle	   (Pagel	   PS	   et	   al.,	  
2003)	  The	  LA	  area	  curve	  shows	  an	  increase	  in	  during	  ventricular	  systole	  (reservoir	  phase)	  followed	  by	  
three	   diastolic	   stages:	   a	   rapid	   decrease	   (conduit	   phase),	   a	   plateau	   (diastasis),	   and	   a	   second	   rapid	  
decrease	  occurring	  during	  atrial	  contraction	  (booster	  pump	  phase)	  (Spencer	  KT	  et	  al.,	  2001).	  
Phases:	  
a)	  reservoir	  or	  left	  atrial	  filling:	  during	  ventricular	  systole	  and	  isovolumic	  relaxation,	  the	  LA	  acts	  as	  a	  
“reservoir”	  that	  receives	  blood	  from	  pulmonary	  veins	  and	  stores	  energy	  in	  the	  form	  of	  pressure.	  	  
The	   left	   atrium	   reservoir	   is	   an	   important	   determinant	   of	   cardiac	   output	   (Suga	   H,	   1974)	   and	   is	  
determined	  by	  left	  atrial	  contraction,	  relaxation	  and	  by	  the	  displacement	  of	  the	  mitral	  annulus	  during	  
left	  ventricular	  contraction	  (Barbier	  P	  et	  al.,	  1999).	  
We	  can	  calculate	  LA	  reservoir	  volume	  as	  difference	  between	  LA	  maximum	  volume	  (just	  before	  mitral	  
valve	  opening)	  and	  LA	  minimum	  volume	  (at	  mitral	  valve	  closure)	  (Abhayaratna	  WP	  et	  al.,	  2006).	  
b)	  conduit	  and	  diastasis	  or	  left	  atrial	  passive	  emptying:	  during	  early	  ventricular	  diastolic	  filling,	  the	  LA	  
operates	  as	  a	   “conduit”	   for	   transfer	   (via	  a	  pressure	  gradient)	  blood	   from	  the	  pulmonary	  veins	   into	  
the	  left	  ventricle	  (LV)	  after	  mitral	  valve	  opening	  (in	  doppler	  flow	  we	  observe	  a	  early	  wave	  E-­‐wave).	  
Left	  atrial	  conduit	  function	  is	  modulate	  by	  left	  ventricular	  relaxation.	  
LA	  (passive)	  conduit	  volume	  is	  calculated	  as	  the	  difference	  between	  LV	  stroke	  volume	  and	  the	  total	  
LA	  emptying	  volume	  (Abhayaratna	  WP	  et	  al.,	  2006).	  
c)	   contraction	   or	   left	   atrial	   active	   empying:	   during	   the	   “contractile”	   function	   LA	  works	   as	   a	   pump	  
which	  normally	  allows	  to	  augment	  the	  LV	  stroke	  volume	  by	  approximately	  25%	  (in	  Doppler	  flow	  we	  




The	  relative	  contribution	  of	  this	  “booster	  pump”	  function	  becomes	  more	  dominant	  in	  the	  setting	  of	  
LV	  dysfunction	  (Appleton	  CP	  et	  al.,	  1988;	  Thomas	  L	  et	  al.,	  2002).	  	  
LA	  active	  emptying	  (contractile)	  volume	  is	  calculated	  as	  the	  difference	  between	  pre-­‐atrial	  contraction	  
LA	   volume	   (at	   the	   onset	   of	   the	   P-­‐wave	   on	   electrocardiography)	   and	   minimum	   LA	   volume	  
(Abhayaratna	  WP	  et	  al.,	  2006).	  
In	   subjects	   with	   normal	   diastolic	   function,	   the	   relative	   contribution	   of	   the	   reservoir,	   conduit,	   and	  
contractile	  function	  of	  the	  LA	  to	  the	  ﬁlling	  of	  the	  LV	  is	  approximately	  40%,	  35%,	  and	  25%,	  respectively	  
(Prioli	   A	   et	   al.,	   1998).	   With	   abnormal	   LV	   relaxation,	   the	   relative	   contribution	   of	   LA	   reservoir	   and	  
contractile	   function	   increases	   and	   conduit	   function	   decreases.	   However,	   as	   LV	   ﬁlling	   pressure	  
progressively	   increases	   with	   advancing	   diastolic	   dysfunction,	   the	   LA	   serves	   predominantly	   as	   a	  
conduit	  (Prioli	  A	  et	  al.,	  1998).	  
	  
	  
Figure	  3.	  Schematic	  representation	  of	  trend	  of	  Left	  Atrial	  (LA)	  area	  and	  Left	  Ventricular	  (LV)	  volume	  during	  the	  
cardiac	   cycle.	   Functional	   atrial	   phases	   are	   labeled:	   R,	   reservoir;	   C,	   conduit;	   B,	   booster	   pump;	   LAmin:	   LA	  
minimum	  area;	  LAmax:	  LA	  maximum	  area;	  LAoae,:	  LA	  onset	  atrial	  emptying	  area.	  Left	  Ventricular	  phases	  are	  
labeled:	  S,	  systole;	  D,	  diastole	  (adaptated	  from	  Spencer	  KT	  et	  al.,	  2003).	  
	  




One hundred and seventy one subjects (81
males and 90 females) aged 3–79 years old
were enrolled from six participating centres.
Subjects were required to have a transthoracic
window adequate for performing automated
border detection. Entry criteria included:
(1) no clinical history of cardiovascular disease;
(2) normal sinus rhythm; (3) absence of left
bundle branch block; (4) normal blood
pressure; (5) absence of wall motion abnormal-
ity on two dimensional echocardiographic
screening; (6) no more than trivial aortic insuf-
ficiency or mild mitral, tricuspid or pulmonic
regurgitation; (7) normal left ventricular mass
determined using the area–length formula;
(8) ejection fraction of >50% calculated from
manual tracings of end systolic and end diasto-
lic frames using the method of discs.
ACOUSTIC QUANTIFICATION
AQ is an automated online technique that
analyses the ultrasound backscatter to identify
the blood–tissue interface of cardiac chambers
and generate area or volume waveforms within
a defined region of interest.8–10 Using a SONOS
5500 (Hewlett Packard, Andover, Massachu-
setts, USA) images were obtained from the
apical four chamber window taking care to
maintain a non-foreshortened, maximally sized
view of the left atrium. The automated border
detection system was activated and optimised,
as previously described,15 by adjusting the total
gain, time gain compensation, and lateral gain.
A region of interest was then drawn around the
left atrium excluding the pulmonary veins. The
LA area waveform was displayed and visual
confirmation of consistent stable waveforms
made (fig 1). Forty five seconds of LA area ver-
sus time data were acquired to magneto-optical
disk. All acquisitions were made during quiet
respiration without breath holding.
ANALYSIS
All atrial AQ waveforms were analysed oV-line
using custom software. All 45 seconds of LA
waveform data were signal averaged resulting
in a single composite waveform. Signal averag-
ing reduces noise and variability of the AQ
waveforms.11 From this signal averaged wave-
form the first derivative of LA area was
computed. The custom software automatically
identified the phases on the LA waveform using
morphologic criteria of the area and derivative
curves. The minimum area (LAmin), maxi-
mum area (LAmax), and the area at the onset
of atrial emptying (LAoae) were then deter-
mined (fig 2).
LA reservoir function was assessed using fill-
ing area (LAmax − LAmin), expansion index
(LAmax − LAmin)/LAmin*100, and the peak
rate of filling (PFR). The overall diastolic emp-
tying index was calculated as (LAmax −
LAmin)/LAmax*100. LA conduit function
was assessed by calculating: the passive empty-
ing percentage of total emptying (PE) =
(LAmax − LAoae)/(LAmax − LAmin)*100,
passive emptying index (PEI) = (LAmax −
LAoae)/LAmax*100, and peak passive empty-
ing rate (PPER). Parameters of atrial booster
pump function included: active emptying
percentage of total emptying (AE) = (LAoae −
LAmin)/(LAmax − LAmin)*100, active emp-
tying index (AEI) = (LAoae − LAmin)/
LAoae*100, and peak active emptying rate
(PAER). All area derivative peak rates were
expressed in absolute units (cm2/s) and
normalised by the maximum atrial area
(LAmax/s).
Figure 1 Apical four chamber view with acoustic
quantification activated and optimised for the left atrium.
The bottom of the figure shows the LA AQ area waveform
(green).
Figure 2 Signal averaged AQ LA area (top) and LA
derivative (middle) waveforms. Left ventricular (LV)
volume waveforms (bottom) are shown for reference. The
phases of the cardiac cycle are labelled: R, reservoir; C,
conduit; B, booster pump; LAmin, minimum area; LAmax,
maximum area; LAoae, onset atrial emptying area; PFR,
peak filling rate; PPER, peak passive emptying rate;
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LA res rvoir funct on was assessed using fill-
ing area (LAmax − LAmin), expansion index
(LAmax − LAmin)/LAmin*100, and the peak
rate of filling (PFR). The ove all diastolic emp-
tying index was calculated as (LAmax −
LA in)/LAmax*100. LA conduit function
was assessed b calculating: the passive empty
ing percentage of total emptying (PE) =
(LAmax − LAoae)/(LAmax − LAmin)*100,
passiv emptying index (PEI) = (LAmax −
LAoae)/LAmax*100, and peak passive empty-
ing rate (PPER). Parameters of atrial booster
pump function included: active emptying
perce tage of total emptying (AE) = (LAoae −
LAmin)/(LAmax − LAmin)*100, activ emp
tying index (AEI) = (LAoae − LAmin)/
LAoae*100, and peak active empty g rate
(PAER). All area derivative peak rates were
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Figure 1 Apical four chamber view with acoustic
quantification activated and optimised for the left atrium.
The bottom of the figure shows the LA AQ area waveform
(green).
Figure 2 Signal averaged AQ LA area (top) and LA
derivative (middle) waveforms. Left ventricular (LV)
volume waveforms (bottom) are shown for reference. The
phases of the cardiac cycle are labelled: R, reservoir; C,
conduit; B, booster pump; LAmin, minimum area; LAmax,
maximum area; LA ae, onset atri l emptying area; PFR,
peak filling rate; PPER, peak passive emptying rate;




















Figure	  4	  Schematic	  representation	  of	  LA	  emptying	  phase	  and	  mitral	  flow	  velocity.	  Functional	  atrial	  phases	  are	  
labeled:	  C:	  conduit;	  D:	  diastases;	  B:	  booster	  pump.	  Mitral	  flow	  wave	  are	  labeled:	  E:	  early,	  A:	  atrial.	  
	  
2.2.3 Left	  Atrium	  Appendage	  
Because	   substantial	   embryologic,	   anatomic,	   and	   functional	   differences	   exist	   between	   the	   LAA	   and	  
the	  LA	  itself,	  the	  LAA	  is	  more	  than	  a	  simple	  ‘appendage’	  and	  should	  be	  considered	  a	  unique	  cardiac	  
chamber	  (Hara	  H	  et	  al.,	  2009).	  During	  embryo	  development	  the	  LAA	  originates	  from	  primordial	  atrial	  
tissue	  and	   is	   formed	  by	  confined	  pectinate	  muscles	  without	  a	  terminal	  crest;	   it’s	   internal	  surface	   is	  
trabeculated.	   It	   has	   a	   narrow	   base,	   a	   hooked	   tubular	   apex	   typically	   pointing	   downward.	   LAA	  
myocardial	  cells	  are	  visually	  similar	  to	  ventricular	  myocardial	  cells	  and	  resemble	  skeletal	  muscle.	  
Interest	  on	  LAA	  has	  grown	  after	  it	  has	  been	  understood	  that	  most	  intracardiac	  thrombus	  originates	  
there	   during	   and	   after	   atrial	   fibrillation	   (AF),	   causing	   stroke,	   infarction,	   and	   emboli.	   Today	  
percutaneous	   LAA	   exclusion	   may	   eventually	   replace	   anticoagulant	   therapy	   while	   simultaneously	  
reducing	  stroke	  risk	  (Sick	  PB	  et	  al.,	  2007;	  Al-­‐Saady	  NM	  et	  al.,	  1999).	  
The	  LAA	  differs	  in	  normal	  sinus	  rhythm	  compared	  with	  patients	  in	  chronic	  AF	  (Shirani	  J	  et	  al.,	  2000),	  
those	  patients	  have	  marked	  fibrous	  endocardial	  thickening	  and	  a	  smoother	  internal	  LAA	  surface.	  LAA	  
histopathology	  in	  hearts	  exhibiting	  spontaneous	  or	  congenital	  thrombosis	  and	  LAA	  infarction	  (Spigel	  J	  





papillary	  fibroelastoma	  (Tsukube	  T	  et	  al.,	  2000),	  and	  found	  changes	  comparable	  with	  other	  myocytes	  
of	  the	  heart	  in	  these	  disorders	  (Hara	  H	  et	  al.,	  2009).	  
2.2.4 Remodeling	  	  
In	   response	   pressure	   and/or	   volume	   overload	   caused	   by	   to	   diastolic	   dysfunction,	   ischemia,	   and	  
valvular	  disease,	  LA	  responds	  with	  an	  adaptive	  (or	  maladaptive)	  process	  named	  ”LA	  remodeling”	   in	  
order	  to	  maintain	  homeostasis	  against	  this	  external	  stressors.	  
The	   type	   and	   extent	   of	   remodeling	   depends	   on	   the	   strength	   and	   duration	   of	   exposure	   to	   the	  
stressors	  (Casaclang-­‐Verzosa	  G	  et	  al.,	  2008).	  
LA	  remodeling	  includes	  	  
-­‐	  myocyte	  growth,	  hypertrophy,	  necrosis,	  and	  apoptosis;	  	  
-­‐	  alterations	  in	  the	  composition	  of	  extracellular	  matrix;	  	  
-­‐	  recalibration	  of	  energy	  production	  and	  expenditure;	  	  
-­‐	  changes	  in	  the	  expression	  of	  cellular	  ionic	  channels	  and	  atrial	  hormones;	  	  
-­‐	  reversal	  to	  a	  fetal	  gene	  program	  (Colucci	  WS	  et	  al.,	  2005).	  
This	   changes	   promote	   a	   cascade	   of	   reactions	   leading	   to	   LA	   remodeling	  with	   structural,	   functional,	  
elettrical,	  metabolic	  and	  neurohormonal	  conseguences	  (Casaclang-­‐Verzosa	  G	  et	  al.,	  2008).	  
In	   normal	   humans,	   the	   LA	   is	   a	   highly	   expandable	   chamber	   with	   relatively	   low	   pressures.	   In	   the	  
presence	  of	  acute	  or	  chronic	  stress	  or	  injury,	  the	  LA	  stretches	  and	  stiffens	  (Hoit	  BD	  et	  al.,	  1998;	  Khan	  
A	  et	  al.,	  2004).	  	  
Ultrastructural	   changes	   in	   heart	   failure-­‐induced	   remodeling	   are	   marked	   by	   extensive	   interstitial	  
fibrosis	  and	  myocyte	  hypertrophy	  (Li	  DS	  et	  al.,	  1999;	  Khan	  A	  et	  al.,	  2004;	  Boixel	  C	  et	  al.,	  2003).	  
There	   is	   strong	   evidence	   that	   left	   atrial	   (LA)	   enlargement	   is	   indicative	   of	   significant	   ventricular	  
(Matsuda	  Y	  et	  al.,	  1983),	  atrial	   (Brodsky	  MA	  et	  al.,	  1989)	  or	  valvular	   (Vaturi	  M	  et	  al.,	  2001)	  disease	  
and	  it	  is	  a	  robust	  predictor	  of	  cardiovascular	  outcomes	  (Abhayaratna	  WP	  et	  al.,	  2006).	  
2.2.4.1 effects	  of	  myocardial	  infarction	  
Myocardial	   infarction	   causes	   abnormal	   LV	   dilatation	   and	   a	   reduction	   in	   LV	   compliance	   as	   a	  
consequence	   of	   altered	   actin–myosin	   interactions,	   increased	   collagen	   deposition	   and	   changes	   of	  
cardiac	  viscoelastic	  properties	  (Dent	  CL	  et	  al.,	  2001).	  
In	   this	   condition	  LV	  end-­‐diastolic	  pressure	   increases	  and	  LA	   is	  directly	  exposed	   to	   this	   increase.	  To	  
maintain	  adequate	  LV	  filling,	  LA	  pressure	  and	  wall	   tension	   increase	  consequently	   (Greenberg	  BH	  et	  
al.,	  1979)	  resulting	  in	  dilatation	  and	  stretching	  of	  atrial	  myocardium	  (Tsang	  TS	  et	  al.,	  2002).	  
So	  LA	  volume	  reflects	  the	  severity	  of	  diastolic	  dysfunction	  and	  the	  long-­‐term	  exposure	  to	  abnormal	  




After	  MI	   LV	   remodeling	   is	   accompanied	   by	   LA	   function	   changes	   and	   remodeling	   (Bozkurt	   E	   et	   al.,	  
2007):	  
• in	  line	  with	  the	  increase	  in	  LV	  diameters	  and	  volumes,	  an	  increase	  in	  both	  supero-­‐inferior	  and	  
medial-­‐lateral	   diameters	   and	   LA	   volumes	   (Vmax,	   Vmin	   Voae)	   is	   observed	   (Matsuda	   Y	   et	   al.,	  
1983);	  
• reduced	  LV	  compliance	  causes	  LA	  passive	  emptying	  fraction	  (LAPEF)	  reduction	  and,	  in	  order	  to	  
maintain	   almost	   constant	   LV	   SV,	   despite	   the	   dramatic	   fall	   in	   EF%,	   increase	   in	   LA	   active	  
emptying	   function	   (LAAEF)	   (Triposkiadis	   F	   et	   al.,	   1995).	   This	   condition	   is	   evident	   from	   the	  
beginning	  of	  the	  acute	  MI	  and	  become	  more	  significant	  from	  the	  first	  month	  after	  MI	  (Bozkurt	  
E	  et	  al.,	  2007);	  
• on	  the	  basis	  of	  point	  2,	   in	  patient	  with	  MI	  the	  ratio	  of	   left	  atrial	  volume	  to	  LV	  SV	   is	  different	  
than	  in	  normal	  subject,	  for	  example	  the	  ratio	  of	  left	  atrium	  active	  emptying	  (LAAE)	  to	  LV	  SV	  is	  
significantly	  higher	  in	  patients	  with	  MI	  than	  in	  normal	  subjects;	  
• left	   atrium	   pressure	   -­‐	   volume	   relation	   change	   in	  MI	   patient,	   in	   fact	   LA	   work	   is	   significantly	  
higher	  in	  MI	  patient	  than	  in	  normal	  subjects,	  and	  this	  correlates	  with	  the	  increase	  of	  the	  ratio	  
LAAE	  to	  LV	  SV	  (Matsuda	  Y	  et	  al.,	  1983).	  
2.2.4.2 effects	  of	  age	  
Aging	  is	  associated	  with	  vascular	  and	  myocardial	  alterations	  that	  are	  related	  to	  the	  pathogenesis	  of	  
cardiac	  dysfunction.	  Vascular	  alteration	  results	  in	  luminal	  dilation	  and	  vascular	  stiffening	  resulting	  in	  
an	  increase	  of	  vascular	  load	  and	  contributing	  to	  the	  development	  of	  cardiac	  hypertrophy;	  moreover	  
the	   deposition	   and	   cross-­‐linking	   of	   extracellular	  matrix	   proteins	   in	   the	   cardiac	   interstitium	  play	   an	  
important	  role	  in	  the	  pathogenesis	  of	  diastolic	  heart	  failure	  (Frangogiannis	  NG	  et	  al.,	  2002).	  
Clinical	  studies	  have	  reported	  conflicting	  results	  regarding	  the	  relationship	  between	  LA	  size	  and	  aging	  
(Kitzman	  DW	  et	  al.,	  1998).	  
The	   development	   of	   LV	   diastolic	   dysfunction	   and	   relaxation	   impairment	   cause	   an	   increase	   in	   LA	  
contractility	  in	  order	  to	  maintain	  LV	  SV	  (Klein	  AL	  et	  al.,	  1994).	  
The	  anatomical	  and	  hemodynamic	  perturbations	  in	  the	  LV	  are	  transmitted	  to	  the	  LA,	  promoting	  atrial	  
stretch	  and	  dilatation	  (Redfield	  MM	  et	  al.,	  2005).	  	  
Aging	  is	  characterized	  by	  atrial	  morphology	  and	  function	  changes:	  
• a	  tendency	  to	  increase	  in	  left	  atrial	  diameters	  and	  volumes	  (Vmax,	  Vmin	  and	  Voae)	  (Nikitin	  NP	  
et	  al.,	  2003);	  
• atrial	   reservoir	   function	   doesn’t	   deteriorate	   and	   LA	   maintains	   its	   ability	   to	   dilatation	   to	  




• left	  ventricular	  relaxation	  deteriorates	  with	  age	  reducing	  the	  left	  atrial	  counduit	  function;	  
• left	  atrial	  passive	  emptying	  fraction,	  highest	  in	  young	  healthy	  subjects,	  declines	  significantly	  in	  
middle	  age	  with	  a	  further	  decline	  in	  the	  oldest	  subjects,	  confirming	  deterioration	  of	  left	  atrial	  
conduit	   function	   with	   age.	   These	   changes	   correspond	   to	   the	   well-­‐described	   age-­‐related	  
reversion	  in	  E/A	  ratio	  (Nikitin	  NP	  et	  al.,	  2003).	  
• left	  atrial	  active	  emptying	  volume	  index	  increases	  with	  age.	  This,	  in	  the	  presence	  of	  left	  atrial	  
dilatation,	   is	  probably	  a	  consequence	  of	   the	  effect	  of	   the	  Starling	  mechanism.	  An	   increase	   in	  
left	   atrial	   active	   contractile	   performance	   with	   age	   was	   further	   confirmed	   by	   a	   progressive	  
increase	  in	  left	  atrial	  kinetic	  energy,	  a	  recently	  proposed	  non-­‐invasive	  index	  of	  left	  atrial	  stroke	  
work	  (Stefanadis	  C	  et	  al.,	  1998).	  
	  
Other	  studies	  show	  that	  atrial	  size,	  active	  emptying	  volume	  and	  ejection	  force	  naturally	  increase	  with	  
aging	   (Triposkiadis	   F	   et	   al.,	   1995),	   but	   more	   recent	   data	   demonstrate	   that	   with	   normal	   aging,	  
maximum	   volume,	   minimum	   volume	   and	   total	   atrial	   contribution	   to	   LV	   SV	   are	   not	   significantly	  
altered,	   supporting	   that	   left	   atrial	   size	   does	   not	   change	   as	   a	   function	   of	   chronologic	   aging	   alone	  





3 ANIMAL	  MODELS	  IN	  CARDIOVASCULAR	  RESEARCH	  
Despite	  progress	   in	  the	  diagnosis	  and	  treatment	  of	  CHD,	  appropriate	  animal	  models	  are	  still	  crucial	  
for	   the	   investigation	   of	   the	   mechanisms	   involved	   in	   the	   pathogenesis	   and	   the	   advancement	   of	  
diagnosis	  and	  therapies	  (Gargiulo	  S	  et	  al.,	  2012).	  
Anatomic	   similarity	   in	   developmental	   and	   postnatal	   heart	   (Gargiulo	   S	   et	   al.,	   2012),	   structural	  
similarities	   and	   evolutionary	   conservation	   between	   genomes	   (Scherrer-­‐Crosbie	   M	   et	   al.,	   2008)	  
advocate	  the	  genetically	  modified	  mouse	  as	  a	  model	  of	  choice	  for	  studying	  the	  human	  cardiovascular	  
system	   (Toischer	   K	   et	   al.,	   2010;	   Joho	   S	   et	   al.,	   2007;	   James	   JF	   et	   al.,	   1998).	  Moreover,	   the	   recent	  
development	   in	   microsurgical	   instruments	   and	   technique,	   compensating	   the	   smaller	   size,	   has	  
allowed	  to	  shift	  most	  of	  animal	  surgery	  in	  cardiovascular	  research	  from	  the	  rat	  to	  the	  mouse	  (Lin	  MC	  
et	  al.,	  1995).	  Mouse,	  being	  smaller,	  is	  easy	  to	  handle	  and	  to	  house,	  have	  a	  rapid	  gestation	  period	  (21	  
days),	  and	  a	  relatively	   low	  maintenance	  costs	  (Tarnavski	  O	  et	  al.,	  2004).	   In	  addition	  mouse	  genome	  
has	   been	   extensively	   characterized,	   and	   gene-­‐targeted	   “knockout”	   and	   transgenic	   overexpression	  
experiments	   are	   currently	   performed	   using	   mice,	   rather	   than	   rats	   (Lin	   MC	   et	   al.,	   1995).	   Several	  
mouse	  models	   of	   cardiovascular	   disease	   are	   today	   available:	  models	   of	   atherothrombotic	   disease,	  
myocardial	   infarction	   by	   coronary	   ligation,	   pressure	   overload	   by	   transverse	   aortic	   constriction,	  
genetic	  or	  pharmacological	  induced	  models	  of	  dilated	  cardiomyopathy	  
Mouse	  heart,	  despite	  very	  small	  (its	  diameter	  is	  approximately	  5	  mm),	  is	  deeply	  studied,	  and	  normal	  
reference	  values	  have	  been	  established	  for	  left	  ventricle	  anatomy,	  mass	  and	  function	  (Gardin	  JM	  et	  
al.,	   1995;	   Collins	   KA	   et	   al.,	   2003),	   in	   normal	   and	   also	   in	   several	   phatological	   animal	   models.	   In	  
contrast,	  probably	  due	  to	  its	  smaller	  size,	  murine	  left	  atrium	  structure	  and	  function	  have	  never	  been	  
systematically	  evaluated.	  Only	  a	  few	  studies	  evaluate	  left	  atrium	  anatomy	  in	  rat	  model	  of	  myocardial	  
infarction	  assessing,	  for	  example,	  the	  enlargement	  of	  left	  atrium	  (Milliez	  P	  et	  al.,	  2005)	  and	  the	  effect	  
of	  a	  pharmacological	  treatment	  on	  the	  LA	  dimension	  and	  fibrosis.	  
Recently,	   specialized	   imaging	   system,	   such	   as	   high	   frequency	   echocardiography,	   have	   undergone	  
impressive	   development	   offering	   new	   approaches	   to	  murine	   heart	   investigation	   (Gardin	   JM	   et	   al.,	  





4 MYOCARDIAL	  INFARCTION	  
4.1 Patology	  
Myocardial	   infarction	   (MI)	   is	   the	  major	   cause	  of	  death	  and	  disability	  worldwide	   (Thygesen	  K	  et	  al.,	  
2007).	   It’s	   a	   result	   of	   rupture	   of	   atherosclerotic	   plaque	   which	   causes	   a	   coronary	   artery	   occlusion	  
leading	  to	  a	  significant	  reduction	  of	  blood	  flow	  and	  oxygen	  supply	  to	  the	  portion	  of	  the	  myocardium	  
subserved.	  
MI	  may	  be	  a	  minor,	  sometimes	  undetected,	  event	  in	  a	  lifelong	  chronic	  disease,	  but	  it	  can	  also	  lead	  to	  
sudden	  death	  or	  severe	  haemodynamic	  deterioration	  (Thygesen	  K	  et	  al.,	  2007).	  
The	  severity	  of	  MI	  depends	  on	  three	  factors:	  the	  position	  of	  the	  coronary	  artery	  occlusion	  (proximal	  
occlusion	   is	  more	  dangerous),	   the	  duration	  of	   the	  occlusion	   (longer	  period	  of	  vessel	  occlusion	  may	  
cause	  irreversible	  myocardial	  damage)	  and	  the	  presence	  of	  collateral	  circulation	  (Bolooki	  HM	  et	  al.,	  
2010).	  
From	   an	   anatomic	   or	   morphologic	   point	   we	   can	   distinguish	   two	   types	   of	   MI:	   transmural	   and	  
nontransmural.	  	  
A	  transmural	  MI	  is	  characterized	  by	  ischemic	  necrosis	  of	  the	  total	  wall	  thickness,	  extending	  from	  the	  
endocardium	  through	  the	  myocardium	  to	  the	  epicardium	  in	  contrast	  with	  a	  nontransmural	  MI.	   In	  a	  
nontransmural	  MI	  the	  area	  of	  ischemic	  necrosis	  is	  limited	  to	  the	  endocardium	  and	  subendocardium	  
because	   these	   zones	   are	   the	   least	   perfused	   regions	   of	   the	   heart	   and	   so	   the	   most	   vulnerable	   to	  
conditions	  of	  ischemia.	  
Myocardial	  infarction	  is	  also	  classified	  by	  the	  clinical	  setting	  into	  various	  subtypes:	  
• spontaneous	   and	   related	   to	   ischemia	   from	   a	   primary	   coronary	   event	   (e.g.,	   plaque	   rupture,	  
thrombotic	  occlusion);	  
• secondary	  to	  ischemia	  from	  a	  supply-­‐and-­‐demand	  mismatch;	  
• resulting	  in	  sudden	  cardiac	  death;	  
• associated	  with	  percutaneous	  coronary	  intervention;	  
• associated	  with	  in-­‐stent	  thrombosis;	  
• associated	  with	  coronary	  artery	  bypass	  surgery	  (Thygesen	  K	  	  et	  al.,	  2007).	  
A	  more	  common	  clinical	  diagnostic	  classification	  scheme	  is	  based	  on	  electrocardiographic	  findings	  as	  
a	  mean	  of	  distinguishing	  between	  two	  types	  of	  MI,	  one	  that	   is	  marked	  by	  ST	  elevation	  (STEMI)	  and	  
one	  that	  is	  not	  (NSTEMI).	  	  
STEMI	  is	  usually	  the	  result	  of	  complete	  coronary	  occlusion	  after	  plaque	  rupture,	  instead	  NSTEMI	  with	  




and	  morbidity	  seen	  in	  STEMI	  and	  the	  eventual	  equalization	  of	  mortality	  between	  STEMI	  and	  NSTEMI	  
after	  1	  year	  (Andreson	  J	  et	  al.,	  2007).	  
4.2 Symptoms	  And	  Detection	  
The	   ischemic	   symptoms	   are	   diffuse,	   not	   localized,	   not	   positional,	   not	   affected	   by	  movement.	   The	  
discomfort	   lasts	   at	   least	   20	   mins	   and	   occurs	   at	   chest,	   upper	   extremity,	   or	   epigastric	   at	   rest	   or	  
exertion.	  Often,	  these	  principal	  symptoms	  may	  be	  accompanied	  by	  dyspnoea,	  diaphoresis,	  nausea,	  or	  
syncope	   which	   are	   not	   specific	   to	   MI	   and	   can	   be	   misdiagnosed	   and	   thus	   attributed	   to	  
gastrointestinal,	  neurological,	  pulmonary,	  or	  musculoskeletal	  disorders	  (Thygesen	  K	  et	  al.,	  2007).	  
Sometimes	   MI	   can	   be	   occur	   without	   symptoms	   and	   detected	   only	   by	   biomarkers	   elevations,	  
electrocardiographic	  changes	  or	  cardiac	  imaging	  (Thygesen	  K	  et	  al.,	  2007).	  
	  
a)	  biomarker	  evaluation	  
Cardiomyocytes	  damage	  and	  death	  can	  be	  recognized	  by	  the	  release	  in	  circulatory	  system	  of	  several	  
proteins	   such	   as	   myoglobin,	   cardiac	   troponin	   T	   and	   I,	   Creatin	   Kinase-­‐MB	   (CKMB)	   and	   lactate	  
dehydrogenase	  (LDH)	  (Jaffe	  AS	  et	  al.,	  2000).	  
Although	   elevations	   in	   these	   biomarkers	   reflect	   myocardial	   necrosis,	   they	   do	   not	   indicate	   its	  
mechanism	  and	  causes	  (Jaffe	  AS	  et	  al.,	  2000;	  Jaffe	  AS	  et	  al.,	  2006);	  in	  fact,	  in	  the	  absence	  of	  clinical	  
evidence	   of	   ischemia,	   an	   elevated	   value	   of	   cardiac	   troponin,	   that	   is	   index	   of	  myocardial	   necrosis,	  
should	   indicate	   other	   pathologies	   such	   as	   myocarditis,	   aortic	   dissection,	   pulmonary	   embolism,	  
congestive	  heart	  or	  renal	  failure.	  
If	   troponin	   assays	   are	   not	   available,	   the	   best	   alternative	   is	   CKMB	   (measured	   by	   mass	   assay).	  
Measurement	  of	  total	  CK	  is	  not	  recommended	  for	  the	  diagnosis	  of	  MI	  because	  of	  the	  large	  skeletal	  
muscle	  distribution	  and	  the	  lack	  of	  specificity	  of	  this	  enzyme	  (Thygesen	  K	  et	  al.,	  2007).	  
	  
b)	  electrocardiographic	  (ECG)	  detection	  	  
In	  patients	  with	  suspected	  MI,	  the	  ECG	  can	  be	  used	  as	  diagnostic	  system	  even	  if	  it’s	  not	  able	  alone	  to	  
identify	   an	   ischemic	   event	   because	   of	   confounding	   condition	   (The	   Joint	   European	   Society	   of	  
Cardiology/American	  College	  of	  Cardiology	  Committee,	  2000;	  Luepker	  RV	  et	  al.,	  2003;	  Antman	  EM	  et	  
al.,	  2004,	  Braunwald	  E	  et	  al.,	  2002).	  
MI	  may	  be	  characterized	  by	  ECG	  abnormalities	  in	  PR	  segment,	  QRS	  complex,	  ST	  segment	  or	  T-­‐waves	  
(Holland	  RP	  et	  al.,	  1975;	  Richeson	  JF	  et	  al.,	  1978).	  
Increased	  T-­‐wave	  amplitude	  with	  prominent	  symmetrical	  T-­‐waves	  is	  an	  early	  sign	  that	  may	  precede	  




Instead,	   increased	   R-­‐wave	   amplitude	   and	   width	   (giant	   R-­‐wave	   with	   S-­‐wave	   diminution)	   are	   often	  
seen	   in	   leads	  exhibiting	  ST	  elevation,	  and	   tall	  T-­‐waves	   reflecting	  conduction	  delay	   in	   the	   ischaemic	  
myocardium	  (Ekmekci	  A	  et	  al.,	  1961).	  
Transient	  Q	  waves	  may	  be	  observed	  during	  an	  episode	  of	  acute	  ischaemia	  or	  rarely	  during	  acute	  MI	  
with	  successful	  reperfusion	  (Matetzky	  S	  et	  al.,	  1995).	  
The	   presence	   of	   Q	   waves	   or	   ST	   segment	   elevation	   is	   associated	   with	   higher	   early	   mortality	   and	  




Figure	   5.	   Chematic	   representation	   of	   ECG	   wave.	   P	   wave	   represents	   the	   atria	   depolarization;	   complex	   QRS	  
represent	  the	  ventricular	  depolarization	  and	  T	  wave	  represents	  the	  repolarization	  of	  the	  ventricles.	  
	  
4.3 Remodeling	  Process	  
During	  the	  first	  minutes	  to	  hours	  after	  infarction,	  the	  balance	  between	  oxygen	  supply	  and	  demand	  is	  
a	  dynamic	  one,	  and	  the	   final	   size	  of	   the	   infarct	  can	  be	   influenced	  by	  changes	   in	   loading	  conditions	  
and	  by	  pharmacologic	  agents	   (Maroko	  PR	  et	  al.,	  1971;	  Miura	  T	  et	  al.,	  1987).	  During	  this	  period	  the	  
heart	  gradually	   loses	   its	  ability	  to	  generate	  systolic	  force	  (Holmes	  JW	  et	  al.,	  2005)	  and	  the	  ischemic	  
myocardium	  behaves	   as	   a	   passive	   elastic	  material,	   displaying	   stretching	   and	   thinning	   during	   filling	  
and	   isovolumic	   contraction,	   then	   recoiling	   passively	   during	   ejection	   and	   isovolumic	   relaxation	  
(Tennant	  R	  et	  al.,	  1935;	  Tyberg	  JV	  et	  al.,	  1974;	  Villarreal	  FJ	  et	  al.,	  1991).	  Several	  hours	  after	  ischemic	  
event	  the	  infarct	  region	  begins	  to	  stiffen	  loosing	  in	  compliance	  and	  contractility.	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After	  infarction	  three	  different	  phases	  can	  be	  recognized:	  necrotic	  (myocyte	  death	  and	  inflammatory	  
response),	  fibrotic	   (fibroblast	  proliferation	  and	  collagen	  deposition)	  and	  remodeling	  (left	  ventricular	  
enlargement	  and	  thinning	  of	  infarcted	  region).	  
Depending	  on	  the	  species,	  this	  entire	  process	  is	  completed	  within	  weeks	  to	  months	  (Fishbein	  MC	  et	  
al.,	  1978).	  
	  
Figure	   6.	   	   Comparative	   diagram	  of	   the	   temporal	   course	   of	   the	   phases	   of	   healing	   defined	   for	   various	   animal	  
models	  (Holmes	  J.W.	  et	  al.,	  2005).	  
	  
Necrotic	  phase	  begins	  within	  a	  few	  hours,	  when	  the	  infarct	  heart	  stiffens,	  and	  ends	  when	  the	  number	  
of	   fibroblasts	   and	   amount	   of	   new	   collagen	   begin	   to	   increase	   rapidly	   in	   the	   healing	   infarct	  
(approximately	   7	   days	   after	   infarction	   in	   the	   human	   (Fishbein	   MC	   et	   al.,	   1978)	   and	   5	   days	   after	  
infarction	  in	  the	  rat	  (Fishbein	  MC	  et	  al.,	  1978).	  
This	   phase	   involves	   (Fishbein	  MC	   et	   al.,	   1978)	   cardiomyocyte	   death,	   degradation	   of	   normal	   ECM,	  
invasion	   of	   inflammatory	   cells	   at	   the	   site	   of	   initial	   injury,	   and	   the	   induction	   of	   pro-­‐inflammatory	  
cytokines	   and	   chemokines,	   such	   as	   interleukin	   IL-­‐1,	   IL-­‐6,	   IL-­‐8	   and	   tumor	   necrosis	   factor	   α	   (TNFα)	  
(Frangogiannis	  NG	  et	  al.,	   2002;	  Frangogiannis	  NG	  et	  al.,	   2005).	  Degradation	  of	   the	  ECM	  during	   the	  
acute	  phase	  is	  considered	  to	  be	  an	  essential	  event	  that	  allows	  for	  the	  ingress	  of	  inflammatory	  cells	  as	  
well	   as	   proliferation	   and	   maturation	   of	   macrophages	   and	   fibroblasts,	   and	   provides	   the	   necessary	  
substructure	  for	  scar	  formation	  (Spinale	  FG,	  2007).	  
Necrosis	   is	   then	   followed	   by	   fibrotic	   phase,	   that	   begins	   when	   the	   number	   of	   fibroblasts,	   most	  
prevalent	   resident	  myocardial	   cell	   type	   (Porter	  KE	  et	   al.,	   2009;	   van	  Nieuwenhoven	  FA	  et	  al.,	   2012)	  
and	   directly	   involved	   in	   this	   process,	   and	   amount	   of	   new	   collagen	   in	   the	   healing	   infarct	   rapidly	  
increase,	  and	  ends	  when	  collagen	  accumulation	  slows.	  This	  response	  is	  essential	  to	  replace	  the	  areas	  
devoid	  of	  cardiomyocytes	  and	  prevent	  rupture	  of	  the	  myocardial	  wall.	  
Fibrotic	   process	   is	   a	   long-­‐term	   phase	   of	   proliferation	   and	   differentiation	   of	   fibroblast	   in	  
myofibroblast,	   cells	   involved	   in	   deposition	   of	   new	   ECM	   components	   (fibronectin,	   laminin	   and	  
collagen	  type	  IV	  (Knowlton	  AA	  et	  al.,	  1992;	  Ulrich	  MM	  et	  al.,	  1997;	  Morishita	  N	  et	  al.,	  1996)	  forming	  a	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of the ischemic region also depresses global ventricular function through a second
mechanism not explicitly incorporated in simple compartmental models. Reduced
systolic ejection eventually leads to a new steady state in which systolic and dias-
tolic volumes are increased relative to control and ejection fraction is depressed,
in other words, to global ventricular dilation (78). Dilation places the noninfarcted
myocardium at a mechanical disadvantage, with higher systolic stresses required
to eject against a given pressure.
In addition to the impact of systolic stretching of the infarct region, studies of
regional function during acute ischemia have indicated that the extent of regional
dysfunction extends beyond the region of reduced blood flow, creating a functional
border zone (31). Recently, a combination of modeling and experimental studies
have shown that border zone dysfunction can be explained by physical coupling
to the ischemic region (79) and elevated border zone stresses (80–83), without
postulating reduced contractility.
THE NECROTIC PHASE
During the first few days after infarction, the dominant pathologic processes are
inflammation and necrosis. We define the necrotic phase as beginning within a
few hours, when the infarct begins to stiffen, and ending when the number of
fibroblasts and amount of new collagen begin to increase rapidly in the healing
infarct [approximately 7 days after infarction in the human (41) and 5 days after
infarction in the rat (40) (Figure 4)]. Infarct rupture is most common during this
period (14, 15). Given that the infarcted muscle is dead and undergoing necrosis,
and significant new collagen has not yet been deposited, it is perhaps surprising
Figure 4 Comparative diagram of the temporal course of the phases of healing de-
fined in this review for various animal models. Time course for other large animal
models is similar to that for dog. Please see text for definition of phases and primary






































































































scaffold	  for	  new	  type	  I	  and	  III	  collagen	  which	  is	  the	  primary	  determinant	  of	  scar	  formation,	  structural	  
and	  mechanical	  changes	  establishing	  after	  MI.	  
While	  historically	   considered	  a	   static	   structure,	   it	   is	  now	  becoming	   recognized	   that	   the	  myocardial	  
ECM	   is	   a	   complex	   microenvironment	   containing	   a	   large	   portfolio	   of	   matrix	   proteins,	   signaling	  
molecules,	   proteases,	   and	   cell	   types	   that	   play	   a	   fundamental	   role	   in	   the	   myocardial	   remodeling	  
process	   (Spinale	   FG,	   2007).	   An	   adequately	   balance	   in	   ECM	   degradation	   and	   accumulation	   is	  
fundamental	  for	  outcome.	  
Post	   infarction	   remodeling	   and	   changes	   involve	   globally	   the	   left	   ventricle	   (MI	   region,	   the	   viable	  
myocardium	  within	  the	  border	  zone	  and	  the	  remote	  region)	  with	  progressive	  ventricular	  architecture	  
alterations	  in	  infarcted	  and	  non-­‐infarcted	  regions.	  Typically,	  after	  initial	  inflammatory	  responses	  and	  
scar	   formation,	   LV	   chamber	   volume	   increases	   and	   a	   distortion	   of	   ventricular	   shape	   occurs	   (it	  
becomes	   less	   elliptical	   and	  more	   spherical)	   to	  maintain	  or	   improve	   cardiac	  output	   (Cohn	   JN	  et	   al.,	  
2000).	  
In	  MI	  region	  the	  ventricular	  remodeling	  is	  associated	  with	  anterior	  wall	  thinning	  in	  particular	  at	  apex	  
(Bozkurt	  E	  et	  al.,	  2007)	  and	  the	  slippage	  of	  myocyte	  fascicles	  (Anversa	  P	  et	  al.,	  1991;	  Olivetti	  G	  et	  al.,	  
1990;	  Weisman	  HF	  et	  al.,	  1988).	  The	  late	  change	  in	  left	  ventricle	  dimension	  is	  due	  to	  lengthening	  of	  
contractile	   tissue	   (remote	   region)	   rather	   than	   further	   expansion	   of	   the	   infarcted,	   non-­‐contractile	  
segment.	  	  
With	  regard	  to	  the	  remote	  region,	  the	  uncompensated	  mechanical	  overload	  prompt	  increased	  ECM	  
deposition	  which	  occurs	  between	  hypertrophied,	  viable	  cardiac	  myocytes	  and	  fascicles	  (Jugdutt	  BI	  et	  
al.,	  1986;	  McCormick	  RJ	  et	  al.,	  1994;	  Peterson	  DJ	  et	  al.,	  1999;	  Volders	  PG	  et	  al.,	  1993;	  Zimmerman	  SD	  
et	   al.,	   2004)	   leading	   to	   progressive	   functional	   deterioration,	   including	   myocardial	   fibrosis	   and	  
ventricular	  dilatation,	  and	  ultimately	  to	  heart	  failure	  or	  death	  if	  untreated	  (Tsuda	  T	  et	  al.,	  2012).	  
4.3.1 Extracellular	  Matrix	  
Deposition	   of	   ECM	   proteins	   and	   their	   increased	   gene	   expression	   after	   MI	   play	   critical	   role	   in	   MI	  
outcome;	   a	   rat	  model	   of	  MI	  was	   use	   to	   describe	   this	  modifications	   (Stanton	   LW	   et	   al.,	   2000)	   and	  
technological	  advances	  in	  the	  production	  of	  cDNA	  microarrays	  have	  made	  it	  possible	  to	  profile	  gene	  
expression	  of	   tens	  of	   thousands	  of	  genes	   simultaneously	   (Duggan	  DJ	  et	  al.,	   1999;	  Brown	  PO	  et	  al.,	  
1999).	   Stanton	   and	   colleagues	   studied	   the	   gene	   pattern	   expression	   separately	   in	   infarcted	   and	   in	  
interventricular	  septum	  (IVS)	  regions	  showing	  an	  enhance	  expression	  both	  in	  infarcted	  region	  and	  in	  
IVS	   over	   normal	   myocardium	   for	   a	   large	   number	   of	   genes	   that	   encode	   ECM	   proteins	   such	   as	  
fibronectin,	   laminin,	   fibrillin,	   fibulin,	   and	   decorin,	   all	   proteins	   conferring	   stiffness	   to	   LV	   increasing	  
ventricular	   dysfunction	   and	   incidence	   of	   cardiac	   rupture.	   Moreover,	   Shuttleworth	   and	   colleagues	  




collagens	   and	   in	   tissue	   remodeling	   (Shuttleworth	   CA,	   1997).	   Stability	   and	   orientation	   of	   the	  
myocardial	  ECM	  are	  finely	  regulated	  by	  balanced	  control	  of	  degradation	  and	  deposition	  of	  different	  
ECM	   components	   by	   members	   of	   the	   matrix	   metalloproteinase	   (MMP)	   family	   (Spinale	   FG,	   2007).	  
TIMPs,	   metalloproteinase	   inhibitors,	   are	   regulators	   of	   MMPs	   in	   that	   they	   inhibit	   the	   activated	  
enzyme	  and	  prevent	  proteolytic	  activity	  of	  MMPs	  and	  degradation	  of	  ECM.	  	  	  
	  
4.4 Pharmacological	  Treatments	  	  
The	  main	   goals	   of	   pharmacological	   treatments	   are	   the	   restoration	   of	   normal	   coronary	   artery	   flow	  
and	  the	  maximum	  salvage	  of	  functional	  myocardium	  (Andreson	  J	  et	  al.,	  2007).	  than	  can	  be	  reached	  
limiting	   infarct	   size	   and	   preserving	   ischemic	   myocardium	   to	   minimize	   infarct	   expansion	   and	  
ventricular	  dilatation,	  improving	  long-­‐term	  prognosis.	  
Unfortunately	  the	  primary	  obstacles	  to	  achieving	  these	  goals	  are	  not	  the	  low	  efficacy	  of	  drug,	  but	  the	  
patient's	   failure	   to	   recognize	   MI	   symptoms	   quickly	   and	   the	   delay	   in	   seeking	   medical	   attention	  
(Andreson	  J	  et	  al.,	  2007).	  	  
4.4.1 Fibrinolytics	  
Coronary	   blood	   flow	   in	  MI	   patients	   can	   be	   restored	   pharmacologically	  with	   the	   use	   of	   fibrinolytic	  
agents.	   The	  most	   critical	   variable	   in	   achieving	   successful	   clinically	   relevant	   fibrinolysis	   is	   time	   from	  
symptom	  onset	   to	  drug	   administration.	   In	   fact	   the	   fibrinolytic	   therapy	   is	  most	   effective	  within	   the	  
first	  hour,	  when	  the	  door-­‐to-­‐needle	  time	  is	  30	  minutes	  or	  less	  and	  it	  is	  indicated	  for	  patients	  with	  a	  
STEMI	  within	  12	  hours.	  
In	  these	  patients	  the	  plasminogen	  activators	  have	  been	  shown	  to	  restore	  normal	  coronary	  blood	  flow	  
in	  50%	  to	  60%	  of	  patient	  (Bolooki	  HM	  et	  al.,	  2010).	  
The	   successful	   use	   of	   fibrinolytic	   agents	   provides	   a	   definite	   survival	   benefit	   that	   is	  maintained	   for	  
years	  (Antman	  E	  et	  al.,	  2008).	  
Absolute	   contraindications	   to	   fibrinolytic	   therapy	   include	   history	   of	   intracranial	   hemorrhage,	  
ischemic	   stroke	   or	   head	   injury	   within	   the	   past	   3	  months,	   presence	   of	   an	   intracranial	   malignancy,	  
signs	  of	  an	  aortic	  dissection,	  or	  active	  bleeding	  (Bolooki	  HM	  et	  al.,	  2010).	  
4.4.2 Antiplatelet	  Agents	  
The	  rupture	  of	  an	  atherosclerotic	  plaque	  and	  the	  persistent	  thrombotic	  occlusion	  may	  result	  in	  acute	  
MI,	  so	  antiplatelet	  agents	  can	  play	  pivotal	  role	  as	  drugs	  of	   first	  choice.	  Relevantly	  aspirin	  alone	  has	  
been	  shown	  to	  reduce	  dramatically	  MI	  mortality	  (Andreson	  et	  al.,	  2007;	  Antman	  et	  al.,	  2008).	  




thromboxane	  A2.	  Within	  minutes,	  aspirin	  prevents	  additional	  platelet	  activation	  and	  interferes	  with	  
their	  adhesion	  and	  cohesion.	   Its	  beneficial	  effect	   is	  observed	  early	   in	  therapy	  and	  persists	  for	  years	  
with	  continued	  use.	  Accordingly	  to	  the	  ACC/AHA	  2007	  guidelines,	  aspirin	  in	  a	  dose	  of	  325	  mg	  should	  
be	  administered	  immediately	  on	  recognition	  of	  MI	  signs	  and	  symptoms	  and	  the	  long-­‐term	  benefit	  is	  
sustained,	  even	  at	  doses	  as	  low	  as	  75	  mg/day	  (Andreson	  et	  al.,	  2007;	  Antman	  et	  al.,	  2008).	  
Clopidogrel,	  a	  drug	  of	  a	  different	  class	  of	  oral	  antiplatelet	  agents,	  blocks	  the	  P2Y12	  component	  of	  the	  
adenosine	   diphosphate	   receptor,	   inhibiting	   platelet	   activation	   and	   aggregation	   (Quinn	   MJ	   et	   al.,	  
1993).	   Clopidogrel	   reduces	   the	   risk	   of	   death	   and	   cardiovascular	   complications	   in	   patients	   with	  
symptomatic	  atherosclerotic	  disease,	  in	  the	  setting	  of	  percutaneous	  coronary	  intervention	  (PCI),	  and	  
in	  patients	  with	  unstable	  angina	  or	  NSTEMI	   (CAPRIE	  Steering	  Committee,	  1996;	  Steinhubl	  SR	  et	  al.,	  
2002;	  Yusuf	  S	  et	  al.,	  2001).	  	  
The	   CLARITY-­‐TIMI	   28	   study	   (Clopidogrel	   as	   Adjunctive	   Reperfusion	   Therapy—Thrombolysis	   in	  
Myocardial	   Infarction	   28)	   	   showed	   a	   benefit	   in	   favor	   of	   clopidogrel	   respect	   to	   placebo(in	   patients	  
receiving	  fibrinolytics	  within	  12	  hours	  of	  STEMI).	  Clopidogrel	  was	  most	  effective	  in	  reducing	  the	  rate	  
of	  occluded	   infarct-­‐related	  artery	  and	  recurrent	  myocardial	   infarction,	  but	  had	  no	  significant	  effect	  
on	  all-­‐cause	  mortality	  (Sabatine	  MS,	  2006).	  
Clopidogrel	   also	   increased	   the	   odds	   of	   achieving	   optimal	   epicardial	   flow	   and	   optimal	   myocardial	  
reperfusion	  and	  reduced	  the	  odds	  of	  intracoronary	  thrombus	  (Sabatine	  MS,	  2006).	  
4.4.3 Nitrates	  
Nitrates	   treatment	   in	   patients	   with	   myocardial	   infarction	   limits	   infarct	   size,	   left	   ventricular	  
remodeling,	  infarct	  expansion,	  infarct	  related-­‐complications	  and	  reduce	  mortality	  for	  up	  to	  1	  year.	  
Intravenous	  nitrates	  should	  be	  administered	  to	  patients	  with	  acute	  coronary	  syndromes,	  congestive	  
heart	   failure,	   persistent	   ischemia,	   or	   large	   anterior	  wall	  MI	   (Andreson	   et	   al.,	   2007;	   Antman	   et	   al.,	  
2008).	  
Also	  when	  administered	  sublingually,	  nitroglycerin	  has	  a	  rapid	  onset	  of	  action	  and	  some	  clinical	  trial	  
data	  have	  supported	  the	  initial	  use	  of	  nitroglycerin	  for	  up	  to	  48	  hours	  in	  MI.	  	  
Nitrates	   are	   metabolized	   in	   the	   vascular	   to	   nitric	   oxide,	   which	   is	   active	   relaxing	   vascular	   smooth	  
muscle	  producing	  a	  vasodilatation	  effect.	  
As	   response	   occurred	   a	   dilatation	   of	   large	   coronary	   arteries	   and	   arterioles,	   which	   may	   lead	   to	  
increased	   perfusion	   of	   ischemic	   myocardium	   and	   a	   dilatation	   of	   the	   venous	   and	   arterial	   system,	  
reducing	   respectively	   cardiac	   preload	   and	   afterload	   and	   decreasing	   the	   myocardial	   oxygen	  
requirements	   needed	   for	   circulation	   at	   a	   fixed	   flow	   rate.	   Vasodilatation	   of	   the	   coronary	   arteries	  
improves	   blood	   flow	   through	   the	   partially	   obstructed	   vessels	   as	  well	   as	   through	   collateral	   vessels.	  




HM	  et	  al.,	  2010).	  
Despite	   these	   positive	   results,	   the	   large	   GISSI-­‐3	   trial	   (Gruppo	   Italiano	   per	   lo	   Studio	   della	  
Sopravvivenza	  nell’infarto	  Miocardico)	  and	  ISIS	  4	  (Fourth	  International	  Study	  of	  Infarct	  Survival)	  failed	  
to	   show	   a	   significant	   mortality	   benefit	   in	   patients	   treated	   with	   nitrates	   after	   acute	   myocardial	  
infarction.	  This	  may	  have	  been	  due	  to	  a	  null	  bias	  related	  to	  extensive	  use	  of	  non-­‐study	  nitrates	  and	  
also	   to	   the	   limited	   efficacy	   of	   the	   nitrate	   regimens	   used.	   However,	   there	   may	   be	   a	   true	   lack	   of	  
additionally	   efficacy	   of	   routine	   nitrate	   therapy	  when	   used	   concurrently	  with	   thrombolysis,	   aspirin,	  
ACE	   inhibitors,	   and	  ß-­‐blockers.	  Although	   routine	   intravenous	  nitroglycerin	  may	  be	  used	  during	   the	  
first	  24	  hours	  after	  myocardial	  infarction,	  nitrates	  are	  not	  recommended	  routinely	  beyond	  this	  time	  
except	  for	  specific	  indications,	  which	  include	  persistent	  ischemia,	  hypertension,	  or	  heart	  failure.	  
Low	  blood	  pressure,	  headache,	  and	  tachyphylaxis	  limit	  the	  use	  of	  nitroglycerin.	  Nitrate	  tolerance	  can	  
be	   overcome	  by	   increasing	   the	   dose	   or	   by	   providing	   a	   daily	   nitrate-­‐free	   interval	   of	   8	   to	   12	   hours.	  
Nitrates	   must	   be	   avoided	   in	   patients	   who	   have	   taken	   a	   phosphodiesterase	   inhibitor	   within	   the	  
previous	  24	  hours	  (Andreson	  et	  al.,	  2007).	  
4.4.4 Beta-­‐Blockers	  
Beta-­‐blockers	  are	  beta-­‐adrenergic	  antagonist	  drugs	  with	  different	  actions	  on	  heart,	  slowing	  the	  heart	  
rate,	   reducing	  myocardial	   contractility	   and	   lowering	   the	   systemic	   blood	  pressure.	   In	  MI	   conditions	  
these	   effects	   may	   be	   beneficial	   reducing	   myocardial	   workload,	   contraction	   and	   oxygen	   demand	  
minimizing	  myocardial	   injury	   and	   death.	   Furthermore,	   beta-­‐blockers	  may	   reduce	   the	   incidence	   of	  
ventricular	   recurrent	   ischemia,	   re-­‐infarction,	  and,	   if	  given	  early	  enough,	   infarct	   size	  and	  short-­‐term	  
mortality	  (Andreson	  et	  al.,	  2007;	  Antman	  et	  al.,	  2008).	  
Administration	   of	   intravenous	   beta-­‐blockers	   within	   12	   to	   24	   hours	   of	   infarction,	   followed	   by	   oral	  
therapy,	  has	  been	  found	  to	  reduce	  the	  mortality	  rate	  approximately	  13	  percent	  within	  the	  first	  week	  
of	   infarction.	   Studies	   indicate	   that	   the	  most	  marked	   reduction	   (25	  %)	   occurs	   in	   the	   first	   two	   days	  
after	  infarction	  (Yusuf	  S	  et	  al.,	  1988).	  	  
Use	   of	   beta-­‐blocker	  within	   days	   to	  weeks	   after	   infarction	   and	   continuation	   of	   therapy	   for	   periods	  
ranging	  from	  several	  months	  to	  three	  years	  was	  found	  in	  randomized	  trials	  to	  reduce	  total	  mortality,	  
nonfatal	  myocardial	   infarction	  and	  sudden	  death	  by	  approximately	  20	  to	  30	  percent	  (Yusuf	  S	  et	  al.,	  
1985).	  	  
The	  use	  of	  a	  beta	  -­‐blocker	  has	  a	  number	  of	  recognized	  adverse	  effects.	  The	  most	  serious	  are	  heart	  
failure,	  bradycardia,	  and	  bronchospasm.	  During	  the	  acute	  phase	  of	  an	  MI,	  beta-­‐blocker	  therapy	  may	  
be	   initiated	   intravenously;	   later,	   patients	   can	   switch	   to	   oral	   therapy	   for	   long-­‐term	   treatment.	   The	  
COMMIT-­‐CCS	  2	  trial	  raised	  safety	  concerns	  about	  the	  use	  of	  early	  intravenous	  beta-­‐blockers	  in	  high-­‐




4.4.5 Renin-­‐Angiotensin-­‐Aldosterone	  System	  (RAAS)	  
The	  renin-­‐angiotensin-­‐aldosterone	  system	  (RAAS)	  has	  a	  central	   role	   in	  regulating	  systemic	  pressure	  
working	  on	  vascular	  resistance	  and	  fluid	  and	  electrolyte	  balance.	  
RAAS	  is	  activated	  in	  response	  to	  a	  decrease	  in	  renal	  perfusion	  pressure	  (hypotension	  condition)	  salt	  
depletion,	  and	  ß1	  adrenergic	  stimulation,	  and	  in	  particular,	  renin,	  a	  protease	  produced	  by	  the	  kidney	  
juxtaglomerular	   cells,	   is	   released	   in	   the	   blood.	   Renin	   cleaves,	   in	   a	   rate-­‐limited	   process,	  
angiotensinogen,	   which	   is	   a	   circulating	   protein,	   synthesized	   by	   liver,	   to	   form	   angiotensin	   I	   (Ang	   I)	  
which	  is	  relatively	  inactive.	  Ang	  I	  activity	  is	  increased	  100-­‐fold	  when	  it	  is	  converted	  to	  angiotensin	  II	  
(Ang	   II)	   by	   the	   angiotensin-­‐converting	   enzyme	   (ACE)	   (Cheung	   BM,	   2002).	   Non-­‐ACE	   pathways	   also	  
exist	  and	  modulate	  the	  production	  of	  Ang	  II.	  Ang	  II	   inhibits	  renin	  secretion,	  via	  a	  negative	  feedback	  
loop	  (Campbell	  DJ,	  1987).	  
Ang	   II	   is	   a	   potent	   stimulant	   for	   the	   contraction	   of	   vascular	   smooth	   muscle	   and	   stimulates	   the	  
synthesis	  and	  release	  of	  aldosterone	  from	  the	  adrenal	  cortex.	  Aldosterone	  increases	  the	  absorption	  
of	   sodium	  and	  excretion	  of	  potassium	   in	   the	  distal	   tubules	  and	  collecting	  ducts	  of	  nephrons	   in	   the	  
kidney,	  increasing	  volemia,	  cardiac	  pre-­‐loading	  and	  also	  systemic	  pressure	  (Cheung	  BM,	  2002).	  	  
Moreover,	   increased	   serum	   levels	   of	   Ang	   II	   are	   seen	   in	   patients	   with	   cardiovascular	   diseases	  
associated	  with	  myocardial	  fibrosis,	  including	  atherosclerosis,	  hypertension,	  cardiac	  hypertrophy	  and	  
heart	  failure	  (Kim	  S	  et	  al.,	  2000;	  Brasier	  AR	  	  et	  al.,	  2002;	  Zhao	  Q	  et	  al.,	  2004).	  	  
The	  cardiac	  effects	  of	  prolonged	  Ang	  II	  stimulation	  have	  been	  well	  documented	  and	  include	  marked	  
cardiac	  hypertrophy	  and	  interstitial	  fibrosis	  (Iwai	  N	  et	  al.,	  1995).	  
Some	   experimental	   studies	   investigated	   the	   role	   of	   Ang	   II	   in	   cardiac	   hypertrophy	   and	   fibrosis.	   In	  
particular	  Ang	  II	  given	  exogenously	  to	  rodents	  has	  been	  shown	  to	  result	  in	  cellular	  changes	  within	  the	  
myocardium,	  hypertrophy	  and	  eventual	  fibrosis,	  similar	  to	  that	  seen	  in	  humans	  (Billet	  S	  et	  al.,	  2008;	  
Harada	  K	  et	  al.,	  1998;	  Li	  HL	  et	  al.,	  2007;	  Liu	  J	  et	  al.,	  2003).	  
Ang	  II	  activity	  is	  mediate	  by	  two	  major	  receptor	  subtypes,	  AT1	  and	  AT2	  G-­‐coupled	  receptor,	  both	  of	  
which	  are	  expressed	  in	  the	  heart,	  kidney,	  SNCs	  and	  brains	  (Ozono	  R	  et	  al.,	  2000).	  
It	  has	  been	  suggested	  that	  AT1	  receptor	  signaling	  mediates	  vasoconstriction,	  aldosterone	  secretion	  
and	  promotes	  cardiomyocyte	  hypertrophy,	  upregulates	  TGFb1,	  which	  stimulates	  the	  expression	  and	  
deposition	  of	  collagen	  type	  I	  and	  type	  III,	  and	  induces	  fibrosis	  through	  its	  action	  on	  cardiac	  fibroblasts	  
proliferation	   and	   matrix	   metalloproteinase	   (Casaclang-­‐Verzosa	   et	   al.,	   2008).	   All	   these	   evidences	  
suggest	  AT1	  receptor	  as	  a	  mediator	  of	  the	  progression	  of	  LV	  remodeling.	  
Experimental	   studies	   showed	   that	   AT1	   knockout	  mice	   have	   severe	   cardiac	   developmental	   defects	  
and	   increased	  mortality	   (Tsuchida	   S	   et	   al.,	   1998).	   Interestingly,	   isolated	   AT1A	   knockout	  mice	   have	  




al.,	   1998).	   Animals	   overexpressing	   AT1-­‐receptors	   exhibit	   marked	   cardiac	   hypertrophy	   and	   fibrosis	  
(Sadoshima	  J	  et	  al.,	  1993).	  
Clinical	   studies	   have	   also	   demonstrated	   that	   the	   AT1-­‐receptor	   (particularly	   AT1A)	   is	   largely	  
responsible	   for	   many	   of	   the	   pathological	   effects	   of	   Ang	   II	   (Studer	   R	   et	   al.,	   1994).	   These	   findings	  
exemplify	  the	  importance	  of	  AT1-­‐receptors	  in	  mediating	  cellular	  growth	  and	  in	  causing	  hypertrophy	  
and	  fibrosis	  during	  remodeling.	  
The	   AT2-­‐receptor	   is	   currently	   regarded	   as	   having	   opposite	   effects	   to	   the	   AT1-­‐receptor.	   Animal	  
studies	   have	   revealed	   that	   stimulation	   of	   the	   AT2-­‐receptor	   results	   in	   suppression	   of	   myocardial	  
hypertrophy	  (Booz	  GW	  et	  al.,	  1996),	  fibroblast	  proliferation	  (Tsutsumi	  Y	  et	  al.,	  1998)	  and	  vascular	  cell	  
hyperplasia	  (Jin	  XQ	  et	  al.,	  2002).	  
In	   addition,	   genetically	   engineered	  mice	  with	   selective	   deletion	   of	   the	   AT2	   subtype	   demonstrated	  
enhanced	  interstitial	  fibrosis	  and	  left	  ventricular	  hypertrophy	  (LVH);	  the	  converse	  was	  the	  case	  with	  
selective	  up-­‐regulation	  of	  this	  receptor.	  
Modulation	  of	  RAAS	  has	  long	  been	  acknowledged	  as	  a	  target	  of	  pharmacologic	  treatment	  for	  primary	  
and	   secondary	   prevention	   of	   cardiovascular	   outcomes	   (Unger	   T,	   2002;	   Brown	   B	   et	   al.,	   2005;	  
Schmieder	  R	  et	  al.,	  2007;	  Chu	  KY	  et	  al.,	  2009).	  The	  two	  most	  widely	  used	  classes	  of	  agents	  that	  target	  
the	   RAAS	   are	   angiotensin-­‐converting	   enzyme	   inhibitors	   (ACEIs)	   and	   angiotensin	   receptor	   blockers	  
(ARBs),	  which	  activity	   improves	   cardiac	   remodeling	   and	  outcomes	   (Pfeffer	  MA	  et	   al.,	   1990;	  Pfeffer	  
MA	  et	  al.,	  1992;	  White	  HD	  et	  al.,	  2004).	  
4.4.6 Angiotensin-­‐Converting-­‐Enzyme	  Inhibitor	  	  
Angiotensin-­‐converting-­‐enzyme	   inhibitor	   (ACE	   inhibitor)	   is	   a	  class	   of	   drug	   for	   the	   treatment	   of	  
hypertension	  and	   congestive	   heart	   failure.	   Clinical	   studies	   have	   demonstrated	   that	   ACE-­‐I,	   when	  
compared	  with	  placebo,	  reduce	  left	  ventricular	  (LV)	  volumes,	  retard	  the	  progression	  of	  LV	  dilatation	  
and	   hypertrophy	   and	   increase	   systolic	   function.	   This	   may	   partially	   explain	   their	   proven	   clinical	  
efficacy	  in	  reducing	  CV	  events	  post-­‐MI	  and	  in	  the	  management	  of	  heart	  failure	  (St	  John	  Sutton	  et	  al.,	  
2003).	   The	   gross	   beneficial	   effects	   of	   these	   compounds	   are	   multifactorial	   and	   include	   transient	  
reductions	   in	  Ang	   II	  and	  aldosterone	   levels	   (both	  of	  which	  have	  direct	  vasoconstrictive	  and	  smooth	  
muscle	   proliferative	   effects)	   and	   reduced	   degradation	   of	   bradykinin	   (an	   established	   vasorelaxant).	  
Despite	  transient	  reductions	  in	  Ang	  II	  formation,	  chronic	  ACE	  inhibition	  is	  associated	  with	  persistent	  
morbidity	  and	  mortality	  benefits	  even	  beginning	  treatment	  1	  week	  after	  MI.	  
Contraindications	   to	   ACE	   inhibitor	   use	   include	   the	   increase	   of	   bradikynin	   levels	   and	   hypotension,	  
declining	  renal	  function.	  For	  patients	  intolerant	  of	  ACE	  inhibitors,	  angiotensin	  receptor	  blocker	  (ARB)	  




4.4.7 Angiotensin	  Receptor	  Blockers	  	  
The	   remarkable	   success	   of	   ACEIs	   in	   the	   treatment	   of	   cardiovascular	   diseases	   has	   prompted	   the	  
search	  for	  better	  alternative	  drugs	  to	  block	  the	  RAAS.	  Hence,	  Ang	  II	  receptor	  antagonists	  have	  been	  
developed	  (Timmermans	  PB	  et	  al.,	  1993).	  
During	   the	   past	   20	   years,	   experimental	   and	   clinic	   studies	   have	   documented	   that	   Angiotensin	  
Receptor	  Blockers	   (ARBs),	  either	  alone	  or	   in	  combination	  with	  drugs	  of	  other	  classes,	   reduce	  blood	  
pressure	   (BP),	   rates	   of	  myocardial	   infarction	   (MI),	   stroke,	   and	   progression	   of	   renal	   impairment	   in	  
hypertensive	  animals	  and	  humans.	  Relevantly	  ARBs	  positively	  impact	  other	  markers	  of	  cardiovascular	  
(CV)	  events	  such	  as	  left	  ventricular	  hypertrophy	  (LVH)	  and	  urinary	  protein	  excretion	  independent	  of	  
their	  effect	  on	  BP	  (Taylor	  AA	  et	  al.,	  2011).	  	  
Sartans	  are	  specific	  blockers	  of	  AT1	  receptor	  and	  their	  activity	  results	   in	  the	  elevation	  of	  circulating	  
Ang	   II	   and	   thus	   an	   overstimulation	   of	   AT2	   receptor	   (Spinale	   FG	   et	   al.,	   1997),	   suggesting	   that	   the	  
effect	  of	  ARBs	  could	  be	  partly	  AT2	  receptor	  mediated.	  
While	   it	   is	   exciting	   to	   speculate	   about	   the	   existence	  of	   such	   actions,	   it	   has	   so	   far	   been	  difﬁcult	   to	  
design	  a	  clinical	  trial	  that	  would	  unequivocally	  identify	  an	  ARB	  pharmacologic	  effect	  in	  patients	  with	  
CV	  disease	  that	  is	  independent	  of	  AT1	  receptor	  blockade	  and	  its	  consequences.	  
It	  was	  demonstrated	  in	  mice	  that	  deletion	  of	  AT2	  receptor	  gene	  caused	  deterioration	  of	  heart	  failure	  
and	   increased	  mortality	  during	  14	  days	  after	  MI	  (Oishi	  Y	  et	  al.,	  2003),	  suggesting	  that	  AT2	  receptor	  
has	  protective	  role	  against	  the	  acute	  phase	  post-­‐infarction	  LV	  remodeling.	  	  
The	   use	   of	   sartans,	   in	   particularly	   valsartan,	   in	   ischemic	   mice	   was	   effective	   in	   inhibition	   of	  
cardiomyocyte	  hypertrophy	  and	  LV	  dilatation	  also	  improving	  survival	  rate	  (Oishi	  Y	  et	  al.,	  2006).	  
Taken	   together,	   this	   evidence	   strongly	   supports	   a	   role	   for	  AngII	   in	   the	  development	  of	  myocardial	  
fibrosis.	  
Commonly,	   ARBs	   are	   used	   in	   patients	   sensitive	   to	   ACEi	   therapy,	   for	   treatment	   of	   diabetic	  
nephropathy	  and	  congestive	  heart	   failure.	  Evidence	   from	  controlled	  clinical	   trials	   suggests	   that	   the	  
sartans	  are	  very	  well	  tolerated	  and	  generally	  have	  a	  side-­‐effect	  profile	  similar	  to	  placebo.	  The	  most	  
frequently	  reported	  side	  effect	  is	  dizziness,	  not	  unexpected	  for	  a	  blood	  pressure–lowering	  drug	  and	  is	  
more	  likely	  to	  occur	  in	  patients	  who	  are	  volume-­‐depleted	  (Cheung	  BM,	  2002).	  
Moreover,	   some	   clinical	   trials	   have	   demonstrated	   significant	   benefit	   in	   the	   prevention	   of	  
cardiovascular	  events.	  
VALIANT	   (Valsartan	   in	   Acute	   Myocardial	   Infarction)	   trials,	   have	   demonstrated	   that	   long-­‐term	  
administration	  of	  valsartan	  plays	  a	  critical	  role	  in	  post-­‐infarction	  LV	  remodeling	  and	  promote	  greater	  
reduction	  in	  LV	  mass	  decreasing	  cardiovascular	  mortality	  and	  morbidity,	  effectively	   in	  patients	  with	  




that	  valsartan	  was	  as	  effective	  as	  ACEi	  (Captopril)	   in	  reducing	  mortality	   in	  post-­‐MI	  patients,	  but	  the	  
combination	   of	   valsartan	   and	   captopril	   increased	   the	   rate	   of	   adverse	   events	   without	   improving	  
survival.	   From	   the	   current	   information	   that	   is	   available,	   it	   would	   appear	   that	   ARBs	   are	   able	   to	  
attenuate	  ventricular	  dilatation;	  however,	  their	  effects	  are	  modest	  in	  comparison	  to	  the	  established	  
anti-­‐remodeling	  effects	  of	  ACE-­‐Is.	  Combination	  therapy	  with	  an	  ACE-­‐I	  and	  ARB	  appears	   to	  be	  more	  
beneficial	  than	  either	  agent	  alone,	  and	  supports	  the	  concept	  that	  more	  complete	  RAAS	  blockade	  at	  
both	  the	  enzyme	  and	  receptor	  level	  should	  further	  attenuate	  remodeling	  (Nagesh	  S	  and	  Solomon	  DS,	  
2005).	  
4.5 Surgical	  Procedure	  	  
Percutaneous	   coronary	   intervention	   (PCI)	   can	   be	   performed	   within	   90	   minutes	   of	   arrival	   at	   the	  
hospital	   in	   patients	   with	   STEMI	   or	   MI	   (Antman	   EM	   et	   al.,	   2008).	   PCI	   is	   a	   diagnostic	   angiography	  
combined	  with	   angioplasty	   and,	  usually,	   stenting	   leading	   to	   a	   restoration	  of	   coronary	   artery	  blood	  
flow.	  This	  procedure	  is	  more	  effective	  than	  fibrinolytic	  therapy,	  but	  needs	  obviously	  to	  be	  performed	  
in	  by	  experienced	  operators	  in	  a	  timely	  fashion	  (Grines	  CL	  et	  al.,	  1993).  
However,	  the	  short-­‐term	  mortality	  advantage	  is	  not	  durable,	  and	  PCI	  and	  fibrinolysis	  appear	  to	  yield	  
similar	  survival	  rates	  over	  the	  long	  term	  (Grines	  CL	  et	  al.,	  1999).	  
Coronary	   artery	   bypass	   grafting	   (CABG)	   is	   a	   surgical	   revascularization	   indicated	   in	   the	   setting	   of	  
mechanical	  complications	  of	  MI,	  such	  as	  ventricular	  septal	  defect,	  free	  wall	  rupture,	  or	  acute	  mitral	  
regurgitation.	  Restoration	  of	  coronary	  blood	  flow	  with	  emergency	  CABG	  can	  limit	  myocardial	   injury	  
and	  cell	  death	  if	  performed	  within	  2	  or	  3	  hours	  of	  symptom	  onset.	  Emergency	  CABG	  carries	  a	  higher	  
risk	   of	   perioperative	   morbidity	   (bleeding	   and	   MI	   extension)	   and	   mortality	   than	   elective	   CABG.	  
Elective	  CABG	  improves	  survival	  in	  post-­‐MI	  patients	  who	  have	  left	  main	  artery	  disease,	  three-­‐vessel	  




5 CARDIAC	  IMAGING	  
Established	   imaging	   modalities	   for	   clinical	   management	   and	   research	   include:	   echocardiography,	  
cardiovascular	   magnetic	   resonance	   (CMR),	   cardiac	   computed	   tomography	   (CT),	   positron	   emission	  
tomography	  (PET),	  single	  photon	  emission	  computed	  tomography	  (SPECT)	  and	  coronary	  angiography.	  
They	  have	  been	  used	  to	  assess	  myocardial	  perfusion	  left	  ventricular	  function,	  and	  coronary	  anatomy.	  
Nuclear	   cardiology	   is	   the	   a	   collective	   term	   for	   the	   modalities	   requiring	   the	   use	   of	   radionuclides	  
(Cerqueira	  MD	  et	  al.,	  2002).	  
Even	   if	  all	   these	  techniques	  produce	   images	  of	  myocardium	  and	  ventricle	  cavity,	   the	  orientation	  of	  
the	   heart,	   the	   angle	   selection	   for	   cardiac	   planes,	   the	   number	   and	   nomenclature	   of	   segments,	   the	  
slice	   display	   and	   thickness	   and	   the	   assignment	   of	   segments	   to	   coronary	   arterial	   territories	   have	  
evolved	   independently	   within	   each	   imaging	   field	   (Cerqueira	   MD	   et	   al.,	   2002).	   To	   optimize	   and	  
facilitate	   communication	   between	   cardiac	   imaging	   modalities	   a	   special	   report	   from	   the	   American	  
Heart	   Association,	   American	   College	   of	   Cardiology,	   and	   Society	   of	   Nuclear	   Medicine	   (AHA,	   ACC,	  
ASNM,	  1992)	  defined	   standards	   for	  plane	   selection	  and	  displayed	  orientation	   for	   serial	  myocardial	  
slices	  generated	  by	  cardiac	  2-­‐dimensional	  (2D)	  or	  tomographic	  imaging.	  
In	  normal	  human	  anatomy	  the	  heart	  is	  positioned	   in	   the	  middle	  of	   the	  thorax	  with	   the	   largest	  part	  
slightly	  offset	  to	  the	  left	  and	  the	  apex	  prominent	  frontally,	  so	  the	  cardiac	  planes	  generated	  by	  using	  
the	  long	  axis	  of	  the	  body	  do	  not	  cleanly	  transect	  the	  ventricles	  and	  atria.	  
SPECT	  and	  2D	  echocardiography,	  the	  two	  most	  widely	  used	  cardiac	  imaging	  modalities,	  have	  defined	  
the	  long	  axis	  of	  the	  left	  ventricle	  transecting	  the	  apex	  and	  the	  center	  of	  the	  mitral	  valve	  plane,	  and	  
short	  axis	  are	  oriented	  at	  90°	  angles	   relative	   to	   the	   long	  axis	   (ASNC,	  1999;	  Schiller	  NB	  et	  al.,	  1989;	  
Feigenbaum	  H,	  1994).	  
Accordingly	   all	   cardiac	   imaging	   modalities	   orient,	   and	   display	   the	   heart	   sections	   following	   this	  
standard	   convention.	   Standard	   names	   for	   the	   orthogonal	   cardiac	   planes	   used	   in	   all	   imaging	  
modalities	  are	  short	  axis,	  vertical	   long	  axis,	  and	  horizontal	   long	  axis.	  These	  correspond	  to	  the	  short	  
axis,	   apical	   2-­‐chamber,	   and	   apical	   4-­‐chamber	   planes,	   traditionally	   used	   in	   2D	   echocardiography	  










Cardiac	   imaging	   techniques	   could	   be	   divided	   into	   structural:	   CT,	   CMR	   and	   high-­‐resolution	  
echocardiography	   providing	   mainly	   high-­‐resolution	   images	   with	   anatomical	   information,	   and	  
functional	  SPECT	  and	  PET	  but	  with	  coarser	  resolution.	  Multimodal	   imaging	  fusing	  different	  types	  of	  
images	  is	  addressed	  to	  deal	  with	  the	  insufficiency	  of	  the	  information	  provided	  by	  a	  single	  modality.	  
5.1 Computed	  Tomography	  (CT)	  
X-­‐ray	  CT	  is	  an	  imaging	  procedure	  that	  uses	  X-­‐rays	  to	  produce	  tomographic	  images	  of	  specific	  part	  of	  
body.	  From	  a	  series	  of	  two-­‐dimensional	  X-­‐ray	  images,	  obtained	  around	  a	  single	  axis	  of	  rotation,	  with	  
a	  computer	  processing,	  a	  three-­‐dimensional	  image	  of	  a	  part	  of	  body	  is	  generated.	  
CT	  offers	  high	  contrast	  between	  bone	  and	  other	  tissues	  such	  as	  liver,	  heart,	  lungs	  and	  gut.	  
Although	  historically	   the	   images	   generated	  were	   in	   the	   axial	   or	   transverse	  plane,	   perpendicular	   to	  
the	   long	   axis	   of	   the	   body,	  modern	   scanners	   allow	   reformatting	   the	   2D	   images	   as	   volumetric	   (3D)	  
representations	  of	  structures	  (Ford	  NL	  et	  al.,	  2003).	  
	  
Figure	  8.	  Example	  of	  computed	  tomography,	  short	  axis	  (SA)	  view	  of	  heart	  (RV=	  right	  ventricle,	  LV=	  left	  ventricle,	  




5.2 Positron	  Emission	  Tomography	  (PET)	  
PET	   is	   a	   highly	   specialized	   imaging	   technique	   that	   allows	  producing	   a	   three-­‐dimensional	   images	  of	  
functional	  processes	  in	  the	  body.	  
The	   patient	   receives	   a	   short	   half-­‐lived	   radiopharmaceutical	   (produced	   by	   a	   facility	   that	  makes	   the	  
tracers	   –cyclotron-­‐	   that	   has	   to	   be	   close)	   such	   as	   fluorodeoxyglucose,	   a	   glucose	   analogue	  which	   is	  
combined	  with	  a	  radioisotope,	  to	  show	  where	  glucose	  is	  being	  used,	  for	  example	  in	  the	  brain,	  heart	  
muscle,	  or	  a	  growing	  tumor.	  	  
The	  system	  detects	  pairs	  of	  gamma	  photons	  emitted	  indirectly	  by	  the	  tracer	  and	  the	  3D	  images	  of	  its	  
concentration	  within	  the	  body	  are	  then	  constructed	  by	  computer	  analysis.	  	  
Because	  the	  radioisotope	  used	  in	  a	  PET	  scan	  is	  short-­‐lived,	  the	  patient	  receives	  amount	  of	  radiation	  
about	  twice	  chest	  X-­‐rays.	  
Molecular	  imaging	  with	  PET	  allows	  evaluating,	  in	  a	  non-­‐invasive	  and	  longitudinal	  manner,	  biological	  
processes	  at	  a	  cellular	  and	  subcellular	  level	  in	  early	  steps	  of	  heart	  diseases,	  to	  perform	  quantitative	  
analysis,	   to	   study	   apoptosis,	   angiogenesis,	   hypoxia,	   inflammation,	   receptor	   density,	   and	   gene	  
expression.	   In	   spite	  of	   the	   great	   specificity	   and	   sensitivity	  of	   PET,	  molecular	   imaging	  approach	   can	  
take	   advantage	   from	   simultaneous	   acquisition	   of	   morphological	   information	   for	   localization	   and	  
quantification.	  Therefore,	  hybrid	  imaging	  with	  PET/CT	  systems	  is	  becoming	  the	  most	  used	  approach	  
in	  cardiovascular	  imaging	  (Gargiulo	  S	  et	  al.,	  2012).	  
PET	  has	  been	  used	  primarily	  in	  cardiology,	  neurology,	  and	  oncology.	  
	  
	  
Figure	   9.	   Example	   of	   positron	   emission	   tomography.	   Images	   of	   [18F]	   fluorodeoxyglucose	   (FDG)	   of	   short	   axis	  
(SA),	   horizontal	   long	   axis	   (HLA)	   and	   vertical	   long	   axis	   (VLA).	   Images	   regions	   with	   normal	   or	   even	   enhanced	  
uptake	  of	  FDG	  as	  a	  marker	  of	  myocardial	  viability	  (Knuuti	  J	  et	  al.,	  2008).	  
	  
5.3 Single-­‐Photon	  Emission	  Computed	  Tomography	  (SPECT)	  	  
SPECT	  is	  a	  nuclear	  medicine	  tomographic	  imaging	  technique	  using,	  as	  PET,	  gamma	  rays	  to	  obtain	  3D	  
information	  presented	  as	  cross-­‐sectional	  slices	  of	  the	  body.	  	  
The use of reporter genes and labelled reporter probes for non-
invasive imaging of transgene expression is another emerging
application of PET. This technique is based on a vector-
mediated transfer of genes which translate into protein
products such as enzymes or receptors that can be targeted by
radiotracers. Accumulation of tracers thus indirectly reflects
gene expression in target tissue. Several studies have reported
proof of this principle for cardiac imaging.59–61 This methodology
can be used to determine location, magnitude and persistence of
transgene expression in the heart and the whole body.
Coexpression of a reporter gene allows indirect imaging of the
expression of a chosen therapeutic gene, and thus permits
monitoring of cardiac gene therapy,62 but this promising
approach is still in the experimental stage and has not yet been
adapted for human application.
Even more than gene therapy, cardiac stem cell therapy is an
innovative and promising therapeutic approach to heart disease.
However, despite an increasing body of experimental and
human data, several questions about the biological mechanisms
of treatment remain to be answered, and unequivocal proof of
clinical efficacy is needed. PET not only provides accurate non-
invasive information about myocardial perfusion, contractile
function and viability, which enables assessment of clinical
benefits of treatment but is also well suited to tracking of
Figure 6 Example of positron emission tomography viability study. The
upper row shows the resting short axis (SA), horizontal long axis (HLA)
and vertical long axis (VLA) perfusion images using rubidium-82. The
corresponding images of [18F]fluorodeoxyglucose (FDG) are displayed in
the lower row. A large anterior and apical region with reduced perfusion
was detected. However, in the FDG i ages the corresponding region had
normal or even enhanced uptake of FDG as a marker of myocardial
viability.
Figure 7 CT angiography images of
patient with suspected coronary heart
disease. Curved multiplanar
reconstructions of major coronary arteries
are shown. Several calcified plaques were
detected in all major coronary arteries.
Figure 8 Hybrid display of three-dimensional rendered images of CT
angiography and positron emission tomography perfusion imaging
([15O]water) during adenosine stress of the same patient as in fig 7.
Despite the coronary plaques myocardial perfusion was quite
homogeneous. Please note also that absolute stress perfusion values
were also high, indicating well preserved flow response to stress (scale
max 5.2 ml/g/min).
Technology and guidelines




SPECT	   is	   similar	   to	   PET	   in	   its	   use	   of	   radioactive	   tracer	   material	   and	   detection	   of	   gamma	   rays.	   In	  
contrast	  with	  PET,	  that	  traces	  simultaneously	  two	  gamma	  photons,	  the	  tracer	  used	  in	  SPECT	  emitted	  
one	   single	  photon;	   this	  difference	   is	   at	   the	  basis	  of	   a	  poorer	   image	   sensitivity	  of	   SPECT	  and	  hither	  
potentiality	  of	  PET	  to	  locate	  radiopharmaceuticals.	  
Compared	  to	  PET,	  SPECT	  is	  more	  competitive	  because	  radioactive	  materials	  used	  have	  longer	  lifetime	  
and	  don’t	  need	  to	  be	  located	  near	  a	  cyclotron.	  
	  
	  
Figure	  10.	  Example	  of	  single-­‐photon	  emission	  computed	  tomography.	  Image	  shows	  heart	  ischemia.	  Short	  axis	  
(SA),	  horizontal	  long	  axis	  (HLA)	  and	  vertical	  long	  axis	  (VLA).	  
	  
5.4 Cardiovascular	  Magnetic	  Resonance	  (CMR)	  	  
CMR	   is	  a	   rapidly	  evolving	   technology	  that	   is	   increasingly	  being	  used	   for	   the	  noninvasive	   imaging	  of	  
the	  expanding	  heart	  failure	  population	  (Karamitsos	  TD	  et	  al.,	  2009).	  
In	   clinic	  CMR	  has	  been	  generally	  performed	  at	   a	  magnetic	   field	   strength	  of	  1.5	  T	   (which	   is	   around	  
30000	  times	  stronger	  than	  the	  earth’s	  magnetic	  field)	  but	  recently	  3.0	  T	  magnets	  are	  becoming	  more	  
and	  more	  widespread.	   The	  magnetic	   field	   is	   used	   to	   align	   the	   nuclear	  magnetization	   of	   hydrogen	  
atoms,	  which	  are	  abundant	  in	  the	  human	  body.	  The	  hydrogen	  nuclei	  (proton)	  are	  excited	  by	  pulses	  of	  
radiofrequency	  waves,	  and	  the	  signal	  emitted	  from	  the	  body	  in	  return	  is	  detected	  with	  receiver	  coils.	  
Signal	  from	  tissues	  (heart	  muscle,	  fat,	  for	  example)	  is	  determined	  by	  proton	  density,	  and	  by	  2	  distinct	  
MR	   relaxation	   parameters,	   longitudinal	   relaxation	   time	   (T1)	   and	   transverse	   relaxation	   time	   (T2).	  
These	  three	  parameters	  can	  be	  substantially	  different	  for	  tissues,	  and	  these	  differences	  are	  used	  to	  
generate	   contrast	   in	  MR	   images	   by	  modulating	   the	  way	   the	   radiofrequency	   pulses	   are	   played	   out	  
(the	  MR	  sequence).	  For	  example,	  in	  so-­‐called	  T1-­‐weighted	  images,	  myocardial	  tissue	  is	  dark,	  whereas	  




are	  used	  to	  show	  myocardial	  edema	  caused	  by	   inflammation	  or	  acute	   ischemia	  (Abdel-­‐Aty	  H	  et	  al.,	  
2007).	  
CMR	   sequence	   consists	  of	   a	   series	  of	   radiofrequency	  pulses,	  magnetic	   gradient	   field	   switches,	   and	  
timed	   data	   acquisitions,	   all	   applied	   in	   a	   precise	   order	   to	   generate	   the	   CMR	   image.	   Spin	   echo	  
sequences	   are	   mainly	   used	   for	   anatomic	   imaging	   and	   tissue	   characterization.	   Gradient	   echo	  
sequences	   show	   fat	   and	  blood	  as	  white	   and	   can	  be	  used	   to	   acquire	   cine	   images.	   The	  most	   recent	  
standard	   cardiac	  MR	   sequences	   are	   steady-­‐state	   free	   precession,	   which	   provide	   the	   best	   contrast	  
between	   chamber	   blood	   (white)	   and	   myocardium	   (dark),	   and	   these	   are	   now	   routinely	   used	   for	  
imaging	  of	  cardiac	  function	  (Karamitsos	  TD	  et	  al.,	  2009).	  
To	  prevent	  artifacts	  from	  cardiac	  motion,	  most	  CMR	  images	  are	  generated	  with	  fast	  sequences	  gated	  
to	   the	  R-­‐wave	  of	   the	  electrocardiogram.	  Respiratory	  motion,	   another	   source	  of	   artifacts,	   is	  usually	  
eliminated	  by	  acquiring	  CMR	  images	  in	  end-­‐expiratory	  breath-­‐hold	  (Karamitsos	  TD	  et	  al.,	  2009).	  
Contrast	  agent,	  such	  as	  gadolinium,	  can	  be	  used	  to	  detect	  infarct	  and	  cardiac	  fibrosis.	  	  
The	   physiological	   basis	   of	   late	   gadolinium	   enhancement	   (LGE)	   is	   an	   increase	   in	   its	   volume	   of	  
distribution	   within	   areas	   of	   scarring	   or	   fibrosis	   and	   an	   abnormally	   prolonged	   washout	   related	   to	  
decreased	  functional	  capillary	  density	  in	  the	  irreversibly	  injured	  myocardium	  (Schaefer	  S	  et	  al.,	  1988;	  
Rehwald	  WG	  	  et	  al.,	  2002;	  Mahrholdt	  H	  et	  al.,	  2005;	  Kim	  RJ	  et	  al.,	  1996).	  The	  increase	  of	  extracellular	  
gadolinium	   volume	   in	   cardiac	   damage	   tissue	   produces	   T1	   shortening,	   which	   manifests	   as	   hyper	  
enhancement	  (high	  signal)	  in	  areas	  of	  myocardial	  injury	  that	  appears	  extremely	  bright	  comparing	  to	  
the	  black	  normal	  myocardium.	  Recently	  the	  use	  of	  contrast	  agent	  as	  gadolinium	  has	  been	  linked	  with	  
acute	   or	   chronic	   severe	   renal	   insufficiency	   or	   dysfunction	   and,	   for	   this,	   gadolinium-­‐based	   contrast	  
agents	  are	  not	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  Administration	  for	  use	  in	  cardiac	  studies	   in	  the	  
U.S.	  (Karamitsos	  TD	  et	  al.,	  2009).	  
Compared	  to	  other	   imaging	  modalities,	  CMR	  does	  not	  need	  ionizing	  radiation	  or	  radioactive,	  and	  is	  
flexible	  enough	  to	  produce	  high	  quality	  both	  anatomical	  and	  functional	  images,	  however	  for	  cellular	  
and	  molecular	   level	  still	   lags	  behind	  other	  modalities	  (Heijman	  E,	  2008).	  CMR	  is	  also	  expensive	  and	  
not	  compatible	  with	  with	  implanted	  electronic	  devices,	  such	  as	  pacemakers	  or	  defibrillators	  (Shellock	  
FG	   et	   al.,	   2004),	   although	   this	  may	   change	   in	   the	   future	  with	   further	   technical	   development	   (MR-­‐
compatible	   pacemakers).	   Some	   neurological	   devices	   such	   as	   cerebrovascular	   clips	   are	   still	  
problematic.	  Nevertheless,	  most	  medical	  metallic	  implants	  are	  safe	  in	  a	  CMR	  environment,	  including	  






Figure	  11.	  Example	  of	  of	  cardiac	  magnetic	  resonance.	  Short	  axis	  (SA):	  end	  diastolic	  frame	  (A)	  and	  end-­‐systolic	  
frame	  (B).	  
	  
5.5 Ultrasound	  Echocardiography	  
Ultrasound	   is	   a	   mechanical	   radiation	   that	   can	   be	   directed	   in	   a	   beam,	   conforms	   to	   the	   laws	   of	  
reflection	  and	  refraction,	  and	  is	  reflected	  by	  small	  object	  (Feigenbaum	  H,	  1994).	  Ultrasound	  requires	  
a	  medium	  for	  propagation	  and	  travels	  poorly	  through	  air	  and	  highly	  dense	  substances,	  such	  as	  lung	  
and	  bone,	  respectively.	  When	  ultrasound	  traveling	  in	  one	  medium	  reaches	  a	  medium	  with	  different	  
acoustic	  impedance	  (density),	  a	  small	  percent	  of	  ultrasound	  energy	  is	  reflected.	  The	  intensity	  of	  the	  
reflected	  energy	  is	  directly	  related	  to	  the	  differences	  in	  acoustic	  impedances	  of	  the	  two	  media	  and	  is	  
used	  by	  the	  scan	  converter	  on	  the	  ultrasonograph	  to	  form	  an	  image.	  Reflection	  is	  also	  related	  to	  the	  
thickness	  of	  the	  target	  and	  the	  angle	  of	  incidence	  between	  the	  target	  and	  the	  ultrasound	  beam.	  An	  
important	  physical	  characteristic	  of	  ultrasound	  is	  that	  it	  is	  attenuated	  as	  it	  travels	  through	  a	  medium,	  
and	  this	  loss	  of	  acoustic	  energy	  is	  directly	  related	  to	  the	  frequency	  of	  ultrasound	  (Hoit	  BD,	  2006).	  
For	  echocardiographic	  examination	   the	  vertical	   long	  axis	   view	   is	  usually	  acquired	   first	  because	   this	  
view	  allows	  a	  general	  assessment	  of	  overall	  LV	  size	  and	  function	  (Collins	  KA	  et	  al.,	  2003).	  
From	  this	  transducer	  position,	  a	  clockwise	  90°	  rotation	  at	  the	  papillary	  muscle	  level	  permit	  to	  obtain	  
the	   short-­‐axis	   view.	   From	   this	   view,	   M-­‐mode-­‐derived	   measures	   of	   LV	   area	   or	   dimensions	   can	   be	  
obtained.	  
M-­‐Mode	   imaging	   is	   a	   1D	   projection	   traced	   along	   time	   allowing	   to	   record	   very	   high	   temporal	  
resolution	  of	   tissue	  motion	   to	   study	   the	  movement	  of	   the	  myocardium,	   valves	  or	   vessel	  walls	   and	  
quantify	  cavity	  dimensions.	  
On	   left	   ventricle	   short	   axis	  M-­‐mode	   traces	   end	  diastolic	   and	   systolic	   diameter	   (LVEDd	   and	   LVESd),	  





Figure	  12.	  Example	  of	  echocardiographic	   image:	  a	  typical	  M	  mode	   image.	  Standard	  measures	  of	  anterior	  and	  
posterior	  wall	   thickness	   (AWTh	  and	  PWTh),	  and	   left	  ventricle	  end-­‐diastolic	  and	  end-­‐systolic	  diameter	   (LVEDd	  
LVESd).	  	  
	  
Echography	  exploits	  Doppler	  effect	  to	  trace	  the	  velocity	  profile	  of	  blood	  in	  a	  sample	  volume	  (usually	  
inside	   a	   vessel)	   allowing	   a	   very	   accurate	   evaluation.	   Likewise	   echo	   color	   Doppler	   shows	   blood	  
velocities	   encoded	   as	   color	   (red	   towards	   the	   transducer,	   blue	   in	   the	   opposite	   direction)	   and	  
brightness	  that	  represents	  velocity.	  	  
	  
Figure	  13.	  PW	  Doppler	  (A)	  and	  Color	  Doppler	  (B)	  of	  mitral	  valve.	  




5.6 Regional	  Analysis	  
For	  regional	  analysis	  of	  left	  ventricular	  function	  or	  myocardial	  perfusion,	  the	  left	  ventricle	  is	  	  divided	  
into	  equal	   thirds	  perpendicular	   to	   the	   long	   axis	   of	   the	  heart,	   and	  anatomic	   landmarks	   are	  used	   to	  
select	  slices:	  basal	  (tips	  of	  the	  mitral	  valve	  leaflet),	  mid-­‐cavity	  (papillary	  muscles)	  and	  apical	  (beyond	  
papillary	  muscles	  but	  before	  cavity	  ends)	  (Cerqueira	  MD	  et	  al.,	  2002).	  
Short	   axis	   are	  divided	   in	   segments	   corresponding	   to	   specific	   areas	   irrorated	  by	  particular	   coronary	  
arteries,	  or	  branch:	  the	  basal	  and	  mid-­‐cavity	  slices	  are	  divided	  in	  6	  segments	  (anterior,	  anteroseptal,	  
inferoseptal,	   inferior,	   inferolateral,	   and	   anterolateral),	   while	   apical	   slice	   is	   divided	   in	   4	   segments	  
(anterior,	  septal,	  inferior	  and	  lateral).	  Segments	  are	  in	  total	  16	  plus	  apex	  that	  can	  be	  considered	  as	  a	  
segment	  itself;	  their	  names	  identify	  their	  circumferential	  location	  on	  the	  ventricular	  wall	  (Figure	  14).	  
The	  slice	  thickness	  is	  decided	  on	  the	  basis	  of	  specific	  resolution	  and	  clinical	  relevance	  (Cerqueira	  MD	  
et	  al.,	  2002).	  
	  
Figure	  14.	  A	  schematic	  representation	  of	  horizontal	  long-­‐axis	  (HLA,	  approximating	  the	  4-­‐chamber	  view),	  vertical	  
long-­‐axis	  (VLA,	  approximating	  the	  2-­‐chamber	  view),	  and	  short-­‐axis	  (SA)	  planes	  showing	  the	  name,	  location,	  and	  
anatomic	  landmarks	  for	  selection	  of	  the	  basal	  (tips	  of	  the	  mitral	  valve	  leaflets),	  mid-­‐cavity	  (papillary	  muscles),	  
and	  apical	  (beyond	  papillary	  muscles	  but	  before	  cavity	  ends)	  short	  axis	  slices	  for	  the	  recommended	  17-­‐segment	  



















Figure	  15.	  Circumferential	  polar	  plot	  of	  the	  17-­‐myocardial	  segments,	  and	  the	  recommended	  nomenclature	  for	  
tomographic	  imaging	  of	  the	  heart.	  	  
Assignment	   of	   the	   17-­‐myocardial	   segments	   to	   the	   territories	   of	   the	   left	   anterior	   descending	   (LAD),	   right	  
coronary	  artery	  (RCA),	  and	  the	  left	  circumflex	  coronary	  artery	  (LCX)	  (Cerqueira	  MD	  et	  al.,	  2002).	  	  
	  
During	  cardiac	  cycle,	   left	  ventricle	  wall	  rotates,	  translates,	  and	  deforms	  in	  three	  different	  directions	  
with	  two	  possible	  orientations:	  	  
• radial	  movement	  is	  described	  as	  a	  contraction	  towards	  the	  center	  of	  the	  LV	  during	  systole	  and	  
as	  an	  expansion	  from	  the	  center	  during	  diastole;	  
• horizontal	   rotation	   which	   represent	   the	   clockwise	   and	   counter	   clockwise	   movement	   of	   the	  
cardiac	  wall	  
• vertical	   rotation	  which	   represent	   the	  movement	   towards	   the	   base	   (upwards)	   during	   systole	  
and	  towards	  the	  apex	  during	  diastole	  (downwards)	  (de	  Sá	  Rebelo	  M	  et	  al.,	  2008).	  
	  
Figure	  16.	  Panel	  (a)	   is	  a	  representation	  of	  radial	  movement;	  (b)	  of	  horizontal	  rotation;	  (c)	  of	  vertical	  rotation.	  
The	  two	  orientations	  for	  each	  direction	  are	  colored	  by	  a	  defined	  coding	  scheme	  (de	  Sá	  Rebelo	  M	  et	  al.,	  2008).	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Using this system, segments 1 and 7 identify the locations
of the anterior wall at the base and mid-cavity. The appro-
priate names are basal anterior and mid-anterior segments.
The septum, delineated by the attachment of the right ventri-
cle, is divided into anterior and inferior segments. Segments
2 nd 3 are named basal a te oseptal and basal infero ep al.
Continuing this approach, segment 4 is the basal inferior,
segment 5 is the basal inferolateral, and segment 6 is the
basal anterolateral. Similar names are used for the 6 seg-
ments, 7 to 12, at the mid-cavity level. The left ventricle
tapers as it approaches the true apex, and it was believed
appropriate to use just 4 segments. The names for segments
13 to 16 are ap cal anterior, apical septal, apical inferior, and
apical lateral. The apical cap represents the true muscle at the
extreme tip of the ventricle where there is no longer cavity
present, and this is defined as segment 17, called the apex.
Although in echocardiography the term posterior is some-
times used, for consistency, the term inferior is recommended.6
Recommendation
The names for the myocardial segments should define the
location relative to the long axis of the heart and the
circumferential location.
Assignment of Segments to Coronary
Arterial Territories
Although there is tremendous variability in the coronary
artery blood supply to myocardial segments, it was believed
to be appropriate to assign individual segments to specific
coronary artery territories.11 The assignment of the 17 seg-
ments to one of the 3 major coronary arteries is shown in
Figure 5. The greatest variability in myocardial blood supply
occurs at the apical cap, segment 17, which can be supplied
by any of the 3 arteries. Segments 1, 2, 7, 8, 13, 14, and 17
are assigned to the left ant rior descending coronary artery
distribution. Segments 3, 4, 9, 10, and 15 are assigned to the
right coronary artery when it is dominant. Segments 5, 6, 11,
12, and 16 generally are assigned to the left circumflex artery.
Recommendation
Individual myocardial segments can be assigned to the 3
major coronary arteries with the recognition that there is
anatomic variability.
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Fig re 4. Display, on a circumferential polar plot, of the 17
myocardial segments and the recommended nomenclature for
to ographic imaging of the heart. Modified from reference 5.
Figure 5. Assignment of the 17 myocardial segments to the ter-
ritories of the left anterior descending (LAD), right coronary
artery (RCA), and the left circumflex coronary artery (LCX). Mod-
ified from reference 5.
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In	   normal	   condition	   the	   myocardium	   moves	   in	   the	   three	   directions	   described	   before,	   but	   in	  
pathological	   conditions	   there	   are	   changes	   in	   the	   expected	   normal	   left	   ventricle	   wall	   movements	  
(Remme	  EW	  et	  al.,	  2004).	  
Even	   if	   global	   indices	   as	   EDV,	   ESV	   and	   EF	   give	   us	   information	   on	   ventricular	   functionality	   and	  
contractility	   the	   analysis	   of	   regional	   cardiac	   movement	   can	   be	   considered	   a	   predictor	   of	  
cardiovascular	  events.	  
Actually,	  it	  is	  demonstrated	  that	  subclinical	  regional	  myocardial	  dysfunction	  (RMD)	  in	  asymptomatic	  
adults	   is	   independently	   associated	   with	   subsequent	   development	   of	   heart	   failure	   and	   adverse	  
cardiovascular	  events	  (Yan	  RT	  et	  al.,	  2011).	  
Specifically,	   the	   presence	   of	   RMD	   doubles	   risk	   for	   heart	   failure	   and	   increased	   risk	   for	   combined	  
adverse	   atherosclerotic	   events	   over	   a	  mean	   follow-­‐up	  of	   4.6	   years	   among	   asymptomatic	   adults	   of	  
four	  different	  ethnic	  groups,	  independent	  of	  indexes	  of	  global	  LV	  assessment	  (Yan	  RT	  et	  al.,	  2011).	  
So	   the	  evaluation	  and	  quantification	  of	  LV	  regional	   function	   is	  a	   fundamental	  goal	  of	  many	  cardiac	  
imaging	  modalities	  (de	  Sá	  Rebelo	  M	  et	  al.,	  2008).	  
In	  the	  last	  years	  echocardiographic	  and	  CMR	  imaging	  technique	  were	  upgraded	  for	  myocardial	  strain	  
analysis	  (Cottrell	  C	  et	  al.,	  2010).	  
Myocardial	  strain	  represents	  the	  fractional	  or	  percentage	  change	  from	  the	  original	  dimension,	  and	  by	  
definition,	  negative	   strain	  means	  shortening	  and	  positive	   strain	  means	  elongation	   (Urheim	  S	  et	  al.,	  
2000).	  
Echocardiographic	  strain	  analysis	  is	  based	  on	  capture	  of	  segmental	  tissue	  motion	  on	  multiple	  planes	  
and	   axes	   (serially	   over	   the	   cardiac	   cycle)	   and	   then	   track	   the	   intramyocardial	   point	   (“speckle”)	  
displacements	  integrating	  detailed	  information	  regarding	  both	  regional	  and	  global	  LV	  function,	  with	  
much	  greater	  sensitivity	  and	  specificity	  than	  conventional	  measures,	   including	  fractional	  shortening	  
(FS)	  or	  ejection	  fraction	  (EF)	  (Cottrell	  C	  et	  al.,	  2010).	  
	  
Figure	  17.	  Timed	  tracking	  of	  myocardial	  deformation	  allows	  for	  the	  direct	  measurement	  of	  myocardial	  strain	  in	  
the	  longitudinal,	  circumferential,	  and	  radial	  axes	  (Bauer	  M	  et	  al.,	  2011).	  
	  
Regional	   ventricular	   function	   can	   be	   expressed	   as	   regional	   ejection	   fraction	   (REF):	   left	   ventricular	  
endocardial	  contours	  were	  traced	  semiautomatically	   frame-­‐by-­‐frame	  and	  manually	  corrected	  when	  
ages based on adequate visualization of the endocardial border and
absence of image artifacts. Three consecutive cardiac cycles were
selected for analysis based on image quality. Semiautomated tracing
of the endocardial and epicardial borders were performed and
verified over all 3 cardiac cycles and then corrected as needed to
achieve good quality tracking throughout each cine loop. Tracked
images were then processed in a frame-by-frame manner for strain
measurements (Figure 1B). Strain measures were averaged over the
obtained cardiac cycles (with temporal smoothing filters turned off
for all measurements), resulting in curvilinear strain and SR data
(Figure 1C). Each long- and short-axis view of the LV myocardium
was divided into 6 standard anatomic segments12 for regional
speckle-tracking based strain analysis throughout the cardiac cycle.
In MI animals, the mid-anterior, apical-anterior, and apical-inferior
wall segments in the long-axis view were designated as the infarct
region and the basal-inferior and mid-inferior wall segments were
designated as the remote (noninfarct) region. Peak strain and SR
measurements were recorded from each of the 6 standard segments
in each view, providing regional strain values. For global strain
values, peak strain and SR measurements were averaged across all 6
segments. Regional strain values were obtained by averaging these





During each cardiac cycle, the LV undergoes a typical pattern
of tissue deformation in multiple planes. This complex
functional pattern includes myocardial shortening in the
longitudinal axis, thickening in the radial axis, and shortening
in the circumferential axis during systole, followed by reverse
changes during diastole (Figure 1A). Myocardial tissue de-
formation in these axes can be assessed, both regionally and
globally, as measures of tissue strain and SR. Speckle-
tracking–based strain analyses of myocardial motion (in the
long- and short-axis images) integrates frame-to-frame
data from cine loops (Figure 1B), allowing for measure-
ments of segmental myocardial strain and calculation of
SR in the longitudinal, radial, and circumferential axes.
These measures are plotted as curvilinear data for each
region tracked (Figure 1C).
Echocardiographic images were obtained in adult mice, as
described in the Methods. Total time for image acquisition
and analyses were similar for conventional and speckle-
tracking based strain measures and, together, totaled less than
25 minutes per animal, typically allowing for imaging and
analysis of 20 mice per day by a single operator. Acquisition
of B-mode images in the parasternal long-axis view, followed
by acquisition of M-mode and B-mode images in the para-
sternal short-axis view, involved 2 to 5 minutes of image
acquisition time per view. During image acquisition, mice
were lightly anesthetized (1% isoflurane in oxygen). As
demonstrated by average heart rates of 560!79 bpm at
baseline (Table 1), echocardiography allowed for in vivo
cardiac assessment at physiological heart rates without sig-
nificantly altering resting hemodynamics. All acquired im-
ages were deemed appropriate for both conventional and
speckle-tracking based strain measurements.
Similar to conventional echocardiographic measures,
speckle-tracking based strain analyses were performed offline
after imaging acquisition was completed. Conventional and
speckle-tracking based strain measurements involved a total
of 7 to 15 minutes of analysis time per study (including image
selection, image tracing/measuring, and data processing),
where up to 15 minutes was needed for a minority of studies
Figure 1. Speckle-tracking based strain
analysis. Normal ventricular function
involves myocardial deformation along the
longitudinal, radial, and circumferential
axes (A). Speckle-tracking based strain
analysis uses acoustic back scatter on
echocardiographic images as tissue
markers, which are tracked frame-to-
frame throughout the cardiac cycle (B).
Timed tracking of myocardial deformation
allows for the direct measurement of
myocardial strain in the longitudinal, cir-
cumferential, and radial axes. For each
axis, separate strain curves (representing
strain measures over time) are generated
for each of the 6 standard myocardial
regions, with a seventh line (black) denot-
ing the average (global) strain at each
time point (C). Regional and global strain
curves are ltered in typical fashion fol-
lowing MI and with ACEi treatment.
910 Circulation Research April 15, 2011





necessary	  to	  optimize	  the	  boundary	  position.	  After	  segmentation	  (Hozumi	  T	  	  et	  al.,	  1996;	  Shiota	  T	  et	  
al.,	  1998),	  regional	  volumes	  were	  calculated	  throughout	  the	  cardiac	  cycle	  in	  order	  to	  obtain	  regional	  
end-­‐diastolic	   and	   end-­‐systolic	   volumes	   (REDV,	   RESV).	   REF	   was	   then	   computed	   as	   the	   difference	  
between	  REDV	  and	  RESV	  in	  percentage	  of	  REDV	  (Jaochim	  Nesser	  H	  et	  al.,	  2007).	  	  
To	  better	  visualize	  regional	  ventricular	  function	  and	  wall	  movement,	  a	  bull’s	  eye	  projection	  is	  used.	  
It’s	  a	  2D	  map	  of	  a	  3D	  left	  ventricle,	  whose	  display	  is	  a	  polar	  projection	  with	  apex	  in	  the	  center,	  mid-­‐
cavity	  in	  the	  middle,	  and	  the	  base	  in	  the	  periphery	  the	  ventricular	  function;	  in	  particular	  the	  three	  LV	  
short	   axis	   sections	  were	   divided	   into	   17	   segments	   according	   to	   American	  Heart	   Association	   (AHA)	  
guidelines	  (Kuhl	  HP	  et	  al.,	  2004).	  	  
	  
	  	  
Figure	   18.	   Schematic	   ‘‘bull’s	   eye’’	   representation	   of	   the	   three-­‐dimensional	   segmentation,	   with	   the	   colour	  
notation	  used	   for	   the	  different	   segments	  and	   the	   regional	   left	  ventricular	  volume-­‐time	  curves.	  Ant:	  anterior;	  
Ant	  sept:	  antero-­‐	  septal;	  Inf:	  inferior;	  Lat:	  lateral;	  Post:	  posterior;	  Sept:	  septal	  (Jaochim	  Nesser	  H	  et	  al.,	  2007).	  
	  
5.7 Assessments	  Of	  Left	  Atrium	  Size	  
The	   assessment	   of	   left	   atrium	   (LA)	   size	   has	   important	   clinical	   implications	   and	   it’s	   necessary	   a	  
comprehensive	  view	  about	  it	  (Abhayaratna	  WP	  et	  al.,	  2006).	  	  
As	  body	  size	  is	  a	  major	  determinant	  of	  LA	  size,	  to	  allow	  meaningful	  comparison	  the	  LA	  size	  should	  be	  
indexed	  to	  a	  measure	  of	  body	  size,	  body	  surface	  area	  is	  the	  most	  commonly	  used	  one	  (Pritchett	  AM	  
et	  al.,	  2003;	  Vasan	  RS	  et	  al.,	  1997).	  	  
LA	   size	   is	   also	   gender	   dependent,	   and	   in	   fact	   men	   have	   been	   shown	   to	   have	   larger	   LA	   size	   in	  
comparison	   with	   women	   (Pritchett	   AM	   et	   al.,	   2003).	   However,	   these	   differences	   are	   nearly	  
completely	  accounted	  for	  by	  variation	  in	  body	  size	  (Spencer	  KT	  et	  al.,	  2001;	  Pritchett	  AM	  et	  al.,	  2003;	  
Knutsen	  KM	  et	  al.,	  1989).	  
	  
	  
interpretations. Receiver operating characteristic (ROC)
analysis15 was then used to optimise the REF thresholds for
the automated detection of RWM abnormalities, as described
below.
Statistical analysis
In protocol 1, for each calculated index of magnitude and
timing of RWM, the significance of the biases between the
RT3DE and CMR measurements was tested using paired t tests.
p Values ,0.05 were considered significant. In protocol 2, for
each patient, the level o agreement between the semiauto-
mated technique and the expert interpretation was assessed by
counting concordant grades (true positive and true negative) as
well as discordant grades (false positive and false negative)
assigned by the automated technique. The counts of concordant
and discordant grades were used to calculate the sensitivity,
specificity, positive and negative predictive values and the
overall accuracy, which were used for optimisation of REF
thresholds.
ROC analysis
REF thresholds for automated detection of RWM abnormalities
varied in each segment on varying the number of standard
deviat on below e mean REF of the normal group from 0 to 2
in 0.1 increments. For each increment, the sensitivity,
specificity, positive and negative predictive values and overall
accuracy of the semi-automated interpretation were calculated
against the expert interpretation. The ROC curve was then
constructed as a plot of sensitivity versus (12specificity) and
used to determine the optimal REF thresholds.15
RESULTS
RT3DE imaging and analysis were feasible in all study subjects,
including the cardiomyopathic patients despite their enlarged
ventricles (CMR-derived end-diastolic volume ranged from 90
to 526 ml and end-systolic volume ranged from 25 to 441 ml).
The time required for image analysis, including data retrieval,
surface detection and segmentation, and the computation of all
indices of RWM, was approximately 30 min on a Pentium 4
personal computer. Manual corrections were necessary to
optimise the position of the endocardial boundaries in 19 of
31 study subjects.
Figure 1B shows an example of a radial long-axis CMR image
obtained at end diastole in a patient with apical hypertrophic
cardiomyopathy. The detected endocardial surface (A) shows in
three d mensions the typ cal left ventricular morphology for
this condition, in close correspondence with the two-dimen-
sional image (B). Regional left ventricular volume curves (D)
show the expected ejection and filling phases of the cardiac
cycle. Figure 2 shows, in the same format, the RT3DE data
obtained in the same patient. The RT3DE-derived regional
volume curves (D) had similar shape, despite the less detailed
endocardial delineation, compared with the CMR images
(fig 1B).
Table 1 shows the results of the comparisons between the
RT3DE-derived indices of regional left ventricular function and
CMR reference values in protocol 1. The intertechnique
agreement was reflected by the high correlation coefficients,
essentially zero biases and relat vely wide limits of agreement.
Figure 3 shows the break-up of these data by left ventricular
level, obtained by separating basal, mid and apical segments. Of
note, there was a clear trend towards lower correlation with
CMR (fig 3A) in more distal segments for all measured indices,
with the exception of REF. The calculated biases were near zero
in all segments, with no significant differences between the
three left ventricular levels (not presented in a graphic format).
Interestingly, the limits of agreement were tighter for the apical
than for the non-apical segments (fig 3B).
In protocol 2, in the 15 patients with normal wall motion,



































Figure 1 Example of radial long-axis
cardiac magnetic resonance image of the left
ventricle obta ed at nd diastole in a patient
with apical hypertrophic cardiomyopathy (B)
and the detected endocardial surface (A).
Schematic ‘‘bull’s eye’’ representation of the
three-dimensional segmentation (C), with the
colour notation used for the different
segments in both the endocardial surface (A)
and the regional left ventricular volume-time
curves (D). Ant, anterior; ant sept, antero-
septal; inf, inferior; lat, lateral; post,
posterior; sept, septal.
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In	  table	  1	  are	  reported	  left	  atrial	  dimension:	  range	  values	  for	  adult	  man.	  
LEFT	  ATRIAL	  DIMENSION	   RANGE	  NORMAL	  
ADULT	  VALUES	  
ANTERO-­‐POSTERIOR	  DIAMETER	  (mm)	   28-­‐40	  
MEDIAL-­‐LATERAL	  DIAMETER	  (mm)	   28-­‐43	  
SUPERO-­‐INFERIOR	  DIAMETER	  (mm)	   41-­‐61	  
AREA	  (cm2)	   ‹	  20	  
VOLUME	  (ML)	   22-­‐58	  
(Data	  from	  Calkins	  H	  et	  al.,	  2007)	  
	  
In	  figure	  19	  echocardiographic	  images	  of	  parasternal	  long	  axis	  view	  and	  apical	  4-­‐chamber	  view.	  
	  
Figure	  19.	  Parasternal	  long	  axis	  view.	  LA-­‐	  left	  atrium	  and	  LA	  antero-­‐posterior	  diameter	  (A).	  Apical	  four	  chamber	  
view.	  Medial–lateral	  and	  Supero-­‐inferior	  diameters	  (B).	  Apical	  four	  chamber	  view.	  LA	  area	  (C).	  
	  




Figure	  20.	  Schematic	  representation	  of:	  parasternal	  long	  axis	  view	  (a),	  apical	  two-­‐chamber	  view	  (b)	  and	  apical	  
four-­‐chamber	  view	  (c).	  
LV	   -­‐	   left	   ventricle,	  RV	  –	   right	   ventricle,	  RA	  –	   right	   atrium,	  Ao	  –	  aortha,	  D1	  –	  antero-­‐posterior	  diameter,	  D2	   -­‐	  
medial–lateral	  diameter,	  L	  -­‐	  supero-­‐inferior	  diameter,	  A2	  –	  maximal	  atrial	  area	  in	  apical	  2	  chamber	  view,	  A4	  -­‐	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bifurcation posteriorly [8]. Therefore, the changes in AP
diameter may not be proportionate to and often underesti-
mate changes in other LA dimensions [9]. This may
explain the greater predictive value of LA volume for
cardiovascular events in comparison with LA AP diameter
[5, 10, 11].
Despite this fundamental limitation, previous studies
have shown the association between increased AP dimen-
sion by M-mode measurement and the development of AF
[12–15]. In the Framingham Heart Study [13], a 5-mm
incremental increase in the AP LA diameter on M-mode
was associated with a 39% increased risk for developing
AF during follow up. Similarly, the Cardiovascular Health
Study [12] reported a fourfold increase in the risk of
developing AF in patients with an AP LA diameter of
[5.0 cm. Increased AP LA dimension has also been
associated with increased risk of stroke [16–18] and
cardiovascular mortality [19–21].
Ellipsoid method
The ellipsoid model assumes that LA can be adequately
represented as a prolate ellipse, and LA volume can thus be
approximated by the equation: p/6 (L 9 D1 9 D2), where
L is long-axis from apical four-chamber, D1 is the AP
dimension from the parasternal long-axis and D2 is the
medial–lateral dimension from the apical four-chamber
view [22]. A simplified version has been reported by
Pritchett et al. [10] who substitute D2 with the septal-
lateral dimension from apical four-chamber view. The latter
method is also known as biplane dimension-length method.
LA volume estimated using this ellipsoid model has
been studied in patients with atrial fibrillation, left ven-
tricular systolic and diastolic dysfunction, as well as car-
diomyopathy (Table 1) [23–28]. Sabharwal et al. [29] have
shown that LA volume derived from this ellipsoid method
was an independent (albeit relatively weak) predictor of
total mortality in 109 patients with ischaemic cardiomy-
opathy, after adjusting for clinical and echocardiographic
variables (hazard ratio of 1.03, 95% CI 1.001–1.057,
p = 0.03). Another study found that LA volume decreased
significantly following successful direct current cardio-
version to sinus rhythm in patients with atrial fibrillation
from 38.5 to 21.7 ml at 3 months and 19.6 ml at 6 months,
following cardioversion of AF (p\ 0.02 for both) [30].
A more recent study on patients with suspected heart
failure referred from community also shown that indexed
LA volume was an independent predictor of mortality
(hazard ratio of 1.25, 95% CI 1.01–1.54, p = 0.04) [31].
Biplane area-length method
The biplane area-length method has been proposed to
overcome the limitations of single plane measurements.
This biplane area-length method is based on the following
equation: 8(A1)(A2)/3p(L), where A1 and A2 are the maxi-
mal LA area from the apical four-chamber and two-chamber
views, respectively, and L is the LA long-axis length mea-
sured from the middle of the plane of the mitral annulus to
the superior aspect of the LA [7]. The LA long-axis length,
L, is measured in both four-chamber and two-chamber
views, and the shorter of these is used in the formula.
Using this biplane area-length method, Tsang et al. [6]
have shown that an increase in LA volume is associated
with age-related cardiovascular events in an elderly cohort
and the development of AF [32] and heart failure [33] in
the community studies. Similarly, other investigators have
demonstrated an association between LA volume by the
biplane area-length method and the development of AF,
Fig. 1 Schematic presentation on methods of LA volume measure-
ment
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LA volume estimated using this ellipsoid model has
been studied in patients with atrial fibrillation, left ven-
tricular systolic and diastolic dysfunction, as well as car-
diomyopathy (Table 1) [23–28]. Sabharwal et al. [29] have
shown that LA volume derived from this ellipsoid method
was an independent (albeit relatively weak) predictor of
total mortality in 109 patients with ischaemic cardiomy-
opathy, after adjusting for clinical and echocardiographic
variables (hazard ratio of 1.03, 95% CI 1.001–1.057,
p = 0.03). Another study found that LA volume decreased
significantly following successful direct current cardio-
version to sinus rhythm in patients with atrial fibrillation
from 38.5 to 21.7 ml at 3 months and 19.6 ml at 6 months,
following cardioversion of AF (p\ 0.02 for both) [30].
A more recent study on patients with suspected heart
failure referred from community also shown that indexed
LA volume was an independent predictor of mortality
(hazard ratio of 1.25, 95% CI 1.01–1.54, p = 0.04) [31].
Biplane area-length method
The biplane area-length method has been proposed to
overcome the limitations of single plane measurements.
This biplane area-length method is based on the following
equation: 8(A1)(A2)/3p(L), where A1 and A2 are the maxi-
mal LA area from the apical four-chamber and two-chamber
views, respectively, and L is the LA long-axis length mea-
sured from the middle of the plane of the mitral annulus to
the superior aspect of the LA [7]. The LA long-axis length,
L, is measured in both four-chamber and two-chamber
views, and the shorter of these is used in the formula.
Using this biplane area-length method, Tsang et al. [6]
have shown that an increase in LA volume is associated
with age-related cardiovascular events in an elderly cohort
and the development of AF [32] and heart failure [33] in
the community studies. Similarly, other investigators have
demonstrated an association between LA volume by the
biplane area-length method and the development of AF,
Fig. 1 Schematic presentation on methods of LA volume measure-
ment
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LA	  size	  is	  usually	  measured	  by	  echocardiography	  at	  end-­‐systole,	  when	  the	  chamber	  is	  at	  its	  greatest	  
dimension,	  different	  methods	  of	  size	  assessment	  have	  been	  reported:	  
	   1)	   M-­‐Mode	   antero-­‐posterior	   diameter	   is	   measured	   from	   the	   leading	   edge	   of	   the	   posterior	  
aortic	  wall	  to	  the	  leading	  edge	  of	  the	  posterior	  LA	  wall	  at	  the	  parasternal	  long	  axis	  view	  (D1	  in	  Figure	  
20a)(Khoo	  CW	  et	  al.,	  2011).	  
Although	   this	   measurement	   has	   been	   used	   extensively	   in	   clinical	   and	   research	   work,	   it	   is	   now	  
recognized	  as	  an	  inaccurate	  representation	  of	  the	  true	  LA	  size	  (Lester	  SJ	  et	  al.,	  1999).	  	  
In	   fact,	   LA	   is	   a	   ellipsoid	   structure	  which	   presents	   three	   different	   diameters:	   longitudinal	   diameter	  
(supero-­‐inferior	  from	  the	  mid	  point	  of	  the	  mitral	  annulus	  to	  the	  superior	  wall),	  transverse	  diameter	  
(medial-­‐lateral,	   from	   the	   interatrial	   septum	   to	   the	   LA	   lateral	   wall)	   and	   antero-­‐posterior	   diameter;	  
enlargement	  of	   the	   LA	   is	  often	  asymmetrical	   and	  may	  occur	   in	   the	  medial-­‐lateral	   as	  well	   as	   in	   the	  
supero-­‐inferior	   axes,	  because	  enlargement	   in	   the	  antero-­‐posterior	  direction	  may	  be	   limited	  by	   the	  
thoracic	  cavity.	  
For	  this	  evidence	  LA	  antero-­‐posterior	  dimension	  is	  not	  an	  accurate	  reflector	  of	  LA	  volume,	  moreover	  
the	  discrepancy	  between	   left	  atrial	  antero-­‐posterior	  dimensions	  and	  volumes	  becomes	   increasingly	  
important	  as	  the	  left	  atrium	  dilates	  (Lester	  SJ	  et	  al.,	  1999).	  	  
It	  is	  not	  surprising	  that	  the	  agreement	  between	  LA	  dimension	  and	  LA	  volume	  was	  only	  fair	  and	  that	  
the	  relationship	  between	  LA	  size	  and	  cardiovascular	  disease	  burden	  and	  outcome	  is	  stronger	  for	  LA	  
volume	  than	  for	  LA	  dimension	  (Pritchett	  AM	  et	  al.,	  2003;	  Tsang	  TS	  et	  al.,	  2006).	  
	  
	   2)	  Ellipsoid	  method	  that	  assumes	  LA	  as	  an	  ellipse,	  and	  LA	  volume,	  obtained	  on	  the	  apical	  four-­‐
chamber	  view	  can	  thus	  be	  approximated	  by	  the	  equation:	  
	  
Volume	  =	  	  π	  	  /	  6	  *	  (L	  *	  D1	  *	  D2)	  π	  
	  
where	  L	  is	  supero-­‐inferior	  and	  D2	  is	  the	  medial–lateral	  diameter	  in	  apical	  four-­‐chamber	  view	  (Figure	  
20	  c);	  D1	  is	  the	  antero-­‐posterior	  diameter	  in	  parasternal	  long-­‐axis	  view	  (Figure	  20	  a).	  
	  
	   3)	   Biplane	   area-­‐length	   method	   that	   proposed	   to	   overcome	   the	   limitations	   of	   single	   plane	  
measurements.	  This	  biplane	  area-­‐length	  method	  is	  based	  on	  the	  following	  equation:	  
	  
Volume	  =	  8	  *	  (A2)	  *	  (A4)	  /	  3	  π	  	  *	  (L)	  
	  




respectively	  (Figure	  20	  a	  and	  b).	  
L	  is	  measured	  in	  both	  four-­‐chamber	  and	  two-­‐chamber	  views,	  and	  the	  shorter	  of	  these	  is	  used	  in	  the	  
formula.	  
	  
	   4)	  Biplane	  Simpson’s	  method	  states	  that	  the	  volume	  of	  a	  geometrical	  figure	  can	  be	  calculated	  
from	   the	   sum	   of	   the	   volumes	   of	   the	   smaller	   figures	   of	   similar	   shape	   (Lang	   RM	   et	   al.,	   2005).	   This	  
measurement	  assumes	  that	  the	  LA	  is	  oval	   in	  shape	  and	  the	  total	  volume	  as	  a	  series	  of	  stacked	  oval	  
discs	  can	  be	  derived	  with	  the	  formula:	  	  
	  
Volume	  =	  π	  	  /4	  *	  (h)*	  ∑(D1)	  *	  (D2)	  
	  
h	  is	  height	  of	  the	  discs.	  
	  
The	  biplane	  measurement	  makes	  fewer	  geometric	  assumptions	  and	  therefore	  is	  more	  accurate.	  
The	   systematic	   difference	   in	   LA	   volume	  between	   the	   ellipsoid	   compared	  with	   the	   area-­‐length	   and	  
Simpson’s	   method	   may	   be	   related	   to	   the	   dependence	   on	   the	   antero-­‐posterior	   dimension	   in	   the	  
former.	   Disproportionate	   increase	   in	   the	   medial–lateral	   and	   supero–inferior	   compared	   with	   the	  
constrained	  antero-­‐posterior	  dimension	  will	  result	   in	  greater	   increase	   in	  LA	  volumes	  derived	  by	  the	  
area-­‐length	  and	  Simpson’s	  method,	  both	  of	  which	  are	  not	  dependent	  on	  measurement	  in	  the	  antero-­‐
posterior	  dimension.	  Hence,	  despite	  good	  reproducibility,	  measurement	  of	  LA	  volume	  by	  either	  area-­‐	  
length	  or	  Simpson’s	  method	  is	  recommended	  (Lang	  RM	  et	  al.,	  2005).	  
Recently,	   it	   has	   been	   shown	   that	   LA	   volume	   by	   two-­‐dimensional	   (2D)	   or	   3D	   echocardiography	  






6 IMAGING	  IN	  ANIMALS	  
Noninvasive	   in	  vivo	   imaging	  has	  acquired	  a	  critical	  role	   in	  mouse	  cardiovascular	  research;	  however,	  
the	  very	  small	  size	  of	  mouse	  heart	  (diameter	  is	  approximately	  5	  mm	  and	  left	  ventricle	  wall	  is	  thinner	  
than	   1	   mm)	   and	   its	   rapid	   rate	   (600	   beats/min)	   pose	   significant	   challenges	   for	   cardiac	   imaging,	  
requiring	  expensive	  and	  specific	  equipment	  and	  established	  expertise.	  
Imaging	  systems	  used	  clinically	  have	  shown	  unable	  to	  provide	  sufficient	  spatial	  resolution	  to	   image	  
the	  equivalent	  anatomy	  of	  a	  mouse	  (Ford	  NL	  et	  al.,	  2003).	  
In	  fact	  some	  researchers	  tried	  to	  use	  a	  human	  magnetic	  resonance	  scanner	  to	  study	  the	  mouse	  heart	  
(as	  Franco	  and	  colleagues,	  who	  used	  a	  1.5T	  Philips	  Gyroscan	  NT	  whole	  body	  MR	  scanner,	  Franco	  F	  et	  
al.,	   1999),	   but	   it	   soon	   became	   clear	   that	   dedicated	   hardware	  was	   necessary	   and	   high	   spatial	   and	  
temporal	  resolution	  is	  mandatory	  (Gargiulo	  S	  et	  al.,	  2012).	  
As	  a	  result,	  specialized	  imaging	  systems	  from	  several	  modalities	  are	  being	  developed	  for	  small	  animal	  
imaging	  applications.	  
In	   Table	   2	   (Gargiulo	   S	   et	   al.,	   2012)	   are	   reported	   the	   different	   imaging	   techniques	   (and	   their	  
characteristic)	   that	   are	   currently	   used	   for	   morphological	   and	   functional	   phenotyping	   of	   mouse	  
cardiovascular	  system.	  
All	   these	   techniques	  are	  non	   invasive	  and	  allow	   to	   study	   longitudinally	   the	  biological,	  physiological	  





Specialized	   imaging	   systems	   are	   needed	   due	   to	   the	   small	   size	   and	   the	   high	   heart	   rates,	   and	   both	  
cardiac	   magnetic	   resonance	   imaging	   (CMR)	   and	   echocardiography	   are	   currently	   potential	   tools.	  
While	   conventional	   ultrasound	   imaging	   uses	   probes	   with	   centre	   frequencies	   up	   to	   15MHz,	   high-­‐




echocardiography	  (hf-­‐echo)	  has	  been	  shown	  to	  give	  accurate	  and	  reproducible	  measurements	  (Bose	  
aK	  et	  al.,	  2007;	  Okajima	  K	  et	  al.,	  2007).	  
Echocardiography	   has	   the	   benefits	   of	   being	   rapid	   and	   flexible,	   and	   the	   cost	   is	   relatively	   low.	  
However,	   image	   artefacts	   and	   or	   restricted	   imaging	   windows	   are	   frequent	   challenges,	   and	   the	  
observer	  dependency	  is	  substantial	  (Amundsen	  BH	  et	  al.,	  2011).	  Modern	  high	  magnetic	  field	  MR	  with	  
specialized	  RF	  coils	  and	  gradient	  systems	  (Slawson	  SE	  et	  al.,	  1998;	  Ruff	  J	  et	  al.,	  1998;	  Wiesmann	  et	  al.,	  
1998)	  can,	  on	  the	  other	  hand,	  give	  high-­‐quality	  images	  of	  the	  beating	  heart	  in	  almost	  any	  orientation,	  
but	  is	  more	  time-­‐consuming	  and	  has	  a	  higher	  cost.	  Murine	  CMR	  underwent	  great	  development	  since	  
the	   first	   results	   reported	   in	  1997	  by	  Siri	  and	  his	  group	  (Siri	  FM	  et	  al.,	  1997).	  At	   that	   time	  scientists	  
were	  not	  very	  optimistic	  about	  using	  MRI	  as	  a	  tool	  for	  imaging	  the	  mouse	  heart.	  James	  (James	  JF	  et	  
al.,	  1998)	  commented	  that	  this	   technique	  would	  not	  be	  widely	  used	  for	  murine	  studies	   in	  the	  near	  
future	   due	   to	   the	   hardware	   and	   software	   requirements.	   These	   have	   been	   fulfilled	   in	   recent	   MR	  
instruments	   and	   the	   study	   of	  mouse	   heart	   function	   is	   now	   routinary.	  Most	  mouse	   cardiac	   studies	  
since	  1997	  were	  aimed	  to	  measure	  the	  global	  heart	  functional	  parameters	  for	  two	  main	  applications:	  
compare	  heart	  function	  of	  phenotyping	  genetically	  modified	  mice	  with	  wild	  type	  controls	  (Franco	  F	  
et	  al.,	  1999;	  Brede	  M	  et	  al.,	  2001;	  Wilding	  JR	  et	  al.,	  2005)	  and	  haracterize	  the	  diseased	  heart	  (Yang	  Z	  
et	  al.,	  2004;	  Zhou	  R	  et	  al.,	  2003;	  Ross	  AJ	  et	  al.,	  2002;	  Wiesmann	  F	  et	  al.,	  2002;	  Hu	  TC	  et	  al.,	  2004),	  
such	  as	  infarcted	  or	  hypertrophic	  heart.	  
As	  in	  human	  CMR,	  ECG	  triggering	  is	  necessary	  to	  acquire	  dynamic	  images,	  and	  ECG	  pads	  or	  needles	  
can	   be	   used.	   ECG	   triggering	   causes	   long-­‐time	   acquisition	   and	   so	   to	   overcome	   this	   problems,	   a	  
sequence	  which	  allows	  retrospective	  self-­‐gating	  for	  dynamic	  cine	  imaging	  has	  been	  designed	  (Wang	  Y	  
et	  al.,	  1996;	  Heijman	  E	  et	  al.,	  2007).	  
For	  retrospective	  self-­‐gating,	  the	  gating	  signals	  are	  MR	  signal	  themselves	  (without	  spatial	  encoding)	  
and	  are	  acquired	  simultaneously	  with	  the	  image	  data,	  and	  by	  using	  time-­‐dependent	  changes	   in	  the	  
gating	   signal,	   a	   trace	   representative	   of	   cardiac	   motion	   can	   be	   reconstructed;	   if	   necessary	   also	  
respiratory	  motion	  can	  be	  accounted	  for	  in	  a	  similar	  manner	  (Wang	  Y	  et	  al.,	  1996;	  Heijman	  E	  et	  al.,	  
2007).	  	  
In	  recent	  years,	  the	  success	  of	  PET-­‐CT	  imaging	  in	  the	  clinical	  field	  has	  triggered	  substantial	  interest	  in	  
noninvasive	  molecular	  and	  anatomical	  imaging	  of	  small	  laboratory	  animals.	  The	  low	  spatial	  resolution	  
and	   high	   specificity	   of	   imaging	   probes	   allow	   only	   acquiring	   limited	  morphologic	   information	   from	  
micro	  PET	  or	  micro	  SPECT	  images,	  making	  molecular	  investigations	  difficult	  to	  interpret	  (Minino	  A	  et	  
al.,	  2001).	  
Today,	   X-­‐ray	   micro	   computed	   tomography	   (micro-­‐CT)	   can	   provide	   images	   with	   high-­‐resolution	  
isotropic	  voxels	  (volume	  elements)	  and	  low	  noise	  in	  relatively	  short	  acquisition	  times	  (Ford	  NL	  et	  al.,	  




Then,	   the	   introduction	   of	   micro-­‐PET/CT	   hybrid	   systems	   for	   imaging	   of	   small	   animals	   has	   greatly	  
enhanced	  the	  performance	  and	  the	  accuracy	  of	  nuclear	  imaging,	  allowing	  a	  fine	  spatial	  localization	  of	  
the	   radiotracer	   biodistribution	   and	   will	   facilitate	   the	   translation	   of	   molecular-­‐based	   imaging	   to	  





















Cardiovascular	  disease	  is	  a	  leading	  cause	  of	  mortality,	  thus	  the	  development	  of	  new	  technologies	  for	  
diagnosis,	   the	   release	   of	   new	   landmarks	   and	   the	   research	   of	   novel	   therapeutic	   agents	   are	  
fundamental	  for	  clinicians	  and	  researcher.	  
The	  use	  of	  animal	  models,	  in	  particular	  transgenic	  mice,	  has	  contributed	  to	  increase	  our	  knowledge,	  
providing	   new	   approaches	   focused	   to	   improve	   the	   diagnostic	   and	   the	   treatments	   of	   these	  
pathologies.	  
In	  mouse	  cardiovascular	   research	   the	  use	  of	   in	  vivo	   imaging,	   for	   its	   characteristic	  on	  non-­‐invasivity	  
and	   for	   the	   possibility	   to	   perform	   longitudinal	   analysis	   in	   the	   same	   animals,	   has	   acquired	   a	  
fundamental	  role.	  
However,	  the	  very	  small	  size	  of	  mouse	  heart	  (diameter	  is	  approximately	  5	  mm	  and	  left	  ventricle	  wall	  
is	   thinner	   than	   1	   mm)	   and	   its	   rapid	   rate	   (600	   beats/min)	   pose	   significant	   challenges	   for	   cardiac	  
imaging,	  requiring	  expensive	  and	  specific	  equipment	  and	  established	  expertise.	  
At	  the	  light	  of	  these	  remarks	  the	  objectives	  of	  the	  experimental	  activity	  were:	  
• set	  up	  an	  animal	  model	  of	  myocardial	   infarction	   (MI)	   induced	  by	  permanent	  coronary	  artery	  
ligation;	  
• set	  up	  of	  cardiac	  imaging	  of	  left	  ventricle,	  left	  atrium	  and	  appendage	  in	  healthy	  mice;	  
• evaluation,	   by	   imaging	   techniques,	   of	   the	   anatomical,	  morphological	   and	   functional	   changes	  
occurring	  at	  cardiac	  level	  in	  animals	  undergoing	  MI	  compared	  to	  healthy	  mice.	  
The	   second	   part	   of	   the	   project	   aimed	   to	   validate	   the	   effect	   of	   pharmacological	   treatments.	   In	  
particular	   we	   evaluate	   the	   effect	   of	   valsartan,	   a	   drug	   known	   to	   exert	   a	   beneficial	   effect	   on	  
cardiovascular	  system,	  investigating	  its	  effects	  on	  left	  ventricular	  and	  atrial	  remodeling	  after	  MI.	  	  
In	   particular	   we	   aimed	   to	   explore	   the	   complex	   interaction	   between	   atrium-­‐appendage	   and	  
ventricular	  remodeling.	  
Moreover	   a	   relation	   between	   the	   results	   of	   imaging	   techniques	   and	   the	   data	   obtained	  with	   gene	  
expression	  analysis	  were	  investigated.	  
	  
In	   order	   to	   reach	   these	   aims	  we	   used	   two	   different	   cardiac	   imaging	   techniques:	   cardiac	  magnetic	  
resonance	  (CMR)	  imaging	  and	  high	  frame	  rate	  echocardiography.	  
CMR	   imaging	   is	   used	   to	   investigate	   global	   and	   regional	   ventricular	   loss	   of	   function	   and	   the	  
remodeling	   occurs	   after	   MI.	   High	   frame	   rate	   echocardiography,	   because	   of	   its	   higher	   spatial	   and	  
temporal	  resolution,	  allow	  to	  visualize	  left	  atrium	  and	  its	  appendage	  and	  to	  assess	  reference	  values	  
of	   anatomy,	  morphology	   and	   function	   of	   these	   structures,	   and	   then	   the	   remodeling	   secondary	   to	  
ventricular	  dysfunction.	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1 ANIMAL	  MODELS	  
The	  procedures	  involving	  animals	  and	  their	  care	  respected	  our	  institutional	  guidelines,	  which	  comply	  
with	  national	  and	   international	   law	  and	  policies	   (4D.L.	  N.116,	  G.U.,	   supplement	  40,	  18-­‐2-­‐1992;	  EEC	  
Council	  Directive	  86/609,	  OJ	   L	  358,1,12-­‐12-­‐1987;	  National	   Institutes	  of	  Health’s	  Guide	   for	   the	  Care	  
and	  Use	  of	  Laboratory	  Animals	  and	  US	  National	  Research	  Council	  1996),	  and	  every	  effort	  was	  made	  
to	  minimize	  the	  number	  of	  animals	  used	  and	  their	  suffering.	  
	  
For	  our	  studies	  we	  used	  male	  and	  female	  C57Bl/6N	  mice	  (Charles	  River	  Laboratories,	  Calco,	  Italy)	  fed	  
ad	  libitum	  with	  standard	  chow	  and	  water.	  
At	   the	  end	  of	  experimental	  protocol	   the	  mice	  were	   sacrificed	  under	  anesthesia	   (intraperitoneal	  75	  
mg/kg	  ketamine	  hydrochloride	  and	  1	  mg/kg	  medetomidine	  hydrochloride).	  
	  
1.1 Myocardial	  Infarction	  
Myocardial	   infarction	   was	   induced	   by	   permanent	   ligation	   of	   the	   left	   anterior	   descending	   (LAD)	  
coronary	   artery.	   Anesthetized	   mice	   (intraperitoneal	   75	   mg/kg	   ketamine	   cloridrate	   and	   1	   mg/kg	  
medetomidine)	  were	  intubated	  endotracheally	  in	  a	  supine	  position	  with	  a	  steel	  tube	  and	  ventilated	  
with	  positive	  airway	  pressure	  (a	  tidal	  volume	  of	  140	  ml	  at	  150	  breaths/min)	  (Tarnavski	  O	  et	  al.,	  2004).	  
Tidal	  volume	  and	  ventilation	  rate	  were	  calculated	  as:	  
Vt	  =	  0.0062	  ·∙	  M1.01	  	  
Ventilation	  rate	  (breaths/minutes)	  =	  53.5	  ·∙	  M	  -­‐0.26	  
Vt	  is	  tidal	  volume	  and	  M	  is	  animal	  mass	  in	  Kg	  	  (Tarnavski	  O	  et	  al.,	  2004).	  
The	  chest	  cavity	  was	  then	  opened	  (with	  dissection	  at	  the	  fourth	  intercostal	  space)	  taking	  caution	  not	  
to	  damage	  the	   lung.	  The	  heart,	  partially	  covered	  by	  the	   lung,	  was	  then	  visible	  and	  the	  pericardium	  
removed	  so	  that	  the	  antero-­‐lateral	  heart	  surface	  was	  exposed.	  The	  LAD	  coronary	  artery	  should	  then	  
be	  visible	  as	  a	  pulsating	  bright	  red	  thin,	  running	  in	  the	  midst	  of	  the	  heart	  wall	  from	  underneath	  the	  
left	  atrium	  toward	   the	  apex.	   If	   the	  LAD	  artery	  couldn’t	  be	  visualized,	   the	   left	  atrial	  appendage	  was	  
lifted	  to	   locate	  the	  origin	  of	  the	  LAD	  artery	  from	  the	  aorta.	  The	  position	  of	  the	  ligation	  depends	  on	  
the	   volume	   of	   infarction	   desired	   (Tarnavski	   O	   et	   al.,	   2004).	   Once	   the	   site	   of	   ligation	   had	   been	  
determined,	  myocardial	   infarction	  was	   then	   induced	  by	  proximal	   ligation	   (1-­‐2	  mm	  below	  the	  tip	  of	  
left	  auricle)	  of	  the	  LAD	  coronary	  artery	  with	  a	  7.0	  silk	  suture.	  Occlusion	  was	  confirmed	  by	  the	  change	  
of	  color	  (becoming	  pale)	  of	  the	  anterior	  wall	  of	  the	  left	  ventricle	  (LV).	  The	  chest	  cavity	  was	  closed	  by	  
bringing	  together	  the	  4th	  and	  the	  5th	  ribs	  with	  one	  or	  two	  5–0	  silk	  suture	  (while	  applying	  pressure	  to	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the	  chest	  wall	  in	  order	  to	  reduce	  the	  volume	  of	  free	  air),	  then	  muscles	  and	  skin	  were	  closed	  layer	  by	  
layer	   with	   5–0	   silk	   suture.	   During	   surgery,	   which	   lasted	   about	   30	   min,	   body	   temperature	   was	  
maintained	  constant	  at	  37.5	  °C	  by	  means	  of	  a	  heating	  carpet.	  	  
As	  control	  of	  surgery	  procedure,	  sham	  operated	  mice	  underwent	  the	  same	  procedure	  but	  for	  tying	  
the	  suture	  that	  was	  nevertheless	  passed	  behind	  the	  LAD	  artery.	  	  
After	  surgery	  atipamezolo	  (0.05	  mg/kg)	  was	  administered	  to	  encourage	  animal	  awakening,	  then	  the	  
animal	  was	  extubated	  and	  monitored.	  
	  
2 EXPERIMENTAL	  PROTOCOLS	  
2.1 Cardiac	  Magnetic	  Resonance	  Setup	  And	  Validation	  	  
Thirty	  C57Bl/6N	   female	  mice	  8-­‐10	  weeks	  old	  were	  divided	   into	   two	  different	  experimental	  groups:	  
Myocardial	  Infarction	  (MI)	  n=20	  and	  sham-­‐operated	  (SHAM)	  n=10.	  
Before	  and	  nine	  days	  after	  surgery	  the	  mice	  were	  visualized	  with	  cardiac	  magnetic	  resonance	  (CMR).	  
At	   the	   end	   of	   last	   CMR	   examination	   the	   animals	   were	   sacrificed	   and	   the	   hearts	   were	   treated	   for	  
histological	  analysis.	  
2.2 Characterization	  Of	  Left	  Atrium	  In	  Normal	  Mice	  
Thirty	  10-­‐weeks-­‐old	  C57BL/6N	  mice	  (15/15	  Male/Female)	  underwent	  echocardiography.	  	  
To	   estimate	  measurement	   reproducibility,	   echocardiography	  was	   repeated,	   by	   the	   same	  operator,	  
after	  one	  week	  in	  10	  mice.	  
Then	  mice	  were	  sacrificed	  and	  heart	  treated	  for	  macroscopic	  inspection	  and	  histological	  analysis.	  
2.3 Echocardiographic	  Study	  Of	  Left	  Atrium	  In	  Infracted	  Mice	  
Thirty	  8-­‐10	  weeks-­‐old	  C57BL/6N	  female	  mice	  were	  divided	  in	  two	  experimental	  groups:	  	  Myocardial	  
Infarction	  (MI)	  n=20	  and	  sham	  operated	  (SHAM)	  n=10.	  
Mice	  underwent	  echocardiography	  and	  CMR	  at	  different	  time	  point:	  before	  and	  48	  hours,	  1,	  4,	  8	  and	  
12	  weeks	  after	  surgery.	  
2.4 Effects	  Of	  Pharmacological	  Treatment	  
Seventy	   C57Bl/6N	   female	   mice	   were	   divided	   into	   two	   different	   experimental	   groups:	   Myocardial	  
Infarction	  (MI,	  n=55)	  and	  sham-­‐operated	  (SHAM,	  n=15)	  mice.	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Twenty-­‐four	   hours	   after	   surgery	  mice	  were	   subjected	   to	   CMR	   and	   echocardiography	   and	   the	   EF%	  
calculated.	  On	  the	  basis	  of	  previous	  analysis,	  we	   included	   into	  the	  study	  MI	  mice	  with	  CMR	  EF%	   in	  
range	  35%-­‐45%.	  
The	  MI	  mice	   survived	   and	   included	  were	  divided	   into	   two	  experimental	   groups:	  MI-­‐Vehicle	   (n=15)	  
and	  MI-­‐Valsartan	  (n=15),	  treated	  daily	  with	  Valsartan	  1	  mg/Kg/die	  in	  drinking	  water.	  
All	   the	   animals	   underwent	   CMR	   at	   different	   time	   point	   1,	   and	   4	   weeks	   after	   surgery;	  
echocardiographic	  examination	  was	  performed	  the	  day	  after	  CMR	  acquisition	  
After	   the	   last	   echocardiographic	   examination	   mice	   were	   sacrificed	   and	   the	   hearts	   treated	   for	  
histological	  and	  genomic	  analysis.	  
	  
3 CARDIAC	  IMAGING	  
3.1 Cardiac	  Magnetic	  Resonance	  (CMR)	  Imaging	  
The	  Department	   of	   Pharmacological	   and	   Biomolecular	   Sciences	   of	   University	   of	  Milan	   is	   equipped	  
with	   a	   4.7	   T	   vertical-­‐bore	   MR	   magnet	   (Bruker	   Avance	   II	   200)	   for	   small	   animals,	   a	   system	   of	  
anesthesia,	  two	  different	  birdcage	  coil	  (3.8	  cm	  diameter	  for	  mice	  and	  6.4	  cm	  diameter	  for	  rats)	  and	  a	  
software	  (Intragate)	  for	  retrospective	  self-­‐gating	  dynamic	  cine	  imaging.	  	  	  
3.1.1 CMR	  Imaging	  Acquisition	  
For	   cardiac	   magnetic	   resonance	   (CMR)	   imaging	   acquisition,	   mice	   were	   anesthetized	   with	   inhaled	  
isofluorane	  (1.5–2	  vol%	  in	  oxygen),	   fixed	  on	  a	  holder	  and	  placed	  into	  the	  3.8	  cm	  coil.	  During	   image	  
acquisition	   isofluorane	   administration	   was	   maintained	   and	   the	   mice	   temperature	   was	   monitored	  
rectally	  (Franzosi	  M	  et	  al.,	  2011).	  
The	  cine	  images	  were	  recorded	  using	  a	  gradient	  echo	  sequence	  with:	  TE=1.9	  ms,	  TR=10	  ms,	  FoV=4x4	  
cm	  with	  a	  slice	  thickness	  of	  1mm	  and	  an	  in-­‐plane	  resolution	  of	  312	  mm2.	  
A	  series	  of	  scout	  images	  were	  first	  acquired	  to	  define	  landmark	  points	  for	  the	  acquisition	  of	  the	  long-­‐
axis	  4	  chamber	  view	  and	  then,	  orthogonally	  to	  it,	  the	  short-­‐axis	  sections.	  
Magnetic	   resonance	   volume	   data	   (to	   evaluate	   left	   ventricular	   function)	   was	   acquired	   in	   multiple	  
contiguous	  short-­‐axis	  slices	  (from	  apex	  to	  base,	  every	  1	  mm	  covering	  all	  the	   left	  ventricle)	  using	  12	  
frames	   for	   each	   cardiac	   cycle.	   Long	   and	   short	   axis	   cine	   acquisition	  was	   based	   on	   a	   gradient	   echo	  
sequence	   (Intragate,	   Bruker)	  with	   a	   non-­‐spatially	   encoded	   free	   induction	  decay	   (FID)	   navigator	   for	  
every	  acquired	  echo	  (Heijman	  E	  et	  al.,	  2007)	  used	  for	  retrospective	  gating	  as	  follows:	  the	  module	  and	  
phase	  of	  the	  FID	  signal,	  together	  with	  their	  derivatives,	  were	  combined	  to	  obtain	  a	  time-­‐dependent	  
signal	  that	  provides	  information	  on	  heartbeat	  and	  respiration	  cycle	  that	  was	  used	  to	  “sort”	  pieces	  of	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information	  that	  give	  rise	  to	  the	  images	  	  to	  the	  right	  cardiac	  frame.	  This	  retrospective	  reconstruction	  
allows	   for	   high	   quality	   cardiac	   cine	   images	   even	   in	   the	   presence	   of	   considerable	   variations	   in	  
respiratory	  and/or	  cardiac	  rates	  during	  the	  acquisition	  time	  (Franzosi	  M	  et	  al.,	  2011).	  
3.1.2 CMR	  Image	  Analysis	  
3.1.2.1 Global	  ventricular	  function	  
The	  magnetic	  resonance	  images	  were	  analyzed	  using	  custom	  software	  implemented	  in	  Matlab	  (The	  
Mathworks	  Inc.,	  Natick,	  MA).	  Our	  software	  measures	  left	  ventricle	  area	  for	  each	  short	  axis	  section.	  
First,	  the	  images	  are	  cropped	  manually	  selecting	  a	  region	  of	  interest	  (ROI)	  surrounding	  the	  LV	  on	  the	  
end-­‐diastolic	  frame	  .	  
In	   each	   images	   the	   endocardial	   border	   is	   semi-­‐automatically	   detected	   using	   a	   local	   thresholding	  




Figure	  21A.	  Selection	  of	  region	  of	  interest	  (ROI)	  included	  left	  and	  right	  ventricles.	  	  
	  
	  
	  Figure	  21B.	  Detection	  of	  left	  ventricle	  endocardial	  border.	  
	  
For	  each	  short	  axis	  slice	  an	  Area	  max	  (A	  max)	  and	  Area	  min	  (A	  min)	  are	  computed.	  
End	  diastolic	  and	  end	  systolic	  volumes	  (EDV	  and	  ESV)	  are	  then	  computed	  as	  sum	  of	  A	  max	  and	  A	  min	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Stroke	   volume	   (SV,	   i.e.	   the	   blood	   volume	   ejected	   for	   each	   beat)	   and	   ejection	   fraction	   (EF%,	  
percentage	  of	  blood	  volume	  ejected	  for	  each	  beat)	  are	  derived	  as:	  
• SV	  =	  EDV-­‐	  ESV.	  
• EF%	  =	  SV	  /	  EDV*100	  
	  
3.1.2.2 Regional	  ventricular	  function	  
For	  a	  quantitative	  analysis	  of	  regional	  endocardial	  wall	  motion	  and	  regional	  ejection	  fraction,	  the	  LV	  
cavity	  of	  each	  short	  axis	  slice	  are	  divided	  into	  six	  60°	  sectors	  (anterior,	  antero-­‐septal,	  septal,	  lateral,	  
posterior	  and	   inferior).	  The	  sectors	  are	  univocally	  determined	  by	   the	  centroid	  of	   the	  cavity	  and	  an	  
operator	   provided	   point	   at	   the	   junction	   between	   the	   right	   ventricular	   free	   wall	   and	   the	  
interventricular	  septum.	  
For	  each	  sector	  the	  software	  produces	  the	  regional	  fractional	  area	  change	  (RFAC)	  as:	  
(Regional	  end	  diastolic	  area	  –	  regional	  end	  systolic	  area)	  /	  regional	  end	  diastolic	  area	  *	  100.	  
This	  procedure	  is	  repeated	  for	  each	  slice.	  
RFAC	   is	  graphically	  displayed	   in	  a	   ‘‘bull’s	  eye’’	   format	   in	  which	   the	   inner	  circle	   represents	   LV	  apex,	  
and	  the	  outer	  rings	  the	  consecutive	  slices	  from	  the	  apex	  to	  the	  base;	  RFAC	  is	  color	  coded:	  red	  tones	  
represent	  lower	  and	  the	  green	  tones	  higher	  values.	  
In	   order	   to	   compute	   group	   averages	   our	   software	   could	   interpolate	   different	   number	   of	   slices	  
according	  to	  the	  length	  of	  each	  ventricle.	  
In	  order	  to	  classify	  RFAC	  values	  in	  “normal”	  and	  “reduced”	  to	  validate	  bull’s	  eye	  with	  histology	  a	  ROC	  
analysis	  was	  performed	  (Franzosi	  M	  et	  al.,	  2011).	  
3.1.2.3 Left	  ventricle	  diameter	  and	  wall	  thickness	  
On	   mid-­‐papillary	   slice,	   in	   end-­‐diastolic	   frame	   we	   measured	   (Photoshop)	   left	   ventricle	   internal	  
diameter	  anterior	  and	  posterior	  wall	  thickness	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3.2 High	  Frame	  Rate	  Echocardiography	  (Echo)	  
The	  Department	   of	   Pharmacological	   and	   Biomolecular	   Sciences	   of	   University	   of	  Milan	   is	   equipped	  
with	  high	  resolution	  echocardiography	  for	  small	  animals	  (Vevo	  2100,	  VisualSonics,	  Toronto,	  Canada).	  
Animals	  were	  anesthetized	   (1%	   isoflurane	   in	  100%	  oxygen)	  and	   laid	  supine	  on	  a	  heated	  support	   to	  
maintain	  physiological	  body	  temperature.	  Their	  legs	  were	  gently	  taped	  to	  conductive	  pads	  to	  provide	  
ECG	  and	  respiration	  monitoring	  and	  recording.	  Animals	  were	  stabilized	  until	  HR	  ≥	  420	  bpm,	  then	  the	  
examination	  lasted	  about	  30	  min.	  
All	   images	   were	   acquired	   using	   a	   30-­‐MHz	   linear	   array	   transducer	   providing	   axial	   and	   lateral	  
resolution	  of	  respectively	  50	  µm	  and110	  µm.	  Respiration	  and	  ECG	  tracings	  were	  synchronised	  with	  
imaging.	  
	  
For	  image	  analisys	  Vevo	  software	  (VisualSonics,	  Toronto,	  Canada)	  was	  used	  for	  left	  ventricle	  (LV)	  M-­‐
mode,	  2D	  measurements,	   and	  pulsed	  Doppler	   velocities;	  Medimatic	   software	   (Medimatic,	  Genova,	  
Italy)	  was	  used	  for	  the	  left	  atrium	  (LA)	  2D	  measurements.	  Recordings	  were	  analysed	  off-­‐line	  blindly.	  
Based	  on	  a	  previous	  pilot	  study,	  mice	  were	  imaged	  in	  four	  views:	  	  
1)	  the	  left	  parasternal	  long	  axis	  view	  (2D	  LV	  long	  axis);	  	  
2)	  the	  parasternal	  short	  axis	  view	  (M-­‐mode	  and	  2D	  LV	  dimensions	  and	  systolic	  function);	  	  
3)	  the	  standard	  apical	  4-­‐chamber	  view	  optimized	  for	  the	  LA	  cavity	  [2D	  LA	  dimensions	  and	  function;	  
mitral	  valve	  (MV)	  annulus	  dimensions	  and	  mitral	  pulsed	  Doppler	  flow	  velocity](Figure	  22).	  
4)	   an	   apical	   4-­‐chamber	   view	   modified	   with	   a	   counter-­‐clockwise	   rotation	   around	   the	   tip	   of	   the	  
transducer	   to	   visualize	   left	   atrium	   appendage	   (LAA)	   (2D	   dimensions	   and	   pulsed	   Doppler	   flow	  
velocity),	  the	  LA-­‐LAA	  duct,	  and	  a	  right	  pulmonary	  vein	  (PV)	  (Figure.	  23A).	  Then,	  from	  this	  view,	  clock-­‐	  
and	  counter-­‐clockwise	  rotations	  around	  the	  transducer	  axis	  allowed	  to	  image	  additional	  PVs	  (Figures.	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Figure	  22.	  Standard	  apical	  4-­‐chamber	  to	  visualize	  Left	  Atrium.	  
	  
	  
Figure	  23.	  Modified	  apical	  4-­‐chamber	  view	  to	  visualize	  left	  atrial	  appendage,	  duct	  and	  the	  right	  superior	  PV	  (A);	  




ECG:	   The	   R-­‐R	   and	   P-­‐R	   (from	   the	   end	   of	   the	   P	   wave	   to	   the	   beginning	   of	   the	   QRS)	   intervals	   were	  
measured,	  and	  the	  Q	  wave	  used	  as	  a	  time	  reference	  for	  pulsed	  Doppler	  blood	  flow	  velocities.	  
3.3.1 Left	  Ventricle	  	  
To	   calculate	   LV	   end-­‐diastolic	   (EDV)	   and	   end-­‐systolic	   volume	   (ESV),	   stroke	   volume	   (SV),	   ejection	  
fraction%	   (EF%)	   and	   cardiac	   output	   (CO)	   we	   used	   Visualsonic’s	   Simpson	   protocol,	   based	   on	   end	  
diastolic	  and	  end	  systolic	  areas	  of	  3	  characteristic	  short	  axis	  slice	  (apical,	  mid-­‐papillary	  and	  base)	  and	  
long	  axis	  dimension	  (on	  end	  diastolic	  and	  end	  systolic	  frame)	  from	  apex	  to	  plane	  of	  the	  mitral	  valve	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leaflet.	   From	   the	   same	   views,	   long	   axis	   systolic	   shortening	   and	   long/short	   axis	   ratio	   were	   also	  
calculated.	  	  
On	   M-­‐mode	   LV	   short	   axis	   view	   we	   measured	   all,	   end	   diastolic	   and	   end	   systolic,	   posterior	   and	  
anterior,	  LV	  wall	  thickness	  and	  LV	  diameter.	  From	  these	  fractional	  shortening	  was	  computed	  and	  LV	  
mass	  estimated.	  
Isovolumic	   contraction	   (IVCT),	   relaxation	   (IVRT)	   and	   LV	   ejection	   times	   were	   measured	   on	   pulsed	  
Doppler	   recordings	   of	   simultaneous	   LV	   outflow	   and	   transmitral	   flow	   and	   used	   to	   calculate	   the	  
myocardial	  performance	  index	  (MPI)	  as	  [(IVCT	  +	  IVRT)	  /	  LV	  ejection	  time].	  
3.3.2 Left	  Atrium	  
	  The	  area	  of	  each	  frame	  of	  three	  consecutive	  cardiac	  cycles	  was	  measured	  by	  planimetry	  and	  plotted	  
as	   LA	   function	   curve.	   Three	   frames	   attracted	   attention:	   the	   minimum	   and	   maximum	   area	   and	   a	  
frame	  (named	  “notch”)	  during	  LA	  filling	  when	  a	  pause	   in	  LA	  dimension	   increase	  was	  observable.	   In	  
these	  frames	  longitudinal	  (supero-­‐inferior,	  from	  the	  mid	  point	  of	  the	  mitral	  annulus	  to	  the	  superior	  
wall)	   and	   transverse	   diameters	   (septal-­‐lateral,	   from	   the	   interatrial	   septum	   to	   the	   LA	   lateral	   wall,	  
using	  the	  upper	  border	  of	  the	  LA-­‐LAA	  duct	  as	  a	  marker)	  were	  also	  measured	  in	  order	  to	  calculate	  LA	  
volumes	   using	   Simpson’s	   formula.	   Accordingly	   absolute	   and	   fractional	   volume	   changes	   were	  
computed	  during:	  early	  (from	  min	  to	  notch),	  late	  (from	  notch	  to	  max)	  and	  total	  LA	  reservoir	  filling.	  
The	  longitudinal/transverse	  LA	  axis	  ratio	  at	  minimum	  and	  maximum	  were	  also	  computed.	  
3.3.3 Left	  Atrial	  Appendage	  
	  The	  LAA	  maximum	  long	  axis	  was	  measured	  as	  the	  mid-­‐line	  curve	  between	  the	  LAA	  apex	  and	  duct.	  
The	  maximum	  and	  minimum	  diameters	  were	  measured	  deriving	  duct	   diameter	   fractional,	   and	   the	  
minimum,	  maximum	  and	  mean	  duct	  areas	  were	  calculated	  (assuming	  a	  circular	  orifice).	  	  
The	  trans-­‐ductal	  LAA	  flow	  pattern	  in	  the	  pilot	  study	  showed	  two	  positive	  early	  and	  late	  filling	  waves,	  
and	  a	  negative	  diastolic	  outflow	  wave.	  Duration,	  peak	  velocity	  and	  the	  velocity-­‐time	  integral	  of	  each	  
were	  measured	   by	   calculating:	   total	   reservoir	   inflow	   integral	   (early	   +	   late	   filling);	   early/late	   inflow	  
integral	   ratio;	   total	   inflow/outflow	   integral	   ratio;	   reservoir	   inflow	   (integral	  ×	  mean	   duct	   area)	   and	  
emptying	  outflow	  volumes	  (integral	  ×	  maximum	  duct	  area).	  
Left	  appendage	  volume	  reservoir	  was	  calculated	  as	  the	  average	  of	  Doppler	  total	  inflow	  and	  outflow	  
reservoir.	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3.3.4 Atrial	  reservoir	  and	  conduit	  flow	  
	  Total	   left	  venous	  reservoir	  volume	  was	  estimated	  as	  sum	  of	  2D	  left	  atrium	  reservoir	  filling	  and	  left	  
appendage	  volume	  reservoir.	  Total	  conduit	  flow	  was	  calculated	  as:	  LV	  SV	  –	  total	  left	  venous	  reservoir	  
volume.	  
3.3.5 Pulmonary	  Vein	  
	  The	  maximum	  diameter	  of	  the	  right	  superior	  PV	  was	  measured	  proximally	  to	  the	  LA	  orifice	  on	  colour	  
Doppler	  images,	  2D	  imaging	  alone	  being	  of	  insufficient	  quality,	  and	  PV	  area	  was	  calculated	  (circular	  
geometry).	  The	  flow	  pattern	  in	  the	  pilot	  study	  showed	  two	  forward	  early	  and	  late	  LA	  filling	  waves,	  a	  
single	   forward	   diastolic	   wave	   and	   no	   reverse	   flow.	   The	   duration,	   peak	   velocity	   and	   velocity-­‐time	  
integral	   of	   each	   wave	   were	   measured,	   diastolic	   flow	   volumes	   (velocity	   integral	   ×	   PV	   area)	   were	  
calculated.	  	  
3.3.6 Mitral	  Valve	  
	  The	   annulus	   diameter	   was	   measured	   as	   the	   distance	   between	   the	   leaflet	   hinge	   points	   at	   valve	  
opening.	   The	  mid-­‐point	   systolic	   displacement	   (LV	  base	  descent)	  was	   also	  measured.	   Peak	   velocity,	  
total	  velocity-­‐time	  integral,	  and	  duration	  of	  flow	  were	  measured	  on	  color	  Doppler	  images.	  	  
	  
4 TISSUE	  ANALYSIS	  
4.1 Mouse	  hearts	  preparation	  
4.1.1 Histology	  	  
The	   abdominal	   aorta	  was	   cannulated,	   the	   heart	   was	   arrested	   in	   diastole	  with	   a	   solution	   of	   CdCl2	  
(0.1M)	  and	  KCl	  (1M),	  retrogradely	  perfused	  for	  10	  min	  with	  0.01M	  phosphate	  saline	  buffer	  (PBS)	  and	  
then	  with	  4%	  (vol/vol)	  phosphate-­‐buffered	  formalin	  for	  10	  min,	  postfixed	  in	  4%	  phosphate-­‐buffered	  
formalin	  for	  24	  hours,	  embedded	  in	  Paraplast	  (Sigma-­‐Aldrich).	  
4.1.2 Macroscopic	  Inspection	  	  
Vascular	   cast	   were	   prepared:	   10	   hearts	   (5/5	   M/F)	   were	   retrogradelly	   perfused	   with	   a	   silicone	  
elastomer	  (1	  ml/min)	  through	  the	  cannulated	  abdominal	  aorta	  to	  build	  vascular	  and	  heart	  cast;	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4.1.3 Genomic	  Studies	  	  
The	  abdominal	  aorta	  was	  cannulated	  and	  the	  heart	  (n=6	  for	  each	  group)	  was	  retrogradely	  perfused	  
for	  10	  mins	  only	  with	  PBS.	  A	  portion	  of	  posterior	  wall	  was	   collected	   in	  RNA	   later	   and	   stored	   for	  2	  
weeks	  at	  4°C,	  then	  they	  were	  removed	  from	  RNA	  later	  and	  freeze	  at	  -­‐80°C.	  	  
	  
4.2 Histological	  Analysis	  
4.2.1 Section	  Preparation	  
Coronal	  or	  axial	  (from	  base	  to	  apex)	  consecutive	  eight	  micrometers	  sections	  were	  prepared.	  An	  axial	  
section	  corresponding	  to	  each	  CMR	  slice	  was	  selected	  for	  hematoxilin	  -­‐	  eosin	  staining.	  	  
4.2.2 Hematoxilin	  –	  Eosin	  And	  Sirius	  Red	  Staining	  
After	  deparaffination	  (6	  +	  6	  mins	  in	  xilene)	  and	  rehydratation	  (3	  mins	  each	  in	  absolute,	  96%,70%,50%	  
ethylic	   alcool	   and	  H2O	  bidist)	   the	   sections	  were	   stained,	   then	  washed,	  disidratated	   (1	  min	  each	   in	  
70%,	  96%	  and	  absolute	  ethylic	   alcool	   and	  10	  mins	   in	   xilene)	   and	  mounted	  with	  DPX	  mountant	   for	  
microscopy	  (BDH)	  and	  acquired	  with	  a	  high-­‐resolution	  digital	  camera	  using	  1:1	  macro-­‐lens.	  	  
For	  hematoxilin-­‐eosin	  staining	  the	  sections	  were	  incubated	  for	  4	  mins	  in	  each	  solution;	  for	  Sirius	  red	  
staining	  the	  sections	  were	  incubated	  with	  0.1%	  Sirius	  Red	  Solution	  (Direct	  Red	  80,	  Sigma	  Alcrich)	  in	  
picric	  acid	  for	  30	  mins.	  
4.2.3 Immunohistochemistry	  
Deparaffinized	  and	   rehydrated	  heart	   sections	  were	   incubated	   in	  10%	  normal	  goat	   serum	   (Dako)	   in	  
0.01M	  PBS,	  0.1%	  Triton	  X-­‐100	   for	  45	  min.	  Primary	  and	  secondary	  antibodies	  were	  prepared	   in	  PBS	  
and	  0.1%	  Triton	  X-­‐100.	  	  
Appropriate	  secondary	  antibodies	  were	  applied	  for	  2	  h	  at	  room	  temperature.	  
For	  nuclear	  staining,	  the	  sections	  were	  washed	  with	  Hoechst	  33258	  (2.5	  g/ml;	  Invitrogen)	  in	  PBS	  for	  
15	  min,	  and	  analysed	  by	  using	  an	  inverted	  fluorescence	  microscope	  (200	  M;	  Zeiss)	  with	  a	  CCD	  camera	  
(AxioCam	  HRm;	  Zeiss)	   connected	   to	  a	  PC	   loaded	  with	  Axiovision	   software	   (Zeiss).	   The	   staining	  was	  
semi-­‐quantitatively	   assessed	   by	   two	   blinded	   reviewers,	   and	   the	   average	   of	   the	   two	   analyses	   was	  
reported.	  
To	   detect,	   respectively,	   cardiomyocytes,	   smooth	  muscle	   cells	   and	   cardiac	   fibroblasts,	   the	   sections	  
were	   incubated	   overnight	   at	   4°C	  with	   a	   dilution	   of	  mouse	  monoclonal	   antibody	   anti	   α-­‐sarcomeric	  
actin	  (1:800),	  α-­‐smooth	  muscle	  actin	  (1:600),	  or	  anti-­‐vimentin	  (1:1500)	  (all	  Sigma-­‐Aldrich).	  To	  detect	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endothelial	   cells,	   endogenous	   peroxidase	   activity	   was	   blocked	   in	   3%	   H2O2	   in	   methyl	   alcohol/PBS	  
50/50	   for	   20	  min,	   and	   the	   sections	   were	   incubated	   overnight	   at	   4°C	   with	   isolectin	   B4	   peroxidase	  
(1:100;	   Sigma-­‐Aldrich).	   Appropriate	   secondary	   antibodies	   (Alexa	   555	   goat	   anti-­‐mouse	   IgG	   [1:600,	  
Invitrogen],	  Alexa	  546	  goat	  anti-­‐mouse	  IgM	  [1:600,	  Invitrogen],	  and	  fluorescein-­‐conjugated	  goat	  anti-­‐
horseradish	  peroxidase	  [1:100	  Jackson	  ImmunoResearch])	  were	  applied	  for	  2	  h	  at	  room	  temperature.	  
The	  staining	  was	  semi-­‐quantitatively	  assessed	  by	  two	  blinded	  reviewers,	  and	  the	  average	  of	  the	  two	  
analyses	  was	  reported.	  	  
4.2.4 Infarct	  Size	  
On	  Sirius	  red	  staining	  (one	  section	  for	  each	  mm)	  for	  5	  hearts/group,	  the	  infarct	  size	  (in	  percent)	  was	  
calculated	  as	  infarct	  length	  divided	  by	  the	  total	  LV	  circumference.	  
	  
4.3 CMR	  Bull’s	  Eyes	  Validation	  With	  Histology	  
On	   images	   of	   hematoxylin-­‐eosin	   staining	   (one	   section	   for	   each	   mm),	   left	   ventricular	   cavity	   was	  
manually	  divided	   into	  six	  60°	  sectors	   (anterior,	  antero-­‐septal,	   septal,	   lateral,	  posterior	  and	   inferior)	  
based	  on	  the	  position	  of	  the	  junction	  between	  the	  right	  ventricular	  free	  wall	  and	  the	  interventricular	  
septum.	  
The	   bull’s	   eye	   sector	   of	   7	   mice	   for	   each	   experimental	   groups	   were	   compared	   to	   respective	  
histological	  one.	  
On	   the	   basis	   of	   scar	   tissue	   and	   fiber	   organization/disorganization	   each	   segment	   was	   classified	   as	  
abnormal	  (ischemic)	  if	  the	  percentage	  of	  scar	  tissue	  contained	  in	  each	  sector	  was	  more	  than	  50%	  of	  
the	  relevant	  myocardium.	  Otherwise,	  it	  was	  classified	  as	  normal.	  
The	   number	   of	   the	   sector	   concordant	   (true	   positive	   and	   negative),	   as	   well	   as	   discordant	   (false	  
positive	  and	  negative)	  were	  counted.	  
Segment	  counts	  were	  used	  to	  calculate	  the	  sensitivity,	  specificity	  and	  accuracy	  
4.4 Gene	  Expression	  Analysis	  
From	   non-­‐infarcted	   posterior	   wall	   of	   6	   hearts/group,	   total	   RNA	   from	  was	   extracted	   using	   Tripure	  
isolation	  buffer	  (Roche,	  Italy)	  and	  RNeasy	  Mini	  kit	  (Qiagen,	  CA,	  USA).	  
RNA	  integrity	  and	  quantity	  was	  assessed	  by	  capillary	  electrophoresis	  using	  RNA	  6000	  Pico	  Chips	  on	  a	  
2100	  Bioanalyzer	  (Agilent	  Technologies).	  
Microarray	  data	  pre-­‐processing	  and	  quality	  assessment	  and	  missing	  data	  imputation	  were	  performed	  
using	   the	  GenomeStudio	   version	  2011.1	   software	   (Illumina).	   The	   software	  package	  BRB-­‐ArrayTools	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version	  4.3.0	  Beta_1,	  developed	  by	  Dr.	  Richard	  Simon	  and	  BRB-­‐ArrayTools	  Development	  Team	  at	  the	  
National	   Cancer	   Institute	   (NCI),	   NIH,	   was	   used	   for	   data	   adjustment,	   gene	   filtering,	   and	   statistical	  
analysis.	  The	  package	  includes	  R	  version	  2.15.1,	  a	  software	  environment	  for	  statistical	  computing	  and	  
graphics,	  and	  tools	  from	  Bioconductor	  version	  2.10	  for	  the	  analysis	  and	  annotation	  of	  Illumina	  chips.	  
Whole-­‐genome	   gene	   expression	   profiling	   will	   be	   performed,	   following	   the	   manufacturer’s	  
instructions,	   using	   Mouse	   Illumina	   Expression	   BeadChip	   microarrays,	   which	   provide	   genomewide	  
transcriptional	  coverage	  of	  all	  annotated	  genes,	  gene	  candidates,	  and	  splice	  variants.	  
Identification	  of	  genes	  differentially	  expressed	  between	  MI-­‐vehicle	  and	  MI-­‐valsartan,	  RNA	  pools	  was	  
performed	  by	  ANOVA	  on	  log	  intensities	  in	  combination	  with	  the	  random	  variance	  model	  (Wright	  GW	  
et	  al.,	  2003),	  setting	  the	  threshold	  p-­‐value	  to	  <	  0.001.	  In	  order	  to	  control	  for	  the	  false	  discovery	  rate	  
(FDR),	   a	  q-­‐value	  was	  estimated	   for	  each	  gene	   (Storey	   JD	  et	   al.,	   2003).	   The	  q-­‐value	  was	  used	  as	  an	  
FDR-­‐based	  measure	  of	  significance	  and	  the	  threshold	  α	  was	  set	  to	  <	  0.01.	  Finally,	  a	  fold	  change	  cut-­‐
off	  of±1.2	  was	  applied	  to	  focus	  on	  meaningful	  differentially	  expressed	  genes.	  
Gene	  functional	  classification	  was	  performed	  using	  the	  online	  Database	  for	  Annotation,	  Visualization	  
and	  Integrated	  Discovery	  (DAVID)	  v.	  6.7	  Bioinformatics	  Resources	  at	  the	  National	  Institute	  of	  Allergy	  
and	   Infectious	   Diseases	   (NIAID),	   NIH	   (http://david.abcc.ncifcrf.gov).	   DAVID	   functional	   annotation	  
chart	  tool	  was	  used	  to	  test	  Gene	  Ontology	  (GO)	  terms	  for	  biological	  process	  and	  molecular	  functions	  
and	   Swiss-­‐Prot	   (SP)	   and	   Protein	   Information	   Resource	   (PIR)	   keywords	   for	   functional	   categories,	   in	  
order	  to	  identify	  significantly	  over-­‐represented	  biological	  themes	  in	  the	  differentially	  expressed	  gene	  
set.	  GO	  gene	  set	  enrichment	  analysis	  was	  performed	  using	  the	  EASE	  algorithm,	  which	  compares	  the	  
representation	  of	   functional	   classes	   for	   genes	  within	  differentially	   regulated	   subset	   to	   the	  entirety	  
represented	   on	   the	   array.	   EASE	   performs	   a	   conservative	   adjustment	   of	   the	   Fisher’s	   exact	   test	   to	  
calculate	   the	  probability	   that	   the	  composition	  of	   the	  differentially	  expressed	   set	  occurs	  by	  chance.	  
The	  DAVID	  tool	  was	  run	  with	  the	  following	  settings:	  a	  function/process	  was	  considered	  modulated	  by	  
treatment	  if	   it	  contains	  at	   least	  3	  genes	  differentially	  expressed	  (count	  threshold	  per	  term)	  and	  the	  
significance	  level	  (modified	  Fisher	  Exact	  p-­‐value,	  EASE	  score)	  was	  less	  than	  0.05.	  
	  
5 STATISTICAL	  ANALYSIS	  
5.1 Cardiac	  Magnetic	  Resonance	  Setup	  And	  Validation	  	  
To	  evaluate	   the	   changes	  occurring	   to	   LV	  parameters	   the	   two	  experimental	   groups	  were	   compared	  
using	  unpaired	  t	  test.	  
In	   order	   to	   test	   the	   reliability	   of	  MR	  with	   retrospective	   gating	   in	   providing	   information	   useful	   for	  
automated	  regional	  wall	  motion	   interpretation,	  we	  proceeded	  as	  follows:	  for	  each	  sector	  (anterior,	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antero-­‐septal,	  septal,	   lateral,	  posterior	  and	   inferior),	  ROC	  analysis	  was	  computed	  by	  comparing	  the	  
histological	  interpretation	  obtained	  in	  the	  sub-­‐group	  of	  7	  mice	  with	  the	  RFAC	  results	  obtained	  from	  
the	   corresponding	   MR	   images	   by	   counting	   the	   segments	   where	   concordant	   (true	   positive	   and	  
negative)	  as	  well	  as	  discordant	  (false	  positive	  and	  negative)	  readings	  were	  made.	  	  
To	  allow	  the	  averaging	  of	  RFAC	  in	  mice	  with	  a	  different	  number	  of	  slices	  covering	  the	  LV,	  the	  values	  
from	   different	   slices	   in	   each	  mouse	  were	   resampled	   using	   cubic	   spline	   interpolation	   to	   obtain	   10	  
values	   for	   each	   of	   the	   six	   sectors.	   These	   values	   were	   then	   averaged	   on	   a	   point-­‐by-­‐point	   basis	   to	  
obtain	  mean	  RFAC±1SD	  and	  mean	  every	  10%	  of	  LV	   length	   from	  the	  base	   to	   the	  apex.	  This	  process	  
was	  used	  for	  all	  the	  mice	  of	  both	  the	  Sham	  and	  MI	  groups,	  and	  allowed	  testing	  for	  differences	  in	  each	  
10%	  of	  LV	  length	  (unpaired	  t-­‐test)	  
	  
All	  of	  the	  echocardiographic	  data	  are	  the	  average	  of	  three	  measurements	  at	  end-­‐expiration.	  
5.2 Characterization	  Of	  Left	  Atrium	  In	  Normal	  Mice	  
Gender	   differences	  were	   compared	  using	   unpaired	   t	   test,	  while	   paired	   t	   test	  was	   used	   for	  within-­‐
group	   comparisons	  of	   the	  echocardiographic	   variables	   in	   the	  different	  phases	  of	   the	   cardiac	   cycle.	  
Selected	  variables	  were	  correlated	  with	  Pearson’s	  coefficient.	  Multiple	  forward	  stepwise	  regression	  
analysis	  was	  used	  to	  find	  the	  independent	  determinants	  of	  LV	  SV,	  based	  on	  the	  results	  of	  univariate	  
analysis.	  	  
Inter-­‐	  and	  intra-­‐observer	  repeatability	  in	  10	  randomly	  selected	  mice,	  and	  intra-­‐animal	  reproducibility	  
(checked	  by	  the	  same	  observer	  making	  repeated	  acquisitions	  after	  one	  week),	  were	  assessed	  as	  the	  
absolute	   difference	   in	   percent	   of	   the	   mean	   of	   the	   repeated	   measurements	   for	   the	   following	  
variables:	  2D	  LA	  maximum	  and	  “notch”	  areas,	   the	  LAA	  diastolic	  wave	   integral,	  and	  the	  LAA	  and	  PV	  
early	  systolic	  integrals.	  These	  statistical	  analyses	  were	  performed	  using	  SPSS	  v.15	  (SPSS	  Inc.).	  	  
5.3 CMR	  –	  Echocardiograpy	  Left	  Ventricle	  Parameters	  Comparison	  
Bland-­‐Altman	   analysis	   was	   performed	   to	   compare	   CMR	   with	   Echocardiographic	   left	   ventricle	  
functional	  parameters.	  
5.4 Echocardiographic	  Study	  Of	  Left	  Atrium	  In	  Infracted	  Mice	  
In	   this	   protocol	   the	   focus	   was	   to	   get	   temporal	   overview	   of	   the	   post	   MI	   remodelling,	   so	   the	   two	  
groups	  were	  compared,	  at	  each	  time,	  using	  unpaired	  t	  test.	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5.5 Effects	  Of	  Pharmacological	  Treatment	  
To	  study	  the	  chronic	  effect	  of	  the	  pharmacological	  treatment	  the	  response	  variables	  were	  considered	  
longitudinally	  at	  1	  and	  4	  weeks	  after	  MI.	  The	  value	  of	  response	  variables	  at	  24h,	  acquired	  just	  before	  
treatment,	  were	  included	  as	  covariates	  to	  model	  the	  surgical	  variability	  (only	  when	  comparing	  MI	  vs.	  
VALSA	  groups,	  i.e.	  the	  infarcted).	  As	  echographic	  measurements	  are	  subject	  to	  the	  quality	  of	  acoustic	  
window	   the	   dataset	   presents	   missing	   values	   and	   consequently	   the	   experiment	   is	   unbalanced,	  
moreover	  the	  sphericity	  of	  variance	  is	  violated.	  To	  avoid	  the	  inflation	  of	  degrees	  of	  freedom	  due	  to	  
the	  pseudo-­‐replication	  of	  the	  longitudinal	  measurements	  (violation	  of	  independence	  of	  within-­‐group	  
errors)	  the	  linear	  mixed	  effect	  (LME)	  model	  was	  chosen.	  This	  model	  can	  discriminate	  between	  fixed	  
effects	  that	  influence	  only	  the	  mean	  and	  random	  effects	  that	  influence	  only	  the	  variance,	  i.e.	  in	  the	  
particular	   case	   of	   longitudinal	   studies	   random	   effects	   explain	   variations	   of	   the	   responses	   in	   each	  
single	  individual	  (mouse)	  that	  could	  be	  caused	  by	  unobserved	  variables.	  To	  assess	  the	  real	  need	  for	  
random	  effects,	  a	  model	  with	  no	  random	  effect,	  a	  model	  with	  only	   random	   intercept	  and	  a	  model	  
with	   random	   intercept	   and	   slope	   were	   compared	   using	   the	   maximum	   likelihood	   principle.	   If	  
differences	   were	   nonsignificant,	   according	   to	   the	   Occam	   Razor	   (or	   principle	   of	   parsimony),	   the	  
simplest	  model	  was	  choosen.	  Then	  fixed	  effects	  were	  assessed	  with	  Anova	  and,	  when	  non	  significant,	  
removed	  one	  at	  a	   time	  starting	  with	   least	  significant	  and	  a	  simpler	  model	   re-­‐fitted	  and	  accepted	   if	  
maximum	   likelihood	  difference	   test	  was	  nonsignificant.	   LME	  analysis	  was	  performed	  using	   the	   lme	  
function	  of	  non	  linear	  mixed	  effect	  (nlme)	  package	  of	  the	  R	  software.	  	  
In	  all	  analysis	  p	  <0.05	  was	  considered	  significant.	  The	  data	  are	  presented	  as	  mean±1	  SD.	  
5.6 Microarray	  Data	  Processing	  And	  Analysis	  
The	  pipeline	  included	  the	  following	  steps:	  
• Signal	   variance	   was	   stabilized	   by	   applying	   Variance	   Stabilization	   Transformation	   (VST),	  
implemented	  in	  the	  lumi	  R	  package.	  
• Data	   were	   normalized	   and	   chips	   were	   scaled	   using	   Robust	   Spline	   Normalization	   (RSN),	  
implemented	  in	  the	  lumi	  R	  package.	  
• To	   focus	   on	   the	  most	   informative	   probes,	  we	   used	   two	   combined	   filtering	   criteria:	   a	   gene	  was	  
excluded	   whether	   (a)	   the	   p-­‐value	   of	   its	   log-­‐variation	   was	   greater	   than	   0.01	   and	   (b)	   the	   33th	  
percentile	  of	  probe	  intensities	  was	  less	  than	  110	  (i.e.,	  a	  gene	  was	  not	  expressed	  by	  at	  least	  all	  the	  
mice	   in	   one	   of	   the	   three	   treatment	   groups).	   The	   signal	   intensity	   threshold	   of	   110	   was	   chosen	  
based	   on	   the	   detection	   p-­‐value	   assigned	   to	   every	   probe	   by	   the	   GenomeStudio	   pre-­‐processing	  
step:	   110	   is	   the	  minimum	   intensity	   value	   above	  which	   every	   positive	   probe	   has	   a	   detection	  p-­‐
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value	  less	  than	  0.01,	  i.e.	  the	  probe	  has	  a	  signal	  that	  is	  significantly	  above	  the	  background	  and	  the	  
negative	  controls.	  
• The	  genes/probes	  that	  passed	  filtering	  criteria	  were	  further	  analyzed.	  
• A	   univariate	   ANOVA	   (F-­‐test)	   on	   VST/RSN	   adjusted	   intensities,	   followed	   by	   estimation	   of	   all	  
pairwise	  class	  contrasts	  controlling	  for	  multiple	  comparisons,	  was	  used	  to	   identify	  genes/probes	  
differentially	  expressed	  between	  sham-­‐,	  vehicle-­‐,	  and	  Valsartan-­‐treated	  mice.	  The	  F-­‐test	  was	  used	  
in	   combination	   with	   the	   random	   variance	  model	   (RVM),	   which	   is	   helpful	   when	   the	   number	   of	  
experiments	  is	  small.	  The	  RVM	  assumes	  that	  the	  variance	  of	  the	  residuals	  in	  ANOVA	  for	  each	  gene	  
is	  a	  random	  variable	  from	  a	  common	  gamma	  distribution	  with	  unknown	  parameters;	  by	  sharing	  
the	  variance	  estimate	  across	  multiple	  genes,	  a	  better	  estimate	  for	  the	  true	  residual	  variance	  of	  a	  
given	   gene	   can	   be	   formed,	   effectively	   boosting	   the	   residual	   degrees	   of	   freedom.	   The	   nominal	  
significance	   level	   of	   each	   univariate	   test	   was	   set	   to	   less	   than	   0.001	   (parametric	   p-­‐value).	   To	  
control	  for	  multiple	  testing	  and	  to	  estimate	  the	  false	  discovery	  rate	  (FDR),	  permutation	  p-­‐values	  
for	  significant	  genes	  were	  computed	  based	  on	  10000	  random	  permutations:	  the	  significance	  level	  
were	  set	  to	  p	  <	  0.005	  and	  FDR	  <	  0.06	  (6%),	  respectively.	  
• Unsupervised	  hierarchical	  clustering	  of	  samples	  and	  differentially	  expressed	  genes	  was	  performed	  
on	   mean	   centered	   values.	   Genes	   and	   samples	   were	   clustered	   by	   uncentered	   Pearson’s	  
correlation,	  as	  distance	  metrics,	  and	  average	  linkage.	  
• We	   then	   performed	   a	   pairwise	   comparison	   between	   classes	   using	   a	   threshold	   for	   significantly	  
different	  gene	  expression	  at	  alpha	  =	  0.01.	  
• Finally,	   to	   focus	  on	   the	  most	  meaningful	  differences,	  we	  kept	  only	   those	  genes	   that	  exhibited	  a	  



















1 CARDIAC	  MAGNETIC	  RESONANCE	  SETUP	  AND	  VALIDATION	  	  
1.1 Cardiac	  Surgery	  
After	  cardiac	  surgery	  the	  survival	  of	  MI	  animals	  was	  70%	  (17%	  of	  mortality	  within	  24	  hours	  and	  13%	  
within	  1	  week	  after	  surgery)	  while	  the	  survival	  of	  sham-­‐operated	  animals	  was	  97%	  (Figure	  24A).	  	  
The	   intrinsic	   surgical	   variability	   in	   the	   occlusion	   point	   along	   the	   variable	   branching	   of	   the	   LAD	  
coronary	  artery	  lead	  to	  three	  distinct	  time	  evolution	  patterns	  that	  could	  be	  classified	  according	  to	  the	  
EF	  measured	  at	  24	  h.	  If	  EF(24h)	  was	  higher	  than	  45%	  (that	  is	  more	  or	  less	  a	  reduction	  of	  15%	  respect	  
the	   normal	   condition)	   the	   damage	   didn’t	   evolve	   anymore	   and	   EF	   remained	   almost	   unchanged	  
(compared	  to	  24h)	  while,	  if	  EF(24h)	  was	  lesser	  than	  35%	  we	  observed	  a	  rapid	  reduction	  of	  EF	  leading	  
to	  death	  in	  5-­‐7	  days.	  
Consequently	   in	  all	   the	  following	  studies	  were	  chosen	  only	  the	  mice	  with	  an	  EF(24h)	  between	  35%	  
and	  45%,	  that	  showed	  a	  progressive	  decrease	  of	  EF	  (Figure	  24B).	  
	  
	  	  	  
	   	  
Figure	  24.	  Graphs	  of	  animal’s	  survival	  (A)	  and	  of	  EF	  evolution	  (B)	  after	  surgery.	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1.2 Cardiac	  Magnetic	  Resonance	  Imaging	  
Two	   series	   of	   T2*-­‐weighted	   scout	   images	   allowed	   us	   to	   find	   the	   anatomic	   landmarks	   needed	   to	  
acquire	  standardized	  4	  chamber	  long-­‐axis	  and	  2	  chamber	  short-­‐axis	  images.	  
Intragate	  sequence,	  with	   its	  retrospective	  gating,	  allowed	  the	  acquisition	  of	  cine	  images	   in	  2–3	  min	  
per	   slice,	   a	   very	   short	   time	  when	   compared	   to	   10	  min	   per	   slice	   (or	  more)	   necessary	   for	   ECG	   and	  
respiration	  triggered	  normal	  gradient	  echo	  cine	  sequence.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Of	   the	   30	   infarcted	   mice	   that	   underwent	   LAD	   coronary	   artery	   ligation	   (MI	   group),	   7	   died	   for	  
complications	   arose	   during	   (or	   shortly	   after)	   surgery,	   and	   2	   died	   during	   the	   CMR	   acquisition	   (70%	  
survival	  rate).	  All,	  except	  one,	  sham-­‐operated	  mice	  survived	  the	  surgery.	  	  
Nine	  days	  after	  surgery,	  we	  observed	  a	  significant	  increase	  in	  left	  ventricular	  volumes	  (end-­‐diastolic	  
and	   end-­‐systolic)	   in	   MI	   group	   compared	   to	   sham-­‐operated	   and	   a	   significant	   reduction	   of	   EF;	   the	  




Figure	   25.	   Graphs	   of	   EDV,	   ESV	   EF	   and	   SV	   Baseline	   and	   in	   Sham	   and	   MI	   groups	   9	   days	   after	   surgery.	   ***	  
p<0.0001	  vs.	  Sham	  and	  Baseline.	  
	  
Left	   ventricular	   end-­‐diastolic	   diameter	   as	   index	   of	   cavity	   enlargement	   was	   measured	   and	   was	  









































Also	  the	  length	  of	  the	  heart	  increased	  in	  MI,	  actually	  while	  Sham	  hearts	  needed	  an	  average	  of	  5	  slices	  
to	  cover	  the	  entire	  left	  ventricle,	  LAD	  hearts	  needed	  6-­‐7.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  26.	  Graphs	  of	  Left	  Ventricle	  Internal	  Diastolic	  Diameter	  for	  Baseline,	  Sham	  and	  MI	  groups,	  9	  days	  after	  






Figure	  27.	  A	  representative	  4-­‐chamber	  long-­‐axis	  and	  short	  axis	  of	  Sham	  (A	  and	  C)	  or	  MI	  mouse	  (B	  and	  D).	  The	  
enlargement	  of	  left	  ventricular	  cavity	  can	  be	  observed.	  LV:	  Left	  Ventricle,	  RV:	  Right	  Ventricle.	  	  
	   	  






















The	  LV	  anterior	  and	  posterior	  wall	  thickness	  also	  varied	  with	  a	  reduction	  in	  anterior	  thickness	  in	  MI	  
mice	  and	  compensatory	  increase	  in	  posterior	  wall	  thickness.	  
	  
Figure	  28.	  Graphs	  of	  Left	  Ventricle	  Anterior	  and	  Posterior	  wall	  thickness	  for	  Baseline,	  Sham	  and	  MI	  groups,	  9	  
days	  after	  surgery.	  **	  p<	  0.05;	  ***	  p<0.0001	  MI	  vs.	  Sham	  and	  Baseline.	  
1.3 Regional	  Ventricular	  Function	  
The	  evaluation	  of	  RFAC	  and	  its	  representation	  with	  bull’s	  eyes	  for	  infarcted	  and	  sham	  operated	  mice	  
confirmed	  the	  occlusion	  of	  LAD	  coronary	  artery	  and	  the	  reduced	  functionality	  of	  anterior	  and	  lateral	  
segments	  from	  apical	  to	  mid-­‐cavity	  slices.	  
In	   sham	  operated	  mice	   bull’s	   eyes	   showed	   an	   increase	   in	   RFAC	   from	   the	   base	   to	   the	   apex	  with	   a	  
minimum	  in	  the	  basal	  septal	  segment	  (55%)	  and	  a	  maximum	  in	  the	  mid-­‐lateral	  segment	  (90%).	  
On	  the	  contrary,	  in	  MI	  mice	  bull’s	  eyes	  showed	  a	  decrease	  in	  RFAC	  and	  this	  reduction	  is	  significant	  in	  
the	  antero-­‐septal,	   septal	   and	   inferior	   sectors	  only	   at	   the	  mid-­‐	   and	  apical-­‐level.	   The	  anterior	   sector	  
resulted	   to	   be	   the	   most	   extensively	   damaged,	   as	   expected	   being	   the	   myocardial	   region	   directly	  
irrorated	  by	  the	  LAD.	  The	  sectors	  adjacent	  to	  the	  anterior	  one	  (i.e.,	  lateral	  and	  antero-­‐septal)	  showed	  
a	  reduced	  RFAC,	  with	  mean	  values	  below	  the	  corresponding	  regional	  normality	  threshold.	  
	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   29.	   Bull’s	   eye	   representations	   of	  mean	   regional	   fractional	   area	   change	   in	   the	   Sham	  operated	   (A)	   and	  
infracted	  mice	  (B).	  The	  slices	  from	  the	  LV	  Apex	  to	  Base	  are	  shown	  from	  the	  inner	  to	  the	  outer	  circle.	  The	  red	  
and	  the	  green	  tones	  indicate	  lower	  and	  higher	  values	  respectively:	  the	  corresponding	  scales	  are	  shown	  as	  color	  
bars	  beside	  the	  panels.	  



































































1.4 Bull’s	  Eyes	  Validation	  
Nine	  days	  after	  MI,	  left	  ventricle	  size	  increased	  so	  that,	  in	  4	  mice	  6	  short	  axis	  slices	  were	  needed	  to	  
cover	   the	   entire	   ventricle	   length,	   in	   the	   remaining	   3	   mice	   7	   slices	   were	   needed.	   A	   total	   of	   270	  
histological	  and	  CMR	  segments	  (45	  short	  axis	  per	  6	  segments	  each)	  were	  analyzed.	  Segments	  were	  
classified	  in	  normal	  and	  ischemic:	  for	  histology	  on	  the	  basis	  of	  cardiomyocytes	  organization	  while	  for	  
RFAC	  a	  ROC	  analysis	  was	  performed.	  	  
MR	   images	   showed	   normal	   RFAC	   in	   145/270	   segments	   (54%)	   while	   normal	   histology	   in	   164/270	  
segments	   (71%)	   and	   abnormally	   reduced	   RFAC	   in	   the	   remaining	   125/270	   segments	   (46%)	   while	  
ischemic	  histology	  in	  106/270	  segments	  (39%).	  
So	  bull’s	  eyes	  interpretation	  disagreed	  with	  the	  ‘‘gold	  standard’’	  in	  37/270	  segments	  (14%),	  of	  which	  
17	  were	  false	  positive,	  and	  20	  were	  false	  negative.	  
Sensibility	  (88%),	  specificity	  (71%)	  and	  accuracy	  (79%)	  were	  computed.	  
When	   this	   analysis	   is	   applied	   to	   the	   Sham	   group,	   the	   regional	   thresholds	   resulted	   in	   6/306	   false	  
positives	   (2%),	   thus	   evidencing	   an	   optimal	   accuracy	   (98%)	   in	   correctly	   interpreting	   segments	  with	  
normal	  wall	  motion.	  
	  
	  
Figure	  30.	  Representative	  bull’s	  eyes	  and	  example	  of	  histological	  section	  at	  mid-­‐apical	  level	  with	  superimposed	  
the	   6-­‐sectors	   (Sep:	   septal,	   A-­‐Sp:	   antero-­‐septal,	   Ant:	   anterior,	   Lat:	   lateral,	   Pst:	   posterior,	   Inf:	   inferior).	   Black	  
contour	  superimposed	  on	  bull’s	  eyes	  indicate	  the	  level	  of	  selected	  histological	  section.	  
*	  Indicate	  sectors	  classified	  as	  abnormal.	  	  	  	  

















2 CHARACTERIZATION	  OF	  LEFT	  ATRIUM	  IN	  NORMAL	  MICE	  
2.1 Left	  Atrium	  And	  Appendage	  Histology	  
Mouse	  heart	  histology	  showed	  a	  very	  little	  left	  atrium	  (compared	  to	  left	  ventricle)	  connected	  through	  
a	  duct	  (DU)	  to	  a	  trabeculate	  appendage	  (LAA)	  comparable	  in	  size	  to	  atrium	  (Figure	  31	  A).	  
Immunofluorescence	   staining	   of	   LA	   and	   LAA	   showed	   that	   these	   structures	   had	   a	   similar	   cells	  
composition	   consist	   of	   two	   layers	   of	   cardiomyocytes	   (α-­‐sarcomeric	   actin	   positive,	   58±10%	   vs.	  
44±5.8%)	   crossing	   each	   other	   and	   cardiac	   fibroblasts	   (vimentin	   positive,	   respectively	   16±6.9%	   vs.	  
28±7.4%).	   Both	   structures	   showed	   a	   dense	   capillary	   network	   (isolectin-­‐B4	   positive,	   19±8.9%	   vs.	  
25±6%)	   and	   few	  well-­‐organized	   α-­‐smooth	  muscle	   actin-­‐positive	   cells	   (5.7±4%	   vs.	   3.5±1	   %)	   (Figure	  




Figure	   31.	   Representative	   murine	   coronal	   section	   and	   zoom	   of	   LAA-­‐LA	   structures.	   The	   LA	   and	   LAA	   bodies	  
consisted	   of	   two	   thin	   layers	   of	   cardiomyocytes	   (A)	   crossing	   each	   other,	   and	   cardiac	   fibroblasts	   (C).	   Both	  
structures	  exhibited	  a	  dense	  capillary	  network	  (D)	  and	  few	  α-­‐smooth	  muscle	  actin	  positive	  cells	  (E).	  LA	  and	  LAA	  
cells	  composition	  percentage	  are	  in	  graphs	  (F).	  	  
a-­‐sarc:	  alpha-­‐sarcomeric	  actin;	  a-­‐sma:	  alpha-­‐smooth	  muscle	  actin;	  AO:	  aorta;	  DU:	  LA-­‐LAA	  duct;	  LA:	  left	  atrium;	  









2.2 Macroscopic	  Anatomy	  Of	  Heart	  And	  Circulatory	  System	  
The	   resin	   cast	   of	   the	   whole	   heart	   showed	   frontally,	   in	   antero-­‐lateral	   position	   to	   LV	   base,	   the	  
trabeculated	  LAA	  that	  hide	  other	  structures	  of	  the	  venous	  reservoir	   (Figure	  32A).	  After	  remove	  the	  
pulmonary	  artery	  (PA),	  Figure	  32B	  showed	  all	  the	  venous	  reservoir	  components:	  LA,	  LAA	  and	  PVs.	  A	  
magnification	  of	  left	  atrium	  showed	  its	  round	  shape	  and	  its	  connections:	  laterally	  with	  LAA	  through	  a	  
duct,	  inferiorly	  with	  LV	  through	  the	  mitral	  valve,	  and	  superiorly	  with	  three	  different	  pulmonary	  veins	  
(PVs)	   entering	   separately	   into	   LA	   and	   identified	   as	   right	   inferior	   PV,	   right	   superior	   PV	   and	   left	   PV	  
(Figures	  32C	  and	  D).	  	  
	  
	  
Figure	  32.	  Resin	  cast	  of	  whole	  mouse	  heart	  (A)	  and	  after	  removing	  left	  venous	  reservoir(B).	  Views	  of	   isolated	  
left	   venous	   reservoir	   and	   its	   connections:	   LA	   (delimited	   by	   the	   dotted	   line)	   (C)	   aorta	   (AO)	   with	   coronary	  
arteries,	  the	  duct	  (DU),	  mitral	  valve	  (MV)	  and	  three	  PVs	  (right	  inferior	  PV,	  right	  superior	  PV	  and	  left	  PV)	  (D).	  
	  
2.3 Echocardiography	  Studies	  
Male	  mice	  weighed	  more	  than	  females	  (25±1	  vs	  19±1.5	  g,	  p<0.001),	  and	  for	  this	  echocardiographic	  
parameters	  were	  normalized	  on	  body	  weight.	  
During	  echocardiographic	  examination	  mice	  heart	  rate	  was	  484±45	  bpm,	  an	  P-­‐R	  interval	  is	  35±5	  ms,	  
without	  significant	  gender	  difference.	  
Mean	  frame	  duration	  was	  3.8	  ms,	  and	  mean	  frames	  per	  cardiac	  cycle	  were	  35.1±7.4	  
2.3.1 Left	  ventricle	  
Among	  all	  ventricle	  parameters	  only	  diastolic	  anterior	  wall	  thickness	  and	  mass	  were	  gender	  related,	  
greater	  in	  male	  mice;	  the	  differences	  disappears	  after	  normalization	  by	  body	  weight.	  
Ejection	   fraction	   is	   74±10%;	   end	   diastolic	   and	   end	   systolic	   volumes	   were	   53±11μl	   and	   14±4μl	  
respectively;	  stroke	  volume	  was	  40±9μl	  and	  cardiac	  output	  20±7ml/min.	  
All	  the	  other	  parameters	  are	  reported	  in	  Table	  3.	  
	  




Table	  3.	  Left	  ventricle:	  anatomy	  and	  function.	  






End-­‐diastolic	  diameter	   mm	   2.1±0.4	   	   	  
End-­‐systolic	  	  diameter	   mm	   3.7±0.7	   	   	  
Anterior	  wall	  thicness,	  diastole	   mm	   0.85±0.2	   0.96±0.3	   0.77±0.1*	  
Posterior	  wall	  thicness,	  diastole	   mm	   0.73±0.1	   	   	  
Anterior	  wall	  thicness,	  systole	   mm	   1.4±0.3	   	   	  
Posterior	  wall	  thicness,	  systole	   mm	   1.2±0.2	   	   	  
Mass	   mg	   101±20	   112±21	   93±14†	  
Fractional	  shortening	   %	   43±7	   	   	  
Long	  axis,	  diastole	   mm	   7.2±0.7	   	   	  
Long	  axis	  shortening	   %	   22±0.9	   	   	  
Long/short	  axis,	  diastole	   	   1.9±0.2	   	   	  
Long/short	  axis,	  systole	   	   2.7±0.6	   	   	  
Isovolumic	  contraction	  time	   ms	   9.2±5.1	   	   	  
Ejection	  time	   ms	   51±6	   	   	  
Isovolumic	  relaxation	  time	   ms	   16.5±6	   	   	  
Myocardial	  performance	  index	   	   0.51±0.16	   	   	  
P	  values	  vs.	  male:	  *p<0.05;	  †p	  <0.01.	  
2.3.2 Left	  Atrium	  and	  Left	  Appendage	  
Left	  atrium	  appeared	  as	  a	  small	  circular	  structure,	   in	  which	   longitudinal	  and	  transversal	  axes	  were:	  
minimum	  1.5	  and	  1.4	  mm,	  maximum	  2.1	  and	  2	  respectively.	  
The	  sphericity	  was	  confirmed	  by	  minimum	  and	  maximum	  longitudinal/transversal	  ratio,	  which	  were	  
0.98±0.16	  and	  1.1±0.1	  respectively.	  
LA	  planimetry	  were	   traced	   frame	  by	   frame	   in	   the	  4-­‐chamber	  view	  and,	   for	  each	  mice,	  plotted	   in	  a	  
function	   curve	   in	   which	   three	   important	   frame	   were	   identifiable:	   minimum	   and	   maximum	   which	  
were	  divided	  by	   an	   intermediate	   frame	  named	   “notch”	  where	   the	   area	   increase	  paused	   for	   a	   few	  
frames	  (Figure	  33).	  
Notch	   frame	  divided	  atrial	   reservoir	  phase	   into	  early	   and	   late	   that	  were	  different	   in	   time	  duration	  
and	  in	  percentage	  of	  volume	  increase.	  
Actually	  the	  duration	  and	  the	  increase	  in	  volume	  during	  early	  reservoir	  is	  almost	  double	  than	  in	  late	  




During	   total	   reservoir	  phase	   the	   increase	   in	  LA	  volume	  was	  greater	   in	  males	   in	  which	   it	  more	   than	  
doubled,	  but	  absolute	  differences	  disappeared	  after	  normalization	  by	  weight.	  
	  
Figure	  33.	  Representative	   smooth	  atrial	   function	   curve	   (A),	   images	  of	  minimum	   (B),	  notch	   (C)	  and	  maximum	  
area	  (D).	  MA:	  mitral	  annulus.	  
	  
The	  left	  atrium	  maximum	  volume	  (mean	  5.4±1.7	  µl,	  male	  6.3±1.7	  µl	  and	  female	  4.7±1.3	  µl)	  is	  about	  
10%	  of	  LV	  maximum	  volume	  (53±11	  µl),	  the	  minimum	  and	  notch	  were	  2.1±0.7	  and	  4.3±1.4µl.	  
Left	   atrium	   communicated	   laterally,	   through	   a	   short	   contractile	   duct	   (maximum	   and	   minimum	  
diameters	   1.3±0.2	  mm	   and	   0.7±0.2	  mm	   respectively	   and	   duct	   diameter	   fractional	   48±2%),	   with	   a	  
large	  appendage	  (LAA)	  which	  length	  (LAAla)	  was	  3.8±0.5	  mm	  (male	  4.3±0.3	  mm	  and	  female	  3.4±0.2	  
mm)	  (Figure	  34);	  duct	  area	  values	  are	  reported	  in	  Table	  5.	  
The	  LAA	  long	  axis	  was	  2	  times	  longer	  than	  the	  LA	  diameters	  and	  correlated	  with	  maximum	  LA	  volume	  
(r=0.63,	  p=0.009),	  LA	  total	  reservoir	  filling	  (r	  =0.62,	  p=0.01),	  and	  LV	  base	  descent	  (r=0.64,	  p=0.007).	  
Two	   filling,	   and	   a	   single	   emptying	  waves	   (corresponding	   to	  blood	   flowing	   from	  and	   to	   left	   atrium)	  
were	  detected	  by	  color	  Doppler.	  	  
The	  modified	  4-­‐chamber	  view	  showed	  increasing	  and	  a	  decreasing	  in	  LAA	  volume	  and	  in	  long	  axis	  and	  
duct	   diameter	   during	   filling	   and	   emptying	   phase	   respectively	   confirming	   the	   contractile	   activity	   of	  
LAA.	  Calculated	  LAA	  systolic	   filling	  and	  diastolic	  emptying	  flow	  volumes	  were	  equivalent	   (Tables	  5),	  
and	   the	   former	  was	  3	   times	   the	   LA	  2D	   total	   reservoir	   volume	   increase	   (Table	  4).	   The	  LAA	  diastolic	  









Figure	   34.	   Apical	   4-­‐chamber	   view	   (A)	   to	   visualize	   LA,	   LV,	   RA	   and	   RV	   (A);	  modified	   apical	   4-­‐chamber	   view	   to	  
visualize	  the	  LAA	  and	  duct	  (*)	  and	  duct	  diameter	  (Dd);	  the	  dotted	  line	  shows	  the	  LAA	  long	  axis	  with	  (LAAla)	  (B).	  
LAA	  color	  Doppler	  flow	  velocities	  in	  diastolic	  (C)	  and	  systolic	  frame	  (D).	  
*:	   LA-­‐LAA	  duct;	   Dd:	   diameter	   duct;	   LA:	   left	   atrium;	   LAA:	   left	   atrial	   appendage;	   LAAla:	   LAA	   long	   axis;	   LV:	   left	  












Table	  4.	  Left	  atrium:	  timings,	  volumes,	  anatomy	  and	  function.	  






ER	  filling	  time	   ms	  (%)	   46±7	  (37)	   	   	  
LR	  filling	  time	   ms	  (%)	   24±5	  (19)	   	   	  
TR	  filling	  time	   ms	  (%)	   70±9	  (55)	   	   	  
ER	  volume	  increase	   µL	   2.2±1.1	   2.7±1.1	   1.8±0.9*	  
ER	  volume	  increase	   %	   110±54	   	   	  
LR	  volume	  increase	   µL	   1.1±0.7	   1.4±0.7	   0.9±0.5*	  
LR	  volume	  increase	   %	   27±16	   	   	  
TR	  volume	  increase	   µL	   3.3±1.3	   4.1±1.2	   2.6±1.9†	  
TR	  volume	  increase	   %	   164±62	   191±59	   141±56*	  
ER:	  Early	  reservoir;	  LR:	  late	  reservoir;	  TR:	  total	  reservoir..P	  values	  vs	  male:	  *p<0.05;	  †p≤0.01.	  
Table	  5.	  LA	  appendage	  anatomy	  and	  pulsed	  Doppler	  flow	  profile.	  
	  
	  






Early	  filling	  wave,	  duration	   ms	   44±6	   	   	  
Early	  filling	  wave,	  integral	   mm	   9.2±2.8	   	   	  
Late	  filling	  wave,	  duration	   ms	   34±5	   	   	  
Late	  filling	  wave,	  integral	   mm	   6.1±1.6	   	   	  
Early/late	  filling	  integral	  ratio	   	   1.5±0.4	   	   	  
Total	  filling	  integral	   mm	   15±4	   	   	  
Emptying	  wave,	  duration	   ms	   44±6	   	   	  
Emptying	  wave,	  integral	   mm	   7.4±2.7	   	   	  
Total	  filling/emptying	  integral	  ratio	   	   2.3±1.3	   	   	  
	   	   n=	  16	   n=	  8	   n=	  8	  
LAA	  /	  LA	  long	  axis,	  maximum	   	   1.8±0.3	   1.9±0.2	   1.7±0.3	  
Duct	  area,	  minimum	  	   mm2	   0.36±0.15	   	   	  
Duct	  area,	  maximum	   mm2	   1.4±0.33	   	   	  
Duct	  area,	  mean	   mm2	   0.79±0.2	   	   	  
Early	  filling	  flow	  volume	   µL	   6.4±2.1	   	   	  
Late	  filling	  flow	  volume	   µL	   4.4±1.6	   	   	  
Total	  filling	  flow	  volume	   µL	   10.8±3.4	   	   	  
Emptying	  flow	  volume	   µL	   10.4±3.4	   	   	  




2.3.3 Pulmonary	  Vein	  Anatomy	  and	  Flow	  Profile.	  
As	   in	   resin	   cast	   also	  with	   echocardiography	   three	   different	   pulmonary	   veins	   (PVs)	   entering	   the	   LA	  
cavity	  at	  different	  angles	  were	  observed:	  
-­‐	  a	  right	  superior	  PV	  (next	  to	  the	  LA	  septum	  and	  opposite	  to	  the	  LAA	  duct)	  (Figure	  35A);	  
-­‐	  a	  right	  inferior	  PV	  (Figure	  35B);	  
-­‐	  a	  left	  PV	  (Figure	  35C).	  
Right	   superior	   PV	   diameter	   (measured	   in	   16/30	   mice)	   did	   not	   change	   during	   the	   cardiac	   cycle,	  
diameter:	  0.6±0.09mm	  and	  area	  0.29±0.08mm2	  .	  
The	   single	   diastolic	   wave	   was	   predominant	   over	   both	   early	   and	   late	   systolic	   waves	   and	   this	   was	  
confirmed	  by	  their	  integral,	  significantly	  different	  p<0.001	  (early	  systolic	  wave	  integral:	  6.6±3.6	  mm,	  
late	   systolic	   wave	   integral:	   5.1±2.1	   mm,	   diastolic	   wave	   integral:	   17.1±5.2	   mm	   and	   total	   PV	   wave	  
integral	  27±2,8	  mm).	  
Both	  the	  total	  and	  PV	  diastolic	  integrals	  correlated	  with	  LV	  SV	  (r=0.63,	  p=0.001	  and	  r=0.8,	  p<0.001).	  	  
Wave	  duration,	  peak	  velocity	  and	  flow	  volume	  data	  are	  reported	  in	  Table	  6	  
	  
	  
Figure	  35.	  Color	  Doppler	  LA	  inflow	  from	  the	  right	  superior	  PV	  (A);	  from	  the	  left	  PV	  (B)	  and	  from	  right	  inferior	  PV	  
(C).LAA:	  left	  atrial	  appendage;	  RA:	  right	  atrium;	  RV:	  right	  ventricle.	  	  	  
	  
Table	  6.	  Right	  superior	  pulmonary	  vein	  diameter	  and	  pulsed	  Doppler	  flow	  profile.	  
	   	   n=	  30	  
Early	  systolic	  wave,	  duration	   ms	   32±4	  
Early	  systolic	  wave,	  peak	  velocity	   mm/s	   210±68	  
Late	  systolic	  wave,	  duration	   Ms	   37±8	  
Late	  systolic	  wave,	  peak	  velocity	   mm/s	   156±47	  
Diastolic	  wave,	  duration	   Ms	   42±5	  




	   	   n=	  16	  
Early	  systolic	  flow	  volume	   µL	   1.9±1.2	  
Late	  systolic	  flow	  volume	   µL	   1.7±1.1	  
Total	  systolic	  flow	  volume	   µL	   3.3±1.5	  
Diastolic	  flow	  volume	   µL	   4.9±2.2	  
Total	  flow	  volume	   µL	   8.1±3.7	  
	  
	  
2.3.4 Mitral	  Annulus	  and	  Valve	  Flow	  Profile	  
Annulus	  size	  was	  1.8±0.3	  mm,	  gender	  independent.	  	  
A	   single	   pulsed	   Doppler	   wave	   (labelled	   as	   A+E	   wave	   in	   Figure	   36)	   was	   detected	   in	   27/30	   mice	  
secondary	  to	  a	  combination	  of	  a	  high	  heart	  rate	  and	  a	  relatively	  long	  P-­‐R	  interval	  (compared	  with	  the	  
49±7	  ms	  duration	  of	  diastolic	  flow).	  The	  remaining	  3	  mice	  were	  excluded.	  
Mitral	   wave	   followed	   the	   ECG	   P	   wave	   and	   peak	   wave=815±153	   cm/s;	   total	   velocity-­‐time	  
integral=22±5	  mm	  were	  gender-­‐independent.	  
The	  LV	  base	  descent	  (0.64±0.14	  mm)	  was	  greater	  in	  males	  (0.7±0.1	  mm	  vs.	  0.59±0.15,	  p<	  0.05),	  but	  
differences	   disappeared	   after	   normalization	   by	  weight.	   It	   correlated	   positively	  with	   cardiac	   output	  
(r=0.4,	   p=0.03)	   and	   LA	   maximum	   and	   total	   reservoir	   filling	   volumes	   (r=0.55,	   p=0.001	   and	   r=0.55,	  
p=0.003).	  
	  
2.3.5 Cardiac	  Cycle	  Timing	  
The	  timing	  of	  atrial	  functional	  curve	  was	  related	  to	  MV,	  LAA	  and	  PV	  (right	  superior)	  flow	  pattern.	  As	  
expected	  the	  early	  and	  late	  atrial	  reservoir	  phase	  were	  synchronous	  with	  the	  two	  distinct	  PV	  systolic	  
filling	  (early	  and	  late	  respectively)	  and	  to	  two	  LAA	  inflow	  Doppler	  peaks.	  
When	   atrial	   pressure	   exceeds	   the	   ventricular	   and	   the	   mitral	   valve	   opens,	   a	   monophasic	   flow	   is	  
observed	   at	   Doppler	   mitral	   flow,	   corresponding	   to	   LAA	   emptying	   flow	   and	   pulmonary	   vein	  





Figure	  36.	   Left	   atrial	   function	   curve	   timing	   related	   to	   pulsed	  Doppler	  pulmonary	   vein	   flows	   (PV	   flow),	  mitral	  
valve	  (A+E)	  flow	  (MV	  flow)	  and	  appendage	  flow	  (LAA	  flow).	  	  
	  
2.3.6 Variability	  of	  Echocardiographic	  Measurements	  
The	  intra-­‐	  and	  inter-­‐operator	  for	  the	  selected	  variables	  were	  respectively:	  2D	  LA	  maximum	  area	  8%,	  
10%;	  2D	  LA	  notch	  area	  11%,	  14%;	  the	  LAA	  diastolic	  wave	  integral:	  9%,	  23%;	  the	  PV	  early	  systolic	  wave	  
integral:	   11%,19%	   and	   the	   LAA	   early	   systolic	  wave	   integral:	   12%,	   27%.	   Intra-­‐animal	   reproducibility	  
was:	  2D	  LA	  maximum	  area	  13%;	  2D	  LA	  notch	  area	  15%;	  the	  LAA	  diastolic	  wave	  integral:	  27%;	  the	  PV	  




3 ECHOCARDIOGRAPHIC	  STUDY	  OF	  LEFT	  ATRIUM	  IN	  INFARCTED	  MICE	  
3.1 CMR	  –	  Echocardiograpy	  Left	  Ventricle	  Parameters	  Comparison	  
EDV,	  ESV	  and	  EF,	  evaluated	  with	  both	  CMR	  and	  echocardiography	  in	  normal	  and	  ischemic	  mice,	  were	  






Figure	  37.	   In	  graphs	  Bland-­‐Altman	  comparison	  between	  CMR	  and	  Echoacrdiographic	  LV	  measurements:	  EDV,	  
ESV	  and	  EF.	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3.2 Body	  Weight	  And	  Heart	  Rate	  
	  
All	  the	  parameters	  we	  evaluated	  were	  similar	  at	  baseline	  within	  the	  two	  groups	  and	  during	  the	  follow	  
up	  period	  remained	  unchanged	  for	  sham-­‐operated	  mice.	  
No	  sham	  operated	  mice	  died	  and	  only	  1	  infarcted	  mouse	  died	  4	  weeks	  after	  surgery;	  1	  week	  after	  MI	  
this	  mouse	  presents	  EDV	  and	  ESV	  outlier	  values.	  
Body	  weight	   in	   two	  groups	   increased	   in	   similar	  way	  along	   the	   follow	  up	  period	  and	   there	  were	  no	  
difference	   between	   the	   two	   groups,	   so	   it	   was	   no	   necessary	   to	   normalize	   the	   variables	   for	   body	  
weight.	  No	  significant	  differences	  were	  found	  in	  heart	  rate	  between	  the	  two	  groups	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  38.	  In	  graph	  body	  weight	  in	  sham	  and	  MI	  groups	  for	  a	  follow	  up	  period	  of	  12	  weeks.	  *	  p<0.05;	  **	  p<0.01	  
	  
3.3 Time	  Course	  Of	  Regional	  Function	  
A	  time	  course	  of	  bull’s	  eyes	  visualization	  showed	  a	  progressive	  expansion	  of	  damaged	  myocardium	  
not	  only	  in	  apical	  and	  anterior	  sectors,	  but	  also	  in	  lateral	  and	  posterior	  mid-­‐basal	  levels	  indicating	  a	  
progressive	  loss	  of	  contractility	  in	  remote	  non-­‐infarcted	  tissue	  as	  showed	  in	  Figure	  39.	  
	  
	  
Figure	  39.	  Time	  course	  of	  bull’s	  eye	  visualization.	  	  












3.4 Echocardiograpy	  Measurements	  
3.4.1 	  Left	  Ventricle	  
Cardiac	  magnetic	  resonance	  and	  echocardiography	  agreed	  in	  showing	  a	  dramatic	  reduction	  of	  EF	  in	  
infracted	  mice	  compared	  to	  sham	  starting	  from	  two	  days	  after	  MI	  (EF(2d)	  35.2±6.7µl	  vs	  66.6±9.1µl;	  
EF(12w)	  27.6±7µl	  vs.	  68.25±5µl),	  the	  reduction	  was	  associated	  to	  an	  infarct	  size	  (12	  weeks	  after	  MI)	  
bigger	  than	  50%	  of	  total	  left	  ventricular	  length.	  
The	  left	  ventricle	  end-­‐diastolic	  and	  end-­‐systolic	  volumes	  (EDV	  and	  ESV)	  immediately	  increased	  in	  MI	  
mice	  with	  an	  initial	  stronger	  and	  predominant	  increase	  of	  ESV	  (2-­‐fold	  after	  two	  days)	  over	  EDV	  (1.3	  
fold	  after	  two	  days)	  leading	  to	  an	  initial	  reduction	  of	  SV	  (SV(2d)	  22.3±3µl	  vs.	  29.1±4.2µl;	  MI	  vs.	  sham)	  
that	  then	  recovers	  between	  1	  and	  4	  weeks	  after	  MI	  (Figure	  40).	  
In	  response	  to	  MI	  we	  also	  observed	  an	  increase	  in	  isovolumic	  contraction	  (IVCT)	  and	  relaxation	  (IVRT)	  
times	  and	  consequently	  in	  MPI	  (MPI	  (12w)	  1.4±0.5	  vs.	  0.7±0.2;	  MI	  vs.	  sham),	  an	  index	  of	  systolic	  and	  
diastolic	  performance,	  which	  is	  higher	  in	  response	  to	  a	  reduction	  of	  ventricular	  contractility.	  
	  
	   	  
	  











































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  40.	  In	  graphs	  Left	  Ventricle	  (LV)	  end-­‐diastolic	  volume	  (EDV),	  end-­‐systolic	  volume	  (ESV),	  ejection	  fraction	  
(EF)	  and	  myocardial	  performance	   index	  (MPI)	  and	  stroke	  volume	  (SV)	   in	  sham	  and	  MI	  groups	  for	  a	   follow	  up	  
period	  of	  12	  weeks.	  *	  p<0.05;	  **	  p<0.01.	  
	  
Long	  axis	  2D	  images	  showed	  cavity	  enlargement	  (Figure	  41)	  and	  anatomical	  measurements	  assessed	  
anterior	   wall	   thinning	   (1.27±0.22mm	   vs.	   0.4±0.1mm	   p<0.001),	   reduction	   of	   long	   axis	   shortening	  
(16±3.4%	  vs.	  9.2±3.0%	  p<0.05)	  and	  reduction	   in	  diastolic	  and	  systolic	   long/short	  axis	   ratio	   (1.7±0.2	  
vs.	   1.3±0.2	   p<0.01	   and	   2.3±0.28	   vs.	   1.4±0.1	   p<0.001),	   indicating	   a	   progressive	   sphericity	   of	   left	  
ventricle.	  	  
	  
Figure	  41.	  Left	  ventricle	  visualized	  in	  2D	  long	  axis.	  Representative	  images	  of	  left	  atrium	  in	  sham	  (A)	  and	  MI	  (B)	  
mice	  8	  weeks	  after	  surgery.	  LV:	  Left	  Ventricle;	  AO:	  Aorta;	  LA:	  Left	  Atrium.	  
	  
3.4.2 Left	  Atrium	  And	  Appendage	  
Left	   ventricular	   remodeling	   doesn’t	   take	   place	   on	   its	   own	   but	   is	   accompanied	   by	   left	   atrial	   (LA)	  
remodeling.	  
Starting	  from	  two	  days	  after	  MI	  both	  maximum	  and	  minimum	  atrial	  volumes	  gradually	  increased	  with	  
the	   progression	   of	   ventricular	   dysfunction	   and	   stabilized	   after	   4	   weeks;	  maximum	   ratio	  minimum	  




















volume	  remained	  almost	  unchanged	  as	  well	  as	  volume	  fractional	  reservoir	  (total	  LA	  reservoir	  filling).	  
In	  particular	  LAmin(12w):	  4.69±1.55µl	  vs.	  2.81±0.95µl	  and	  LAmax	  (12w):	  8.52±2.4µl	  vs.	  5.56±1.06µl	  
MI	  vs.	  sham,	  all	  p‹0.01.	  
The	   enlargement	   of	   left	   atrial	   cavity	   8	   weeks	   after	   MI	   compared	   to	   sham	   operated	   mice	   can	   be	  
observed	  in	  Figure	  42.	  
	  
Figure	  42.	  Left	  atrium	  visualized	  in	  four	  chamber	  view.	  Representative	  images	  of	  left	  atrium	  in	  sham	  (A)	  and	  MI	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  43.	  In	  graphs	  Left	  Atrial	  (LA)	  volume	  maximum	  (Max),	  minimum	  (Min)	  and	  Fractional	  Reservoir	  in	  sham	  
and	  MI	  groups	  for	  a	  follow	  up	  period	  of	  12	  weeks.	  *	  p<0.05;	  **	  p<0.01.	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Also	  left	  atrial	  appendage	  increased	  in	  dimension,	  following	  the	  left	  atrial	  enlargement,	  in	  particular	  
in	  long	  axis	  length	  and	  in	  duct	  dimension	  with	  a	  significant	  reduction	  in	  fractional	  duct	  diameter	  an	  
index	  of	  duct	  contractility.In	  particular	  LAAla(12w):	  4.6±0.6µl	  vs.	  3.55±0.33µl	  and	  LAA	  duct	  fractional	  
diameter(12w):	  18.8±6.2%	  vs.	  52.8.±5%	  MI	  vs.	  sham,	  all	  p‹0.01.	  
	  
Figure	   44.	   Left	   appendage	   visualized	   in	   modified	   apical	   four	   chamber	   view.	   Representative	   images	   of	   left	  
appendage	   in	   sham	   (A)	   and	  MI	   (B)	  mice	  8	  weeks	   after	   surgery.	   LV:	   Left	  Ventricle;	   LA:	   Left	  Atrium;	  RA:	  Right	  





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  45.	  In	  graphs	  Left	  Atrial	  Appendage	  (LAA)	  duct	  diameter	  maximum	  (Max),	  minimum	  (Min)	  and	  fractional,	  
and	  LAA	  long	  axis	  length	  in	  sham	  and	  MI	  groups	  for	  a	  follow	  up	  period	  of	  12	  weeks.	  *	  p<0.05;	  **	  p<0.01	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LA	   2D	   volume	   reservoir	   showed	   a	   significant	   increase	   starting	   from	   1	   week	   while	   LAA	   volume	  
reservoir	   (Doppler)	   showed	   a	   significant	   reduction	   two	   days	   after	   injury	   and	   then	   recovered.	   As	   a	  
combination	  of	  LA	  2D	  volume	  reservoir	  and	  LAA	  volume	  reservoir	   (Doppler)	   total	  volume	  reservoir	  
showed	  an	  initial	  dramatic	  decrease,	  when	  LAA	  flow	  volume	  can	  not	  be	  compensated	  by	  LA	  reservoir	  
increase,	   followed	  by	  a	  recovery	   in	  chronic	  that,	  after	  1	  week	  restored	  the	  baseline	  conditions;	  the	  




Figure	  46.	  In	  graphs	  LA	  volume	  reservoir,	  LAA	  volume	  reservoir,	  total	  (LA+LAA)	  volume	  reservoir	  and	  LA	  volume	  
conduit	  in	  sham	  and	  MI	  groups	  for	  a	  follow	  up	  period	  of	  12	  weeks.	  *	  p<0.05;	  **	  p<0.01.	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3.5 Effects	  Of	  Pharmacological	  Treatment	  
As	  described	  previously	   all	   the	  parameters	  we	  evaluated	  were	   similar	   at	   baseline	  within	   the	   three	  
experimental	  groups	  and	  during	  the	  protocol	  remained	  unchanged	  for	  sham-­‐operated	  mice.	  
In	  the	  follow	  up	  period	  body	  weight	  increased	  without	  difference	  between	  groups,	  as	  a	  consequence	  
no	  weight	  normalization	  was	  needed.	  Mice	  survival	  was	  in	  line	  with	  our	  previous	  studies.	  	  
3.5.1 Assessment	  Of	  Global	  LV	  Function	  
Global	  left	  ventricular	  parameters	  evaluated	  with	  CMR	  agreed	  with	  the	  same	  parameters	  evaluated	  
by	  echocardiography.	  
As	  previously	  described,	  after	  surgery	  left	  ventricle	  EF	  immediately	  decreased	  in	  MI-­‐vehicle	  and	  MI-­‐
valsartan	  compared	  to	  sham	  group;	  the	  pharmacological	  treatment	  didn’t	  affect	  EF	  decreasing	  trend.	  
The	   increase	   of	   ESV,	   related	   to	   the	   initial	   and	   predominant	   effect	   of	   surgery,	  was	   not	   affected	   by	  
pharmacological	  treatment,	  while	  a	  significant	  effect	  was	  observed	  in	  LV	  EDV	  (an	  index	  of	  LV	  chronic	  
remodeling):	   a	   moderate	   increase	   was	   observed	   in	   MI-­‐valsartan	   group	   compared	   to	   dramatic	  
increase	  in	  MI-­‐vehicle.	  
Stroke	   volume	   (LV	   SV),	   after	   initial	   decrease	   in	   MI-­‐vehicle	   and	   MI-­‐valsartan,	   without	   differences	  
between	  the	  two	  MI	  groups,	  recovers	  in	  chronic.	  
LV	   internal	  diastolic	  diameter	  (LViDd)	  moderately	   increased	   in	  MI-­‐valsartan	  group	  compared	  to	  MI-­‐
vehicle	  group,	  reflecting	  the	  LV	  EDV	  evolution.	  LV	  internal	  systolic	  diameter	  LViSd	  was	  not	  affected	  as	  







Figure	  47.	  In	  graphs	  follow-­‐up	  evolution	  of	  Left	  Ventricle	  ejection	  fraction	  (EF)	  evaluated	  with	  Echo	  and	  CMR,	  
Left	   Ventricle	   end	   diastolic,	   end	   systolic	   volumes	   and	   stroke	   volume	   (LV	   EDV,	   LV	   ESV	   and	   LV	   SV),	   and	   Left	  
Ventricle	   internal	   diastolic	   diameter	   (LViDd)	   in	   sham,	  MI-­‐vehicle	   and	  MI-­‐valsartan	   groups.	   ***	   p<0.001	  MI-­‐
vehicle	  vs.	  Sham;	  ###	  p<0.001	  MI-­‐valsartan	  vs.	  Sham;	  	  §	  p<0.05	  MI-­‐valsartan	  vs.	  MI-­‐vehicle.	  
	  
	  
At	   4	   weeks,	   anterior	   wall	   thickness	   was	   severely	   depressed	   in	   both	   MI-­‐valsartan	   and	   MI-­‐vehicle	  
groups	  compared	  to	  sham	  (0.4±0.05	  mm	  vs.	  0.8±0.12	  mm).	  
The	   posterior	   wall	   systolic	   thickness	   (PWTkS)	   and	   left	   ventricle	   mass	   (LV	   mass)	   both	   increased	  
starting	  from	  twenty-­‐four	  hours	  after	  myocardial	  infarction	  and	  in	  chronic	  remained	  unchanged	  and	  






Figure	   48.	   In	   graphs	   posterior	   wall	   systolic	   thickness	   (PWTkS)	   and	   left	   ventricle	   mass	   (LV	   mass)	   follow-­‐up	  
evolution	   in	   sham,	  MI-­‐vehicle	   and	  MI-­‐valsartan	   groups.	   *	   p<0.05	   and	   ***	   p<0.001	   	   MI-­‐vehicle	   vs.	   Sham;	   §§	  
p<0.01	  and	  §§§	  p<0.001	  MI-­‐valsartan	  vs.	  MI-­‐vehicle.	  
	  
	  	  
In	  vivo	  findings	  are	  in	  agreement	  with	  those	  of	  infarct	  size	  measured	  on	  histology	  sections:	  in	  the	  MI-­‐
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Figure	   49.	   In	   panel	  A	   sirius	   red	   staining	   representative	   for	   each	   experimenatal	   group	   (sections	   from	  base	   to	  
apex);	   in	   panel	   B	   graph	   of	   infarct	   size%.	   **	   p<0.01	   	  MI-­‐vehicle	   vs.	   Sham;	   #	   p<0.05	  MI-­‐valsartan	   vs.	   Sham;	   §	  
p<0.05	  MI-­‐valsartan	  vs.	  MI-­‐vehicle.	  
	  	  
3.5.2 Assessment	  Of	  Regional	  LV	  Function	  
Bull’s	   eyes	   representation	   of	   regional	   LV	   function	   showed,	   24	   hours	   after	   MI,	   a	   similar	   condition	  
between	  MI-­‐vehicle	  and	  MI-­‐valsartan	  group	  with	  reduced	  functionality	  of	  apex,	  anterior	  and	  lateral	  
















At	  the	  end	  of	  follow	  up	  period	  (4w),	  a	  dramatic	  reduced	  function	  was	  observed	  in	  MI-­‐vehicle	  also	  at	  
the	  basal	  and	  posterior	  segment,	  while	  the	  pharmacological	  treatment	  localized	  and	  limited	  the	  loss	  
of	  function	  most	  in	  apical,	  anterior	  and	  lateral	  mid-­‐cavity	  segments.	  
	  
Figure	  50.	  Bull’s	  eye	  representations	  of	  mean	  regional	  fractional	  area	  change	  in	  the	  Sham,	  MI-­‐vehicle	  
and	  MI-­‐valsartan	  groups	  24	  hour	  and	  4w	  after	  MI.	  
	  
3.5.3 Gene	  Expression	  Of	  Non-­‐Infarcted	  Wall	  
In	  mouse	  heart	  tissue	  analyzed	  a	  total	  of	  12996	  cDNA	  sequences	  were	  expressed	  at	  detectable	  levels,	  
224	   of	   which	   were	   significant	   at	   0.001	   level	   of	   the	   univariate	   test.	   The	   final	   list	   included	   138	  
transcripts	   (probes),	   41	   of	  which	  were	   duplicates	   or	   triplicates	   (two	   or	   three	   probes	   for	   the	   same	  
gene):	   thus,	  we	   identified	  119	   relevant	   (unique)	   genes	   that	  were	   differentially	   expressed	  between	  
MI-­‐vehicle	  and	  sham	  at	  0.01	  level.	  	  
These	  were	  gene	  involved	  in	  regulation	  of	  cell	  adhesion,	  growth,	  and	  apoptosis	  and	  involved	  in	  ECM	  
deposition	  and	  remodeling.	  
Among	  these	  genes,	  38	  were	  differentially	  expressed	  between	  MI-­‐vehicle	  and	  MI-­‐valsartan.	  
In	   particular	   genes	   encoded	   for	   ECM	   proteins	   displayed	   enhanced	   expression	   in	   MI-­‐vehicle	   MI-­‐
valsartan,	  for	  example	  expression	  of	  fibulin-­‐2,	  procollagen,	  collagen	  VIII	  proteins	  involved	  in	  fibrotic	  
and	   hypertrophic	   process,	  microfibrillar	   associated	   protein	   5	   (Mfap5)	   and	   secreted	   acidic	   cysteine	  






rich	   glycoprotein	   (Sparc)	   glycoproteins	   involved	   in	   ECM	   remodeling,	   actin	   Acta1	   characteristic	   of	  
activated	  fibroblast	  and	  metalloproteinase	  (MMP)	  was	  higher	  expressed	  in	  untreated	  group.	  
	  
	  	  
















3.5.4 Assessment	  Of	  LA-­‐LAA	  Function	  	  
In	  chronic,	  starting	  from	  1	  week	  after	  injury,	  LA	  volume	  minimum	  was	  preserved	  in	  MI-­‐valsartan	  mice	  
while	  a	  progressive	  increase	  was	  observed	  in	  MI-­‐vehicle	  and	  this	  difference	  is	  significant	  between	  the	  
two	   experimental	   groups;	   also	   LA	   volume	   maximum	   shows	   a	   recover	   in	   MI-­‐valsartan,	   but	   not	  
significantly.	  LA	  volume	  fractional	  reservoir	  was	  preserved	   in	  MI-­‐valsartan	  (no	  significant	  difference	  
to	  sham)	  while	  deteriorate	  in	  MI-­‐vehicle.	  
At	  the	  end	  of	  the	  follow	  up	  period,	  LAmax	  and	  LAmin	  volumes	  were	  in	  MI-­‐vehicle	  and	  MI-­‐valsartan	  
respectively	   LAmax(4w):	   10.71±4.16	  μl	   vs.	   4.67±0.89μl	   and	   LAmin(4w):	   6.65±3.4μl	   vs.	   1.98±0.47	   μl	  





Figure	  52.	  In	  graphs	  LAmax	  and	  LAmin	  volumes	  and	  Fractional	  reservoir	  follow-­‐up	  evolution	  in	  sham,	  MI-­‐vehicle	  
and	  MI-­‐valsartan	  groups.	  *	  p<0.05	  and	  ***	  p<0.001	  MI-­‐vehicle	  vs.	  Sham;	  ###	  p<0.001	  MI-­‐valsartan	  vs.	  Sham;	  	  §	  






Appendage	   long	  axis	   length	   remained	  almost	  unchanged	  two	  days	  after	  surgery	   in	  both	  MI-­‐vehicle	  
and	   MI-­‐valsartan	   groups,	   and,	   in	   chronic,	   LAAla	   length	   was	   maintained	   in	   MI-­‐valsartan	   group	   in	  
contrast	   with	   the	   dramatic	   increase	   occurred	   in	   MI-­‐vehicle	   (3.9±0.59	   mm	   vs.	   4.7±0.54	   mm,	   MI-­‐
valsartan	  vs.	  MI-­‐vehicle).	  
In	  MI-­‐valsartan	  group	  LAA	  maintained	  not	  only	   its	  dimension	  but	  also	   its	   contractility,	   in	  particular	  
maximum	  and	  minimum	  duct	  dimension	  were	  unchanged	  compared	  to	   twenty-­‐four	  hour	  measure,	  
and	   duct	   fractional	   diameter	   was	   preserved	   in	   contrast	   with	   MI-­‐vehicle	   group	   that	   showed	   an	  
increase	  in	  both	  values	  and	  a	  loss	  of	  contractility	  compared	  to	  MI-­‐valsartan	  (duct	  fractional	  diameter	  
41.8±5%	  vs.	  22.3±7%,	  MI-­‐valsartan	  vs.	  MI-­‐vehicle).	  
	  
	  
Figure	  53.	  In	  graphs	  LAA	  long	  axis	  (LAAla)	  and	  duct	  fractional	  diameter	  follow-­‐up	  evolution	  in	  sham,	  MI-­‐vehicle	  
and	  MI-­‐valsartan	   groups.	   ***	   p<0.001	  MI-­‐vehicle	   vs.	   Sham;	   #	   p<0.05	  MI-­‐valsartan	   vs.	   Sham;	   §	   p<0.05	   and	   §§	  



















Cardiovascular	   disease	   (CVD)	   defines	   several	   pathological	   conditions	   occurring	   to	   heart	   and	  
circulatory	  system	  and	  is	  among	  the	  leading	  causes	  of	  death	  and	  disability	  in	  the	  world	  (Kovacic	  JC	  et	  
al.,	  2011).	  	  
The	  most	  common	  CVDs	  are	  ischemic	  heart	  disease	  (43%)	  and	  cerebrovascular	  disease	  (33%),	  while	  
the	   remaining	   are	   peripheral	   vascular	   disease,	   rheumatic	   and	   congenital	   heart	   disease,	   aortic	  
aneurysm	  and	  dissection,	  deep	  venous	  thrombosis	  and	  pulmonary	  embolism.	  
Despite	   progress	   in	   diagnosis	   and	   treatment	   led	   to	   a	   significant	   reduction	   of	   the	   rate	   of	   death	  
attributable	  to	  CVDs	  (minus	  30.6%	  from	  1998	  to	  2008),	  many	  efforts	  ought	  to	  be	  done	  to	  modify	  the	  
extent	  of	  disease,	  outcome	  and	  to	  enhance	  protection.	  
Therefore,	   the	   development	   of	   new	   technologies	   in	   support	   of	   diagnosis,	   the	   release	   of	   new	  
landmarks	   and	   the	   research	   of	   novel	   therapeutic	   agents	   are	   important	   targets	   for	   clinicians	   and	  
researchers.	  	  
During	   the	   past	   40	   years,	   basic	   and	   translational	   researches	   have	   used	   small	   animal	   models	   to	  
explore	   the	  pathophysiology	  of	  heart	   failure	  and	   to	  develop	  novel	   therapies	   that	  might	  slow	  down	  
the	  progression	  of	  this	  widespread	  and	  fatal	  disease.	  Heart	  failure	  models	  are	  commonly	  developed	  
in	  mouse	  because	  of	  numerous	  potential	  advantages	  such	  as	  much	  lower	  cost	  than	  for	  large	  animals	  
for	   their	   housing	   and	   maintenance	   and	   the	   possibility	   to	   obtain	   transgenic	   animals	   facilitating	   a	  
particularly	  elegant	  approach	  to	  identify	  novel	  therapeutic	  targets	  and	  offering	  a	  “proof	  of	  principle”	  
approach	  to	  explore	  the	  mechanisms	  underlying	  heart	  failure	  and	  its	  progression	  (Pattern	  RD	  et	  al.,	  
2009).	  
In	  addition,	  more	  recent	  technological	  advances	  in	  noninvasive	  in	  vivo	   imaging	  techniques	  for	  small	  
animals	  allow	  a	  very	  detailed	  study	  of	  mouse	  heart	  anatomy	  and	  function.	  
The	  imaging	  approach	  offers	  the	  possibility	  to	  perform	  longitudinal	  studies,	   in	  which	  each	  animal	   is	  
its	   own	   control,	   thus	   reducing	   the	   number	   of	   animals	   used	   and	   the	   interindividual	   variability	  
according	  to	  the	  principle	  of	  “refinement,	  reduction,	  and	  replacement”	  (Gargiulo	  S	  et	  al.,	  2012),	  also	  
improving	  the	  statistical	  power.	  
Moreover,	   another	   important	   feature	   of	   in	   vivo	   imaging,	   being	   the	   same	   used	   in	   clinics,	   is	   the	  
translational	  potential	  towards	  human	  studies.	  
Among	   CVDs,	   myocardial	   infarction	   (MI)	   is	   the	   most	   common;	   clinical	   evidence	   suggests	   that	   MI	  
affects	  both	  left	  ventricle	  (LV),	  which	  is	  directly	  damaged,	  and	  left	  atrium	  (LA).	  The	  LA	  modulates	  left	  
ventricular	  filling	   in	  three	  LA	  phases:	  the	  reservoir,	  or	  expansion,	  during	  systole,	  the	  conduit	  during	  
early	   diastole,	   and	   the	   active	   contractile	   phase	   during	   late	   diastole.	   Tsang	   and	   colleagues	   also	  
reported	  the	  ability	  of	  LA	  to	  respond	  to	  a	  decrease	  in	  LV	  compliance	  by	  increasing	  its	  size:	  after	  MI,	  
LV	  end-­‐diastolic	  pressure	  increases	  and	  LA	  is	  directly	  exposed	  to	  this	  increase.	  To	  maintain	  adequate	  




dilatation	  and	  stretching	  of	  atrial	  myocardium	  (Tsang	  TS	  et	  al.,	  2002).	  Therefore	  LA	  volume	  reflects	  
the	   severity	   of	   diastolic	   dysfunction	   and	   the	   long-­‐term	  exposure	   to	   abnormal	   LV	  diastolic	   function	  
(Tsang	   TS	   et	   al.,	   2002).	   Strong	   evidence	   also	   suggests	   that	   the	   LA	   plays	   a	   central	   role	   in	   the	   early	  
detection	  of	  cardiac	  disease	  and	  prognosis	  (Suh	  IW	  et	  al.,	  2008)	  and	  in	  particular	  LA	  size	  predicts	  the	  
risk	  of	  ventricular	  and	  valvular	  disease	  (Matsuda	  Y	  et	  al.,	  1983;	  Vaturi	  M	  et	  al.,	  2001).	  
However	  whereas	   in	   clinic	   the	   role	  of	   atrium	  and	   its	   remodeling	   are	  well	   known,	   in	  basic	   sciences	  
only	   few	  studies,	  performed	   in	  rats	   (Milliez	  P	  et	  al.,	  2005),	  evaluate	  only	  anatomical/morphological	  
LA	  remodeling	  occurring	  after	  MI	  finding	  LA	  increase	  in	  size	  and	  collagen	  deposition.	  
In	  this	  work	  we	  focused	  our	  attention	  on	  a	  mouse	  model	  of	  myocardial	  infarction	  (MI)	  investigating	  
the	  effect	  on	  left	  ventricle	  and,	  for	  the	  first	  time,	  its	  consequence	  on	  both	  left	  atrium	  and	  left	  atrium	  
appendage	   (together	   named	   as	   left	   venous	   reservoir	   system).	   Mouse	   models	   of	   MI,	   induced	   by	  
permanent	  ligation	  of	  left	  anterior	  descending	  (LAD)	  coronary	  artery,	  and	  the	  availability	  of	  imaging	  
techniques	  for	  small	   laboratory	  animals,	  such	  as	  cardiac	  magnetic	  resonance	  (CMR)	  and	  high	  frame	  
rate	   echocardiography,	   offer	   the	   great	   opportunity	   to	   investigate	   early	   and	   long	   term	   heart	  
remodeling,	  and	  the	  changes	  in	  function	  occurring	  after	  MI	  and	  pharmacological	  intervention.	  
The	  first	  step	   in	  this	  study	  was	  to	  set	  up	  the	  surgery	  procedure	  and	  to	  assess	  the	  extent	  of	  cardiac	  
damage	  by	  CMR	  imaging	  considered	  in	  clinic	  as	  the	  reference	  technique.	  This	  passage	  was	  hampered	  
by	  many	   difficulties,	  when	   compared	   to	   human	   setting:	   the	   small	   dimension	   of	  murine	   heart,	   the	  
much	  higher	  heart	  rate,	  the	  need	  of	  anesthesia	  and	  the	  impossibility	  to	  acquire	  breath-­‐held	  images	  
limited	  somewhat	  the	  damage	  extent	  assessment	  to	  LV	  function	  only.	   	  Our	  results	  showed	  that	  the	  
time	  evolution	  of	   LV	  damage	   is	  highly	   influenced	  by	   the	   surgical	   variability.	   In	  particular	  mice	  with	  
ejection	   fraction	   (EF)(24h)>45%	   did	   not	   develop	   a	   significant	   LV	   remodeling,	   whereas	   mice	   with	  
EF(24h)<35%	  developed	  a	  large	  LV	  remodeling	  and,	  worst,	  seldom	  lived	  to	  4w	  after	  MI.	  Therefore	  the	  
use	  of	  CMR	  EF(24h)	  to	  select	  infarcted	  mice	  in	  this	  restrained	  range	  become	  fundamental	   in	  all	  our	  
following	   studies.	   The	   longitudinal	   imaging	   evaluation	   of	   selected	   MI	   animals	   vs.	   sham	   operated	  
showed	  a	  development	  of	  LV	  dysfunction	  in	  the	  similar	  way	  as	  described	  in	  Bauer	  et	  al.,	  2011,	  Protti	  
et	  al.,	  2012	  and	  Yang	  et	  al.,	  2002.	  We	  observed	  a	  significant	  increase	  in	  LV	  dimension	  (EDV,	  ESV	  and	  
ventricle	  diameters),	  anterior	  wall	  thickness	  thinning,	  a	  dramatic	  reduction	  in	  EF	  occurred	  already	  24	  
hours	  after	   injury	  and	  consequently,	  a	  progressive	  deterioration	  in	  all	  LV	  functions	  occurring	  during	  
the	  12	  weeks	  follow-­‐up	  period.	  
Regional	  fractional	  area	  change	  analysis	  (RFAC)	  and	  its	  visualization	  with	  bull’s	  eyes,	  applied	  for	  the	  
first	   time	   in	  mice,	  has	  been	  useful	   in	   confirming	   that,	   immediately	  after	  MI,	   the	  ventricular	   loss	  of	  





A	  time	  course	  of	  bull’s	  eyes	  visualization	  showed	  a	  progressive	  expansion	  of	  damaged	  myocardium	  
not	  only	  in	  apical	  and	  anterior	  sectors,	  but	  also	  in	  lateral	  and	  posterior	  mid-­‐basal	  levels	  indicating	  a	  
progressive	   loss	   of	   contractility	   in	   remote	   non-­‐infarcted	   tissue,	   as	   a	   result	   of	   LV	   stiffness	   and	  
remodeling.	   RFAC	   analysis	  was	   also	   able	   to	   detect	   small	   variations	   in	   contractility	   in	   the	   posterior	  
myocardium	   i.e.	   regions	   not	   directly	   connected	  with	   LAD	   and	   had	   good	   sensibility,	   specificity	   and	  
accuracy	  versus	  histology	  gold	  standard.	  
Nevertheless	  our	   results	   showed	   that	  CMR,	  despite	  being	   the	  clinic	  gold	   standard,	  both	   for	   lack	  of	  
spatial	  and	  temporal	  resolution,	  was	  unable	  to	  refine	  the	  post	  MI	  assessment	  to	  smaller	  structures	  
such	   as	   LA,	   so	  we	   turned	   towards	   echocardiography	   that	   in	   very	   recent	   time	   had	   experienced	   an	  
impressive	   evolution	   for	   laboratory	   animal	   application.	   Compared	   to	   CMR,	   echocardiography	  
certainly	  overcomes	  both	  spatial	  and	  temporal	  resolution	  limitations,	  however	  it	  is	  dependent	  on	  the	  
very	   variable	   acoustic	   window	   that	   suffers	   particularly	   in	   the	   early	   post	   surgery	   time.	   Also,	   the	  
evaluation	  of	  LV	  volumes	   in	  echocardiography	   is	  based	  on	  extrapolation	  and	  geometric	  assumption	  
on	  LV	  shape	  that	  changes	  significantly	  during	  MI	  remodeling.	  For	  all	  these	  reason,	  after	  having	  been	  
reassured	   by	   the	   strong	   correlation	   between	   CMR	   and	   echocardiographic	   data,	   we	   choose	   to	   use	  
CMR	  EF(24h)	  to	  select	  MI	  animals	  since	  at	  this	  stage	  the	  use	  of	  echocardiography	  is	  hampered	  by	  the	  
surgery	   suture	   and	   then	   to	   use	   longitudinally	   CMR	   to	   evaluate	   the	   development	   of	   systolic	  
ventricular	  dysfunction	  (EF)	  and	  echocardiography	  to	  assess	  all	  the	  other	  anatomical	  and	  functional	  
parameters.	  
Following	   these	   initial	   settings,	   next	   step	  was	   to	   characterize	  murine	   left	   venous	   reservoir,	   to	   our	  
knowledge	   never	   studied	   before.	   In	   order	   to	   reach	   this	   goal	   we	   used	   a	   double	   approach:	  
echocardiography	   for	   the	   function,	   and	   resin	   casts	   and	   histology	   for	   morphology	   and	   tissue	  
characterization.	  	  
Echocardiographic	  data	   showed	   that	   left	   atrial	   appendage	   (LAA)	  was	   two	   times	   longer	   than	   LA;	   its	  
Doppler	  estimated	  volume	  increase	  being	  twice	  than	  LA,	  and	  its	  cellular	  composition	  was	  similar	  to	  
LA,	  with	  predominant	  cardiomyocyte	  component,	  making	  it	  a	  contractile	  chamber	  together	  with	  LA.	  
All	   these	  data	  show	  incontrovertibly	  that,	  studying	  the	  mouse,	  the	  appendage	  cannot	  be	  neglected	  
as	  usual	  in	  humans,	  in	  which	  LAA	  can	  be	  surgically	  removed	  to	  prevent	  thrombosis	  risk.	  	  
Another	   noticeable	   finding	   obtained	   independently	   by	   macroscopic	   anatomy	   and	   color	   Doppler	  
imaging	   of	   LAA,	   both	   techniques	   never	   performed	   before,	   is	   that	   LA	   is	   unequivocally	   supplied	   by	  
three	   pulmonary	   veins	   (PVs).	   In	   previous	   literature	   there	   are	   few	   histological	   studies	   describing	   a	  
single	  PV	  entering	  the	  LA	  chamber	  dorsally	  (Kruithof	  BP	  et	  al.,	  2003;	  Wessels	  A	  et	  al.,	  2003),	  that	   is	  
not	  surprising	  because	  even	  ours	  histological	  results	  were	  unable	  to	  describe	  the	  anatomy	  and	  clarify	  
the	  numbers	  of	  PVs.	  Also	  a	  single	  combined	  in	  vivo	  echocardiography	  and	  corpse	  magnetic	  resonance	  




echocardiographic	  equipment	  was	  less	  capable	  than	  the	  one	  that	  was	  used	  in	  this	  study	  with	  respect	  
to	  both	  temporal	  and	  spatial	  resolution,	  further	  on	  the	  corpse	  it	  is	  likely	  that	  some	  PVs	  were	  hidden	  
by	  their	  collapse	  after	  death.	  
As	   LAA	   assumed	   a	   primary	   role	   in	   venous	   reservoir	   system	   we	   characterized	   its	   dimensions,	   its	  
Doppler	  flows,	  and	  its	  connection	  with	  LA:	  a	  contractile	  large	  duct	  that,	  being	  open	  and	  large	  almost	  
as	   much	   as	   LA	   itself	   during	   the	   systolic	   filling,	   let	   LAA	   enhance	   the	   LA	   reservoir	   function	   almost	  
constituting	   together	  a	  single	  chamber.	  This	   is	   further	  supported	  by	   the	  synchronicity	  of	   filling	  and	  
emptying	  Doppler	  flow	  pattern	  of	  LA	  and	  LAA.	  
In	  this	  experiment	  a	  full	  set	  of	  normality	  parameters	  of	  both	  LV	  and	  venous	  reservoir	  were	  recorded	  
and	  used	  as	  a	  reference	  in	  the	  following	  studies.	  A	  multiple	  linear	  regression	  between	  them	  suggests	  
that	  LV	  SV	   is	   influenced	  by	  LAA	  diastolic	   flow,	  both	  total	   (systolic	  +	  diastolic)	  and	  diastolic	  PV	  flow,	  
and	  LV	  base	  descent.	  
After	  characterization	  of	  left	  venous	  reservoir	  in	  normal	  mouse,	  we	  then	  went	  to	  study	  its	  acute	  and	  
chronic	   response	   after	   MI	   using	   echocardiography.	   Our	   results,	   according	   to	   literature,	   show	   a	  
dramatic	  initial	  loss	  of	  contractility	  and	  consequently	  decline	  in	  systolic	  function	  resulting	  in	  an	  initial	  
fall	  in	  LV	  SV.	  	  
In	   a	   short/mid	   term	   LA	   volume	   and	   LAA	   length	   increase,	   probably	   for	   increase	   in	   LV	   afterload,	   to	  
reach	   their	  maximum	   at	   1-­‐4	  weeks	   after	  MI	  when	   LV	   SV	   recovers.	   Increase	   in	   afterload	   is	   due	   to	  
increase	  of	   LV	   rigidity	  due	   to	   several	   factors:	   increase	   in	  peripheral	   vascular	   resistance,	   increase	   in	  
force	  of	   contractility,	   and	   activation	  of	   neurohumoral	   (noradrenergic	   and	   angiotensin-­‐aldosterone)	  
systems.	  During	  this	  process	  the	  duct	  between	  LA	  and	  LAA	  is	  heavily	  involved:	  loosing	  its	  contractility	  
it	   seems	   to	   enhances	   LAA	   contribution	   to	   atrial	   function	   not	   only	   during	   systole	   as	   observed	   in	  
normal	  mice	  but	  even	  during	  diastole.	  The	  echocardiographic	  longitudinal	  analysis	  show	  also	  that	  the	  
total	  (LA+LAA)	  venous	  reservoir	  compliance,	  after	   initial	  decrease,	   is	  completely	  restored	  in	  chronic	  
helping	   to	   maintain	   LV	   preload	   thus	   helping	   to	   preserve	   LV	   SV.	   The	   LV	   SV	   recovers	   only	   at	   the	  
expense	  of	   increase	   in	   length	  of	  LAA	  and	  LA	  volume,	  and	  reduction	  of	  duct	  contractility,	   indexes	  of	  
increased	  venous	  volume	  reservoir.	  
In	  order	  to	  evaluate	  the	  applicability	  of	  all	   the	  above	  techniques	  to	  pharmacological	  studies	  and	  to	  
better	  investigate	  the	  role	  of	  venous	  reservoir	  system	  in	  MI,	  we	  finally	  choose	  to	  block	  the	  activation	  
of	  RAAS,	  which	   is	   involved	   in	  after	  and	  preload	   in	  several	  cardiovascular	  diseases.	  Moreover,	  some	  
clinical	  trials	  have	  demonstrated	  that	  long-­‐term	  administration	  of	  blockers	  of	  RAAS,	  such	  as	  ACEi	  and	  
ARBs,	  plays	  a	  critical	  role	  in	  post-­‐infarction	  LV	  remodeling	  and	  promote	  greater	  reduction	  in	  LV	  mass	  
decreasing	  cardiovascular	  mortality	  and	  morbidity.	  
To	   totally	   block	   the	   RAAS	   activity,	   we	   choose,	   as	   pharmacological	   treatment,	   to	   use	   valsartan,	   a	  




1mg/kg/die	  was	  chosen	  as	  known	  not	  having	  effects	  on	  systemic	  pressure	  (Ohishi	  Y	  et	  al.,	  2006).	  Our	  
LV	  EDV,	  LV	  RFAC	  bull’s	  eyes,	  posterior	  wall	  thickness,	  LV	  mass,	  infarct	  size	  assed	  with	  histology,	  and	  
ECM	  gene	  expression	  data,	  all	  significant	  vs.	  MI-­‐vehicle,	  confirm	  the	  known	  effect	  on	  LV	  remodeling	  
of	  valsartan	  at	   this	  dose.	   In	  particular,	  despite	  not	   significant	  difference	   in	  global	  EF	   (the	  observed	  
difference	  was	   slightly	   lower	   than	  we	  expected	  and	  not	   significant	  as	  our	  planned	  experiment	  had	  
not	  enough	  statistical	  power:	  to	  detect	  it	  there	  would	  have	  needed	  many	  more	  animals)	  at	  the	  end	  
of	  follow-­‐up	  period,	  bull’s	  eyes	  showed	  a	  protective	  effect	  of	  pharmacological	  treatment	  on	  posterior	  
wall	   contractility	   compared	   to	   MI-­‐vehicle	   together	   with	   a	   reduction	   in	   posterior	   wall	   thickening.	  
These	  data	  were	  also	   supported	  by	  microchip	   study	  of	   the	  mRNA	  expression	   in	   the	  posterior	  non-­‐
infarcted	  myocardium	  of	  MI-­‐group	  treated	  with	  valsartan	  compare	  to	  the	  untreated	  one.	  We	  found	  
that	   a	   total	   of	   25	   genes	  were	   differently	   expressed	   compare	   to	   untreated	  mice.	   In	   particular,	   we	  
found	  an	  important	  modulation	  in	  ECM	  gene	  expression,	  such	  as	  fibulin-­‐2,	  procollagen,	  collagen	  VIII	  
proteins	  involved	  in	  fibrotic	  and	  hypertrophic	  process,	  microfibrillar	  associated	  protein	  5	  (Mfap5)	  and	  
secreted	   acidic	   cysteine	   rich	   glycoprotein	   (Sparc)	   glycoproteins	   involved	   in	   ECM	   remodeling,	   actin	  
Acta1	  characteristic	  of	  activated	  fibroblast	  and	  metalloproteinase	  (MMP).	  
The	   techniques	  we	  set	  up	   for	   left	   venous	  characterization	   showed	  even	  more	   significant	  effects	  of	  
the	   pharmacologic	   treatment	   in	   LA	   volume	   min,	   LA	   fractional	   reservoir,	   LAA	   long	   axis,	   and	   duct	  
fractional	  diameter.	  Noticeably	  both	  LA	  fractional	  reservoir	  and	  LAA	  long	  axis	  were	  also	  not	  different	  
vs.	  sham.	  As	  for	  MI-­‐vehicle	  also	  in	  MI-­‐valsartan	  the	  LV	  SV	  recovers	  but	  without	  LAA	  and	  LA	  increase	  in	  
dimension.	  
Conclusions	  
Our	   cardiac	   magnetic	   resonance	   and	   high	   frame	   rate	   echocardiography	   results	   show	   that	   murine	  
model	  can	  be	  used	  to	  study	  pharmacological	   treatment	  of	  MI	  at	  a	  deeper	   level	   than	  the	  simple	  LV	  
function.	  
Many	  aspects	  of	  novelty	  appears	  in	  this	  work,	  in	  particular:	  i)	  for	  the	  first	  time	  RFAC	  was	  applied	  to	  
evaluate	   LV	   function	   on	   murine	   heart	   and	   represented	   it	   as	   bull’s	   eye;	   ii)	   the	   first	   anatomic	   and	  
physiopathologic	   investigation	   of	   the	   LAA	   was	   performed	   in	   order	   to	   define	   new	   reference	   value	  
useful	   in	   detecting	   changes	   after	   surgical	   and	   pharmacological	   modulations,	   and	   iii)	   an	   original	  
comprehensive	  characterization	  of	   LA	  was	  carried	  out	   in	  mice.	  All	   the	  above	  new	   techniques	  were	  
applied	   in	   synergy	  with	  other	  already	  established	  such	  as	  gene	  expression	  analysis	   to	  demonstrate	  
their	   efficacy	   in	   the	   evaluation	   of	   damage	   and	   recover	   after	   MI	   with	   or	   without	   pharmacologic	  
treatment.	  Nevertheless	  this	  study	  needs	  to	  be	  supported	  by	  histological	  and	   in	  vivo	  hemodynamic	  
studies	  through	  pressure/volume	  catheterism.	  
We	   are	   confident	   that	   this	   comprehensive	   approach	   could	   be	   used	   to	   give	   new	   insights	   in	   many	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